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A B S T R A C T
Background
Studies evaluating mass drug administration (MDA) in malarious areas have shown reductions in malaria immediately following the
intervention. However, these eGects vary by endemicity and are not sustained. Since the 2013 version of this Cochrane Review on this topic,
additional studies have been published.
Objectives
Primary objectives
To assess the sustained eGect of MDA with antimalarial drugs on:
- the reduction in malaria transmission in moderate- to high-transmission settings;
- the interruption of transmission in very low- to low-transmission settings.
Secondary objective
To summarize the risk of drug-associated adverse eGects following MDA.
Search methods
We searched several trial registries, citation databases, conference proceedings, and reference lists for relevant articles up to 11 February
2021. We also communicated with researchers to identify additional published and unpublished studies.
Selection criteria
Randomized controlled trials (RCTs) and non-randomized studies comparing MDA to no MDA with balanced co-interventions across study
arms and at least two geographically distinct sites per study arm.
Data collection and analysis
Two review authors independently assessed trials for eligibility and extracted data. We calculated relative risk (RR) and rate ratios with
corresponding 95% confidence intervals (CIs) to compare prevalence and incidence, respectively, in MDA compared to no-MDA groups.
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We stratified analyses by malaria transmission and by malaria species. For cluster-randomized controlled trials (cRCTs), we adjusted
standard errors using the intracluster correlation coeGicient. We assessed the certainty of the evidence using the GRADE approach. For
non-randomized controlled before-and-aLer (CBA) studies, we summarized the data using diGerence-in-diGerences (DiD) analyses.
Main results
Thirteen studies met our criteria for inclusion. Ten were cRCTs and three were CBAs.
Cluster-randomized controlled trials
Moderate- to high-endemicity areas (prevalence ≥ 10%)
We included data from two studies conducted in The Gambia and Zambia.
At one to three months aLer MDA, the Plasmodium falciparum (hereaLer, P falciparum) parasitaemia prevalence estimates may be higher
compared to control but the CIs included no eGect (RR 1.76, 95% CI 0.58 to 5.36; Zambia study; low-certainty evidence); parasitaemia
incidence was probably lower (RR 0.61, 95% CI 0.40 to 0.92; The Gambia study; moderate-certainty evidence); and confirmed malaria illness
incidence may be substantially lower,  but the CIs included no eGect (rate ratio 0.41, 95% CI 0.04 to 4.42; Zambia study; low-certainty
evidence).
At four to six months aLer MDA, MDA showed little or no eGect on P falciparum parasitaemia prevalence (RR 1.18, 95% CI 0.89 to 1.56; The
Gambia study; moderate-certainty evidence) and, no persisting eGect was demonstrated with parasitaemia incidence (rate ratio 0.91, 95%
CI 0.55 to 1.50; The Gambia study).
Very low- to low-endemicity areas (prevalence < 10%)
Seven studies from Cambodia, Laos, Myanmar (two studies), Vietnam, Zambia, and Zanzibar evaluated the eGects of multiple rounds of
MDA on P falciparum. Immediately following MDA (less than one month aLer MDA), parasitaemia prevalence was reduced (RR 0.12, 95% CI
0.03 to 0.52; one study; low-certainty evidence). At one to three months aLer MDA, there was a reduction in both parasitaemia incidence
(rate ratio 0.37, 95% CI 0.21 to 0.55; 1 study; moderate-certainty evidence) and prevalence (RR 0.25, 95% CI 0.15 to 0.41; 7 studies; low-
certainty evidence). For confirmed malaria incidence, absolute rates were low, and it is uncertain whether MDA had an eGect on this
outcome (rate ratio 0.58, 95% CI 0.12 to 2.73; 2 studies; very low-certainty evidence).
For P falciparum prevalence, the relative diGerences declined over time, from RR 0.63 (95% CI 0.36 to 1.12; 4 studies) at four to six
months aLer MDA, to RR 0.86 (95% CI 0.55 to 1.36; 5 studies) at 7 to 12 months aLer MDA. Longer-term prevalence estimates showed overall
low absolute risks, and relative eGect estimates of the eGect of MDA on prevalence varied from RR 0.82 (95% CI 0.20 to 3.34) at 13 to 18
months aLer MDA, to RR 1.25 (95% CI 0.25 to 6.31) at 31 to 36 months aLer MDA in one study.
Five studies from Cambodia, Laos, Myanmar (2 studies), and Vietnam evaluated the eGect of MDA on Plasmodium vivax (hereaLer, P
vivax). One month following MDA, P vivax prevalence was lower (RR 0.18, 95% CI 0.08 to 0.40; 1 study; low-certainty evidence). At one to
three months aLer MDA, there was a reduction in P vivax prevalence (RR 0.15, 95% CI 0.10 to 0.24; 5 studies; low-certainty evidence). The
immediate reduction on P vivax prevalence was not sustained over time, from RR 0.78 (95% CI 0.63 to 0.95; 4 studies) at four to six months
aLer MDA, to RR 1.12 (95% CI 0.94 to 1.32; 5 studies) at 7 to 12 months aLer MDA. One of the studies in Myanmar provided estimates of
longer-term eGects, where overall absolute risks were low, ranging from RR 0.81 (95% CI 0.44 to 1.48) at 13 to 18 months aLer MDA, to RR
1.20 (95% CI 0.44 to 3.29) at 31 to 36 months aLer MDA.
Non-randomized studies
Three CBA studies were conducted in moderate- to high-transmission areas in Burkina Faso, Kenya, and Nigeria. There was a reduction in
P falciparum parasitaemia prevalence in MDA groups compared to control groups during MDA (DiD range: -15.8 to -61.4 percentage points),
but the eGect varied at one to three months aLer MDA (DiD range: 14.9 to -41.1 percentage points).
Authors' conclusions
In moderate- to high-transmission settings, no studies reported important eGects on P falciparum parasitaemia prevalence within six
months aLer MDA. In very low- to low-transmission settings, parasitaemia prevalence and incidence were reduced initially for up to three
months for both P falciparum and P vivax; longer-term data did not demonstrate an eGect aLer four months, but absolute risks in both
intervention and control groups were low. No studies provided evidence of interruption of malaria transmission.
P L A I N   L A N G U A G E   S U M M A R Y
Administration of antimalarial drugs to whole populations for reducing malaria
What is mass drug administration (MDA) for malaria?
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MDA for malaria consists of giving a full treatment course of antimalarial medicine (even to persons with no symptoms of malaria and
regardless of whether malaria is present) to every member of a defined population or every person living in a defined geographical area
(except to those for whom the medicine could be harmful) at approximately the same time and oLen at repeated intervals.
How can MDA reduce malaria transmission in a population?
The life cycle of the malaria parasite consists of human liver, human blood, and mosquito stages. Malaria infection begins with the bite
of an Anopheles species mosquito carrying the malaria parasite. During the bite, the infective mosquito injects the malaria parasite into
the human host. ALer initially replicating in the liver, the parasites are released into the bloodstream. During the blood stage, parasites
multiply in red blood cells, sometimes causing fever and other symptoms characteristic of malaria. Some of these parasites become a form
which is infectious to mosquitoes. When the infected person is bitten again, the mosquito ingests blood containing the parasites, which
then restarts the transmission cycle.
MDA with antimalarial drugs temporarily prevents new and clears existing malaria infections in the population. Depending on the
characteristics of the antimalarial drug used, MDA targets parasites at diGerent stages, which can lead to reduced disease burden and
transmission in the population. Whether MDA can successfully reduce or interrupt malaria transmission may depend on how much malaria
there is in the area; the use of other tools to control malaria, including preventing mosquito bites; the proportion of the population who
receive at least one round of MDA; population movement; and when MDA rounds occur in relation to the peak malaria transmission season.
What was the aim of the review?
To guide policy-making and future research for malaria control and elimination, the aim of this review was to update the evidence
evaluating the eGect of MDA compared to no MDA on malaria outcomes in moderate- to high-transmission settings and very low- to low-
transmission settings. Our search of relevant published and unpublished literature identified 13 studies that met our inclusion criteria.
What are the main findings of the review?
Malaria burden was compared in people receiving MDA and those who did not receive MDA, at diGerent time points. The findings diGered
by malaria transmission setting. In areas with malaria prevalence of 10% or higher (moderate- to high-transmission areas), based on one
trial, MDA did not reduce malaria in the population (low-certainty evidence). In areas with malaria prevalence under 10% (very low- to low-
endemicity areas), evidence from seven trials indicates that MDA reduced malaria in the population immediately aLer MDA has stopped
(low-certainty evidence), but we are uncertain if the decline continues long-term because the number of malaria cases in both intervention
and control groups were low (very low-certainty evidence).
In all settings of malaria transmission, the type of antimalarial drug used for MDA, co-interventions such as mosquito control, coverage
of MDA, and risk of re-introduction may have an impact on the eGect of MDA compared to no MDA. However, we were unable to explore
these factors due to the limited number of studies.
How up to date is the review?
We included studies available up to 11 February 2021.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   MDA compared to no MDA for Plasmodium falciparum malaria (moderate to high endemicity, short-term follow-up)
Patient or population: People of all ages living in an area with moderate to high endemicity of P falciparum malaria (≥ 10% prevalence)
Setting: Moderate to high endemicity defined as ≥10% prevalence of P falciparum
Intervention: MDA
















Follow-up: 1 to 3 months
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At 1-3 months post-MDA, parasite prevalence may in-
crease in MDA compared no MDA. However, the ef-
fects vary and it is possible that MDA makes little or
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At 1-3 months post-MDA, there may be a reduction
in confirmed malaria illness incidence in MDA com-
pared to no MDA.
Follow-up: 4 to 6 months
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At 4-6 months post-MDA, there is probably little or no
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*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; cRCT: cluster-randomized controlled trial; MDA: mass drug administration; RCT: randomized controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
aNot downgraded for inconsistency; the comparison presented is reported from a single study.
bNot downgraded for indirectness; outcome was evaluated in all ages or assessed in children (considered the most appropriate population to measure malaria transmission in
moderate- to high-endemicity areas).
cDowngraded 2 levels for imprecision due to very wide CIs.
dDowngraded 1 level for imprecision due to wide CIs.
eDowngraded 2 levels for risk of bias since malaria cases in outcome were defined as fever plus parasitaemia > 5000, which excludes all afebrile and low density infections and
results in an underestimate of the outcome.
 
 
Summary of findings 2.   MDA compared to no MDA for Plasmodium falciparum malaria (very low to low endemicity, short-term follow-up)
Patient or population: People of all ages living in an area with very low to low endemicity of P falciparum malaria (< 10% prevalence)
Setting: Very low to low endemicity defined as < 10% prevalence of P falciparum
Intervention: MDA





























Due to risk of bias and
imprecision
At < 1 month post-MDA, there may a reduction in
parasitaemia prevalence in MDA compared to no
MDA.



































































































































































Due to risk of bias
At 1-3 months post-MDA, there may a reduction
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6 per 1000 pop-
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Due to risk of bias and
imprecision
We do not know if MDA has an effect on con-
firmed malaria illness incidence at 1-3 months
post-MDA compared to no MDA.
Follow-up: 4 to 6 months
Parasitaemia
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Due to risk of bias and
imprecision
We do not know if MDA has an effect on para-
sitaemia prevalence at 4-6 months post-MDA
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Due to risk of bias and
imprecision
We do not know if MDA has an effect on con-
firmed malaria illness incidence at 4-6 months
post-MDA compared to no MDA.
Follow-up: 7 to 12 months
Parasitaemia
prevalence








Due to risk of bias and
imprecision
We do not know if MDA has an effect on para-
sitaemia prevalence at 7-12 months post-MDA
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Due to risk of bias and
imprecision
We do not know if MDA has an effect on con-
firmed malaria illness incidence at 7-12 months
post-MDA compared to no MDA.


























































































































































CI: confidence interval; cRCT: cluster-randomized controlled trial; MDA: mass drug administration; RCT: randomized controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
aDowngraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.
bNot downgraded for inconsistency; the comparison presented is reported from a single study.
cNot downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed
by a highly sensitive diagnostic method (ultrasensitive PCR).
dDowngraded 1 level for imprecision due to wide CIs.
eEight included studies reported parasitaemia prevalence during the 1-3 month post-MDA follow-up period; however, one study did not contribute data in the meta-analysis due
to no events at baseline before MDA or at any follow-up time points.
fDowngraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance and high risk of contamination in several studies.
gNot downgraded for inconsistency based on I2 statistic; however, reasons for heterogeneity explored in post-hoc sub-group analysis by continent (sub-Saharan Africa and
Southeast Asia; Analysis 4.1).
hNot downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting so there is no concern with
assessing this outcome in diGerent age groups across studies.
iNot downgraded for imprecision due to appreciable benefit of pooled eGect as reported by seven studies.
jNot downgraded for indirectness since outcome was assessed in all ages and by routine detection methods.
kDowngraded 2 levels for imprecision due to very wide CIs.
lNot downgraded for inconsistency based on I2 statistic.
mDowngraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance, high risk of contamination, and a large unexplained
increase in sampled population in the MDA group at this time point.
 
 
Summary of findings 3.   MDA compared to no MDA for Plasmodium falciparum malaria (very low to low endemicity, long-term follow-up)
Patient or population: People of all ages living in an area with very low to low endemicity of P falciparum malaria ( < 10% prevalence)
Setting: Very low to low endemicity defined as < 10% prevalence of P falciparum
Intervention: MDA








































































































































































Follow-up: 13 to 18 months
Parasitaemia
prevalence








Due to risk of bias and
imprecision
We do not know if MDA has an effect on par-
asitaemia prevalence at 13-18 months post-














Due to risk of bias and
imprecision
We do not know if MDA has an effect on con-
firmed malaria illness incidence at 13-18
months post-MDA compared to no MDA.













Due to risk of bias and
imprecision
We do not know if MDA has an effect on par-
asitaemia prevalence at 19-24 months post-
MDA compared to no MDA.













Due to risk of bias and
imprecision
We do not know if MDA has an effect on par-
asitaemia prevalence at 25-30 months post-













Due to risk of bias and
imprecision
We do not know if MDA has an effect on par-
asitaemia prevalence at 31-36 months post-
MDA compared to no MDA.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; cRCT: cluster-randomized controlled trial; MDA: mass drug administration; RCT: randomized controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different

























































































































































Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
aDowngraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance, high risk of contamination, and a large unexplained
increase in sampled population in the MDA group at this time point.
bNot downgraded for inconsistency; the comparison presented is reported from a single study.
cNot downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed
by a highly sensitive diagnostic method (ultrasensitive PCR).
dDowngraded 2 levels for imprecision due to very wide CIs.
eDowngraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.
fNot downgraded for indirectness since outcome was assessed in all ages and by routine detection methods.
 
 
Summary of findings 4.   MDA compared to no MDA for P vivax malaria (very low to low endemicity, short-term follow-up)
Patient or population: People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence)
Setting: Very low to low endemicity defined as < 10% prevalence of P vivax
Intervention: MDA





























Due to risk of bias and
imprecision
At < 1 month post-MDA, there may a reduction
in parasitaemia prevalence in MDA compared
to no MDA.
Follow-up: 1 to 3 months
Parasitaemia
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Due to risk of bias
At 1-3 months post-MDA, there may a reduction
in parasitaemia prevalence in MDA compared
to no MDA.





































































































































































Due to risk of bias and
imprecision
We do not know if MDA reduces parasitaemia
prevalence at 4-6 months post-MDA compared
to no MDA.
Follow-up: 7 to 12 months
Parasitaemia
prevalence








Due to risk of bias and
imprecision
We do not know if MDA has an effect on para-
sitaemia prevalence at 7-12 months post-MDA















Due to risk of bias and
imprecision
We do not know if MDA has an effect on con-
firmed malaria illness incidence at 7-12 months
post-MDA compared to no MDA.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; cRCT: cluster-randomized controlled trial; MDA: mass drug administration; RCT: randomized controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
aDowngraded 1 level for risk of bias due to several criteria scored as high or unclear risk of bias.
bNot downgraded for inconsistency; the comparison presented is reported from a single study.
cNot downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed
by a highly sensitive diagnostic method (ultrasensitive PCR).
dDowngraded 1 level for imprecision due to wide CIs.
eNot downgraded for imprecision due to appreciable benefit of pooled eGect as reported by five studies.
fDowngraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including baseline imbalance and high risk of contamination.
gNot downgraded for inconsistency despite the large value of the I2 statistic since the direction of eGect was consistent with large imprecision.
hNot downgraded for inconsistency based on I2 statistic.
iDowngraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including a large unexplained increase in sampled population in the MDA group
at this time point.




























































































































































Summary of findings 5.   MDA compared to no MDA for P vivax malaria (very low to low endemicity, long-term follow-up)
Patient or population: People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence)
Setting: Very low to low endemicity < 10% prevalence of P vivax
Intervention: MDA
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Due to risk of bias and
imprecision
We do not know if MDA reduces para-
sitaemia prevalence at 13-18 months
post-MDA compared to no MDA.













Due to risk of bias and
imprecision
We do not know if MDA reduces para-
sitaemia prevalence at 19-24 months
post-MDA compared to no MDA.













Due to risk of bias and
imprecision
We do not know if MDA reduces para-
sitaemia prevalence at 25-30 months













Due to risk of bias and
imprecision
We do not know if MDA reduces para-
sitaemia prevalence at 31-36 months
post-MDA compared to no MDA.



























































































































































CI: confidence interval; cRCT: cluster-randomized controlled trial; MDA: mass drug administration; RCT: randomized controlled trial; RR: risk ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect
aDowngraded 2 levels for risk of bias due to several criteria scored as high or unclear risk of bias, including a large unexplained increase in sampled population in the MDA group
at this time point.
bNot downgraded for inconsistency; the comparison presented is reported from a single study.
cNot downgraded for indirectness; all ages are at similar risk of malaria transmission, given the local epidemiology of malaria in this study setting and the outcomes were assessed
by a highly sensitive diagnostic method (ultrasensitive PCR).
dDowngraded 1 level for imprecision due to wide CIs.
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B A C K G R O U N D
Description of the condition
Malaria remains a leading cause of morbidity and mortality, and
was responsible for an estimated 229  million clinical cases and
409,000 deaths in 2019, mostly in children under five years of age
living in sub-Saharan Africa. Malaria is a parasitic disease that is
transmitted to humans by the bite of a female Anopheles species
mosquito. Among the four Plasmodium species of human malaria
(P falciparum, P vivax, P ovale, and P malariae), P falciparum
and P vivax cause the largest number of malaria cases, while
P falciparum  is responsible for a majority of severe and fatal
infections. Without eGective treatment, malaria may manifest with
severe complications and lead to death (WHO 2020a).
Since 2000, the global burden of malaria has been reduced
considerably due to the expansion of eGective malaria control
strategies such as vector control and case management (Bhatt
2015; WHO 2020a). Currently recommended vector control
tools include the use of insecticide-treated bed nets (ITNs),
indoor residual spraying (IRS) with insecticides, and larval
source management. Case management of malaria, which
relies on the prompt diagnosis (parasitological confirmation)
and administration of eGective antimalarial treatment, has
been enhanced by the use of rapid diagnostic tests (RDTs)
and artemisinin-based combination therapy (ACTs). Intermittent
preventive treatment (IPT) with antimalarial drugs in certain high
risk populations, such as pregnant women, children, and infants,
is another key malaria control strategy. However, challenges in
achieving and maintaining high levels of coverage with these
proven interventions, as well as the emergence of insecticide
resistance in mosquitos and antimalarial drug resistance in
parasites, threaten the success of these interventions. Therefore,
additional strategies must be considered to complement existing
tools to accelerate progress towards malaria elimination. Recent
World Malaria Reports from the World Health Organization (WHO)
have noted  a stagnation in reductions of malaria cases (WHO
2020a). This finding underscores the need for continued evaluation
and improved targeting of malaria control and elimination
strategies to identify those activities that will have a positive impact
on malaria transmission.
In the past decade, there has been renewed interest in mass drug
administration (MDA), which was a component of many malaria
elimination programmes during the eradication era in the mid-
twentieth century. MDA has been used widely for controlling
and eliminating the five most highly prevalent neglected tropical
diseases (lymphatic filariasis, onchocerciasis, schistosomiasis, soil-
transmitted helminths, and trachoma) (Hotez 2009). However, the
role of MDA for malaria has been less clear due to the fear of rapid
emergence of antimalarial drug resistance and the varying success
of the intervention in sustaining reductions in malaria burden and
interrupting malaria transmission. A Cochrane Review found MDA
to be eGective in reducing malaria parasitaemia prevalence within
one month following the intervention (Poirot 2013), but results on
sustaining the impact four to six months aLer the intervention were
mixed or the evidence was of low quality. Since the publication
of the previous review, additional studies have been conducted
to assess both the immediate- and longer-term eGects of MDA in
low-transmission and moderate- to high-transmission settings. The
additional evidence provides the opportunity to address gaps in
knowledge surrounding MDA as a strategy to accelerate progress
towards malaria elimination across transmission settings.
Description of the intervention
MDA for malaria consists of administering a full therapeutic course
of antimalarial medicine (irrespective of the presence of symptoms
or infection) to every member of a defined population or every
person living in a defined geographical area (except to those for
whom the medicine is contraindicated) at approximately the same
time and oLen at repeated intervals. MDA for malaria is intended to
reduce or interrupt transmission, curtail morbidity and mortality,
or prevent reoccurrence and resulting malaria transmission (WHO
2015a).
Many early studies of MDA for malaria (dating back to the
1930s) observed a marked decrease in parasite prevalence
following MDA, but oLen MDA did not result in interruption
of transmission. Subsequent studies that evaluated MDA in
conjunction with other malaria control tools, including the Garki
Project conducted in 1969 in Northern Nigeria (Molineaux 1980),
oLen demonstrated substantial decreases in, but not interruption
of, malaria transmission (Greenwood 2004; von Seidlein 2003).
In Nicaragua, MDA was administered to approximately 8 million
people in 1981 and resulted in marked immediate decline in
malaria incidence, but rates eventually reverted back to those
observed prior to MDA (Garfield 1983). Notably, MDA in conjunction
with ITNs on Aneityum Island, Vanuatu in 1991 was an exception,
and interruption of transmission was achieved following eight
rounds of MDA with chloroquine, sulfadoxine-pyrimethamine, and
primaquine (Kaneko 2000 VUT). On another island setting (Anjouan
Island, Comoros), two rounds of MDA, with artemisinin-piperaquine
or artemisinin-piperaquine with single low dose primaquine, were
associated with a rapid 99% decrease in malaria cases (from 7362
before to 47 cases aLer MDA rounds) (Deng 2018 COM). More
recently, the role of MDA to curb malaria morbidity and mortality
in complex emergency settings was highlighted during the Ebola
outbreak in West Africa (Aregawi 2016 SLE; Kuehne 2016).
How the intervention might work
MDA targets the human parasite reservoir through the
administration of a curative antimalarial dose to the entire
population, irrespective of symptoms or parasitaemia. MDA
provides a prophylactic eGect, whereby new infections are
temporarily prevented, and a treatment eGect, in which
parasitaemia is cleared. Unlike case management, in which
symptomatic cases are treated, MDA also targets asymptomatic
malaria infections, that are believed to   contribute to
ongoing malaria transmission (Lindblade 2013). Theoretically, in
combination with high levels of vector control, clearing the human
parasite reservoir could lead to an interruption of transmission
in areas of low endemicity or a temporary decline in malaria
burden in higher transmission settings. However, MDA eGectiveness
may be limited by factors such as antimalarial properties and
operational considerations including population coverage, risk of
re-introduction, and timing.
The Plasmodium parasite life cycle includes stages in humans
(liver and blood) and mosquitoes. In particular, parasitic infections
during the exo-erythrocytic and erythrocytic cycles in humans have
important implications for clinical illness, diagnosis, treatment,
and prevention. Once Plasmodium sporozoites are injected by
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mosquitoes in a human host, parasites invade and multiply in liver
cells, leading to hepatocytic rupture and the release of parasites
into the blood stream. P vivax and P ovale can persist in a dormant
liver stage as hypnozoites, leading to relapsing erythrocytic stage
infections months or years aLer initial infection. During the blood
stage, asexual reproduction of merozoites in red blood cells results
in a cycle of parasite maturation and erythrocytic destruction,
triggering clinical symptoms such as fever, headache, and chills.
Some parasites undergo sexual diGerentiation (gametocytes) in
humans, which subsequently leads to malaria transmission once
the gametocytes are ingested during a mosquito blood meal.
The life cycle of the Plasmodium parasite oGers numerous
vulnerable stages that could be exploited in a MDA strategy
to reduce disease burden and transmission. Most antimalarial
drugs are eGective schizonticides against asexual blood stage
parasites and can eliminate blood stream infections and prevent
illness, and may reduce the overall density of asexual parasites,
leading to a decline in gametocyte density. Artemisinins and
8-aminoquinolines (e.g. primaquine and tafenoquine) have
gametocytocidal properties and act directly on circulating
gametocytes. Primaquine has long been the only available
drug with unique activity against mature gametocytes of P
falciparum and the hypnozoite stage of P vivax and P ovale
species, reducing the possibility of transmission and relapse (WHO
2015b). Tafenoquine, another 8-aminoquinoline, recently received
regulatory approval for the radical cure of P vivax infections in
persons older than 16 years (GlaxoSmithKline 2018). The addition
of ivermectin, or other endectocides, could potentially reduce
malaria transmission by shortening the lifespan of mosquitos,
thus preventing parasite development in the mosquito. Although
ivermectin is not an antimalarial drug, it is oLen used to control
other parasitic infections in malaria-endemic settings and the
eGect of MDA with ivermectin on malaria transmission has been
summarized in a separate Cochrane Review (Chaccour 2010; Tesh
1990; de Souza 2021).
Operationally, high levels of MDA coverage may not be achieved
since a proportion of the population may be excluded from MDA
due to contraindications to antimalarials or health conditions,
absence during treatment rounds, or refusal. Although conducting
multiple rounds of MDA can improve intervention coverage, the
same people are oLen repeatedly excluded from MDA rounds,
which reduces the eGective coverage, or the proportion of the
population receiving at least one round of MDA. High rates of
population movement or migration also pose a challenge by
increasing the risk of re-introduction. Additionally, mathematical
modelling has provided insights into the optimal timing in which
rounds should take place in relation to the malaria transmission
season. Implementation of MDA prior to the rainy season has been
shown to have the greatest eGect, due to widespread parasite
clearance just prior to the high transmission season (Brady 2017;
Okell 2011).
Why it is important to do this review
Despite unprecedented success in malaria control, progress has
stalled in recent years (Alonso 2017). In addition to increased
financial and political commitment, technical and operational
strategies are needed to accelerate progress towards malaria
elimination. Given the variable success of MDA, more recent studies
have been conducted with consideration of transmission setting,
seasonality of malaria, duration of intervention, MDA coverage,
antimalarials with longer prophylactic action, and measurement of
longer-term eGects. Recent mathematical models have suggested
that malaria reduction following MDA is more likely to be sustained
in lower transmission settings compared to higher, in conjunction
with vector control interventions, and when the intervention is
continued over two years compared to one (Brady 2017; Okell
2011). Additionally, there has been recent debate within the malaria
community on the role of MDA in malaria elimination (Eisele 2019;
Mendis 2019).
Currently, the WHO recommends the use of MDA for P falciparum in
areas approaching elimination, for the elimination of P falciparum
in areas of multidrug resistance in the Greater Mekong subregion,
epidemics, and complex emergency settings (WHO 2015a). At
the time the recommendations were released (2015), insuGicient
evidence was available to provide guidance on the use of MDA
for P vivax, or for the use of MDA for P falciparum in areas of
moderate to high transmission. However, use of MDA could be
considered in areas approaching interruption of transmission of P
falciparum with good coverage of vector control, implementation
of surveillance, access to treatment, and minimal risk of re-
introduction of infection. Since the publication of the previous
Cochrane Review (Poirot 2013), and the release of the WHO
guidelines, additional studies have been conducted in both
very low- to low-transmission settings and moderate- to high-
transmission settings, including both P falciparum and P vivax. Due
to renewed interest in MDA as a strategy to accelerate progress
towards malaria elimination, an update to the previous review
to address whether MDA provides sustained impact in very low-
to low-transmission settings and moderate- to high-transmission
settings will provide evidence to evaluate the appropriateness of
existing recommendations, guide future policies, highlight current
knowledge gaps, and direct future research.
O B J E C T I V E S
Primary objectives
To assess the sustained eGect of mass drug administration (MDA)
with antimalarial drugs on:
• the reduction in malaria transmission in moderate- to high-
transmission settings;
• the interruption of transmission in very low- to low-transmission
settings.
Secondary objective
To summarize the risk of drug-associated adverse eGects following
MDA.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered the following study designs.
• Randomized controlled trials (RCTs) with: (a) the unit of
randomization being a cluster, and (b) at least two clusters per
arm.
• Randomized cross-over trials with: (a) the unit of randomization
being a cluster, (b) at least two clusters per arm, and (c) a
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suitable washout period during which the intervention is no
longer applied.
• Quasi-experimental designs, including stepped wedge where
sites are randomly allocated.
• Non-randomized controlled before-and-aLer studies (CBAs)
with: (a) a contemporaneous control group, and (b) at least two
sites per arm.
• Interrupted time series (ITS) studies with: (a) a clearly defined
point in time when the intervention occurred, and (b) at least
three data points collected over one year both before and aLer
MDA.
We excluded studies if we observed any of the following.
• The follow-up periods for the intervention and control periods
were not identical.
• The intervention was applied at the individual level.
• There was no control arm for RCTs or CBAs, or insuGicient pre-
or post-intervention data points for ITS.
Types of participants
Children and adults living in areas of any malaria endemicities
were included and analysed by transmission setting according to
the objectives. Due to the nature of the intervention, we included
only studies that were carried out on entire populations at the
same time. We excluded studies in which chemoprevention was
delivered in the form of individually-timed, intermittent, preventive
treatment in sub-populations (i.e. pregnant women, children or
infants) or seasonal malaria chemoprevention. We did not exclude
studies in special groups (i.e. refugees and soldiers), but none of
these met eligibility criteria.
Types of interventions
Intervention
For the purpose of this review, we defined MDA as the direct
administration of a full therapeutic course of antimalarial medicine
(irrespective of the presence of symptoms or infection) to every
member of a defined population or every person living in a defined
geographical area (except for those for whom the medicine was
contraindicated) at approximately the same time and oLen at
repeated intervals. We included only studies that provided doses of
antimalarials intended for curative purposes.
Control
We included studies in which all other malaria and non-malaria co-
interventions were balanced in all arms. These included the use of
ITNs, IRS, source reduction activities, environmental management,
mass drug campaigns for other neglected tropical diseases, and
mass nutritional supplementation activities such as vitamin A
distribution.
Types of outcome measures
Studies must have reported at least one primary outcome for
inclusion.
Primary outcomes
• Parasitaemia prevalence, as measured by microscopy, malaria
RDT, or molecular method, such as polymerase chain reaction
(PCR).
• Parasitaemia incidence (e.g. incidence of infection through
active surveillance as measured in a cohort).
• Confirmed malaria illness incidence, defined as febrile illness
with diagnostically confirmed parasitaemia (WHO 2015c) (e.g.
incidence of confirmed clinical infection as measured in passive
or routine surveillance data collected at health facilities).
Secondary outcomes
• All-cause and malaria-specific mortality.
• Gametocytaemia prevalence, as measured by microscopy or
molecular method.
• Known adverse eGects related to MDA drugs using WHO
definitions (Edwards 2000).
Search methods for identification of studies
Electronic searches
Search strategy for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, ongoing).
Databases
We searched the following databases on 11 February 2021, using
the search terms and strategy described in Appendix 1.
• Cochrane Infectious Diseases Group Specialized Register
(searched 11 February 2021).
• Cochrane Central Register of Controlled Trials (CENTRAL),
published in the Cochrane Library (Issue 2 of 12, February 2021).
• MEDLINE (PubMed; 1966 to 11 February 2021).
• Embase (Ovid; 1947 to 11 February 2021).
• LILACS (Latin American and Caribbean Health Science
Information database, BIREME; 1982 to 11 February 2021).
We also searched the WHO International Clinical Trials Registry
Platform (ICTRP; www.who.int/ictrp/en/) and ClinicalTrials.gov
(clinicaltrials.gov/ct2/home) for trials in progress, using 'malaria'
and 'mass drug administration' as search terms.
Searching other resources
Reference lists 
We checked the reference lists of all studies and articles identified
by the above methods and of previously published reviews, as well
as references listed in review articles (Greenwood 2004; Newby
2015; Poirot 2013; Shanks 2012; von Seidlein 2003).
Conference proceedings
We searched the following recent proceedings for relevant
abstracts.
• Sixth Multilateral Initiative on Malaria Pan-African Malaria
Conference (Durban, South Africa; October 2013).
• American Society of Tropical Medicine and Hygiene (ASTMH)
62nd Annual Meeting (Washington, DC, USA; November 2013).
• ASTMH 63rd Annual Meeting (New Orleans, LA, USA; November
2014).
• ASTMH 64th Annual Meeting (Philadelphia, PA, USA; October
2015).
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• ASTMH 65th Annual Meeting (Atlanta, GA, USA; November 2016).
• ASTMH 66th Annual Meeting (Baltimore, MD, USA; November
2017).
• ASTMH 67th Annual Meeting (New Orleans, Louisiana, USA;
October 2018).
Researchers and organizations
In addition to the electronic searches described above, we reached
out to the Malaria Elimination Initiative and other relevant groups
to identify both published and unpublished studies that might
be available from other sources. We also contacted the Malaria
Eradication Research Agenda Consortium and the Bill and Melinda
Gates Foundation.
Data collection and analysis
Selection of studies
Two review authors (MPS and MD) independently assessed
the titles and abstracts of trials identified by the literature
searches. We obtained the full-text versions of any potentially
relevant articles identified by at least one of the review authors.
The same two review authors assessed the full-text articles
of potentially relevant studies for inclusion, using an eligibility
form based on predetermined inclusion criteria. We resolved any
disagreements by discussion and consensus, with arbitration by
a third review author (KAL) when necessary. We ensured that
multiple publications of the same trial were included only once.
We listed studies excluded aLer full-text assessment, together
with their reasons for exclusion, in the Characteristics of excluded
studies table. We illustrated the study selection process using a
Preferred Reporting Items of Systematic reviews and Meta-Analyses
(PRISMA) diagram.
Data extraction and management
Two review authors (MPS and MD) independently extracted
information from the trials using pre-piloted electronic data
extraction forms. In case of diGerences in extracted data, the two
review authors discussed these diGerences to reach consensus. If
unresolved, further discussion involved a third review author (KAL).
In case of missing data, we contacted the original study author(s)
for clarification.
We extracted the following data.
• Trial design: type of trial; method of participant selection;
adjustment for clustering (for cRCTs); sample size; method of
blinding of participants and personnel.
• Participants: trial settings (country, transmission season,
endemicity, antimalarial drug resistance context, parasite and
vector species of interest) and population characteristics;
recruitment rates; withdrawal and loss to follow-up.
• Intervention: MDA regimen, coverage, and timing (number
of rounds/campaigns, years of implementation, and timing
relative to transmission season).
• Outcomes: definition of outcome; diagnostic or surveillance
method; number of events; number of participants or person
time; time point at which outcome was assessed in relation to
MDA; statistical power; unit of analysis; incomplete outcomes or
missing data.
For dichotomous data (parasitaemia prevalence and
gametocytaemia prevalence), we extracted the number of
participants experiencing each outcome and the number of
participants in each treatment group. For count data (parasitaemia
incidence, confirmed malaria illness incidence, and mortality),
we extracted the number of events in the treatment and control
groups, and the total person time at risk in each group or the rate
ratio, and a measure of variance (for example, standard error). We
did not extract any continuous data.
For cRCTs, we recorded the number of clusters randomized,
number of clusters analysed, and the intracluster correlation
coeGicient (ICC) value.
For non-randomized studies, there were no studies that reported
adjusted measures of intervention eGects, so we were unable to
obtain an eGect estimate that controlled for confounding.
We included pre-intervention data up to one year prior to the
intervention. We included all post-MDA data, and outcomes were
reported according to designated time points of: less than 1 month,
1 to 3 months, 4 to 6 months, 7 to 12 months, 13 to 18 months, 19
to 24 months, 25 to 30 months, and 31 to 36 months aLer MDA. For
studies with multiple rounds of MDA, we defined 'during MDA' as the
intervention time period - i.e. the time between the start of the first
round and end of the last round of MDA - and the 'post-MDA' follow-
up period as the time following the last round of MDA.
Assessment of risk of bias in included studies
Two review authors (MPS and MD) independently assessed the risk
of bias for each included cluster-RCT using the Cochrane risk of
bias tool and the five additional criteria listed in Section 16.3.2
of the Cochrane Handbook for Systematic Reviews of Interventions
that relate specifically to cluster-RCTs (Higgins 2011a; Higgins
2011b). We assessed non-randomized controlled studies for risk
of bias using the Cochrane EGective Practice and Organisation
of Care (EPOC) risk of bias tool. We resolved any discrepancies
through discussion or by consulting a third review author (KAL). We
classified judgements of risk of bias as either at low, high, or unclear
risk of bias, and we used summary graphs (risk of bias summary and
risk of bias graph) to display results.
Measures of treatment e<ect
We compared intervention and control groups by calculating risk
ratios (RR) or rate ratios for incidence data. We presented all results
with their corresponding 95% confidence intervals (CIs). At all time
periods, a RR less than 1.0 indicates that parasitaemia prevalence
was lower in the MDA compared to control arm, while a RR greater
than 1.0 indicates that parasitaemia prevalence was higher in the
MDA compared to control arm. Similarly, a rate ratio less than 1.0
can be interpreted as a lower rate of malaria infection (incidence) in
the MDA compared to control arm, and a rate ratio greater than 1.0
reflects a higher malaria incidence measured in the MDA compared
to control arm.
For non-randomized studies, since adjusted eGect measures were
not provided, we did not present a measure of treatment eGect.
Instead, we described the eGect of MDA compared to no MDA using
a diGerence-in-diGerences (DiD) analysis in which we calculated
the diGerence in dichotomous outcomes between pre- and during-
MDA time periods, and pre- and post-MDA time periods within
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intervention and control arms and then took the diGerence of those
values between intervention and control groups.
Unit of analysis issues
Since a variety of analytical methods were used to adjust for
clustering in cRCTs, we extracted raw data and estimated eGective
sample sizes adjusted for clustering using either: (1) the study-
provided ICC (as indicated in the Characteristics of included studies
tables), or, (2) for studies that did not report an ICC, an estimated
ICC calculated as the average of other study-provided ICCs in the
same malaria transmission setting (0.02766 for areas of very low
to low transmission, and 0.1225 for areas of moderate to high
transmission). We only presented results from cRCTs that were
adjusted for clustering. No cRCTs included multiple intervention
arms so adjustment for multiple comparison in meta-analysis was
not required (Richardson 2016).
Dealing with missing data
We attempted to contact study investigators to obtain missing data.
We applied no imputation measures for working with missing data.
Assessment of heterogeneity
We inspected forest plots for overlapping CIs and assessed
statistical heterogeneity in each meta-analysis using the I2 statistic
and Chi2 test. We regarded heterogeneity as moderate if the I2
statistic values were between 30% and 60%; substantial if they
were between 50% and 90%; and considerable if they were
between 75% and 100%. We regarded a Chi2 test statistic with a
P value of less than or equal to 0.10 as indicative of statistically
significant heterogeneity. We explored clinical and methodological
heterogeneity through consideration of the trial populations,
methods, and interventions, and by visualization of trial results.
If there was considerable heterogeneity (i.e. an I2 statistic value of
75% to 100%) and inconsistency in the direction of the eGect, then
we did not perform a meta-analysis.
Assessment of reporting biases
Since there were fewer than 10 trials included in each meta-
analysis, we did not investigate reporting biases (such as
publication bias) using funnel plots.
Data synthesis
We analysed data using Review Manager 5 (RevMan 5) (Review
Manager 5). We used a fixed-eGect meta-analysis to combine
data if heterogeneity was absent. We pooled estimates where
considerable heterogeneity was present if the direction of eGect
was consistent.
Malaria endemicity was classified as very low to low (prevalence of
P falciparum or P vivax < 10%), or moderate to high (≥ 10%) (WHO
2017). Study-specific endemicity was defined by baseline malaria
prevalence by microscopy or RDT or annual parasite incidence in
the control group, and preferentially using data from (1) children,
or (2) all ages. If only molecular data were available, we used a tool
developed by Okell 2012 to estimate microscopy prevalence from
PCR data in the control group at baseline.
For the main objective in moderate- to high-transmission settings,
we defined a reduction in malaria transmission as a 50% reduction
in median malaria parasite prevalence or incidence, or both,
at 12 months post-intervention. For the main objective in very
low- to low-transmission settings, we considered interruption of
transmission as a reduction in number of indigenous malaria
infections to zero at six months post-intervention. To evaluate both
objectives, we stratified analyses by study design (i.e. cRCTs and
non-randomized controlled studies) and post-intervention time
periods (i.e. less than 1 month aLer MDA, 1 to 3 months, 4 to 6
months, 7 to 12 months, 13 to 18 months, 19 to 24 months, 25 to
30 months, and 31 to 36 months aLer MDA). For studies with data
from multiple time points within the same post-intervention time
period (Landier 2017 MMRa; Pongvongsa 2018 LAO; Tripura 2018
KHM; von Seidlein 2019 VNM), we used the latest time point for
analysis for that category. We did not stratify studies by number
of MDA rounds due to few studies aLer previous stratification. We
only conducted a meta-analysis if we identified a suGicient number
of studies (> 1) with both an outcome indicator estimate and a
measure of precision.
Subgroup analysis and investigation of heterogeneity
We stratified outcomes by malaria transmission setting (very low-
to low-transmission and moderate- to high-transmission settings)
and Plasmodium species (P falciparum or P vivax). Given the
few number of studies aLer stratification, we did not carry out
subgroup analyses to explore causes of heterogeneity. However, for
a single outcome where studies conducted in sub-Saharan Africa
and Southeast Asia were combined (P falciparum prevalence at one
to three months aLer MDA in very low- to low-endemicity settings),
we carried out a supplementary post-hoc subgroup analysis by
continent (Africa and Asia), to consider whether the geographical
diGerences in malaria epidemiology may explain heterogeneity in
eGect of MDA.
Sensitivity analysis
Due to an insuGicient number of studies, we did not perform
sensitivity analyses on the primary outcomes to assess the eGect
of excluding trials at high risk of bias (for baseline imbalance
and incomplete outcome data) on the overall results. We did not
undertake sensitivity analyses to investigate the impact of varying
the ICC value on meta-analysis results since the ICC values were
obtained directly from studies or applied from comparable studies.
Summary of findings and assessment of the certainty of the
evidence
We assessed the certainty of evidence using the GRADE approach
(Guyatt 2011). We rated each important outcome as described by
Balshem 2011.
• High: we are very confident that the true eGect lies close to that
of the estimate of the eGect.
• Moderate: we are moderately confident in the eGect estimate.
The true eGect is likely to be close to the estimate of the eGect.
• Low: our confidence in the eGect estimate is limited. The true
eGect may be substantially diGerent from the estimate of the
eGect.
• Very low: we have very little confidence in the eGect estimate.
The true eGect is likely to be substantially diGerent from the
estimate of eGect.
RCTs started as high quality evidence but could be downgraded if
there were valid reasons within the following five categories: risk of
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bias, imprecision, inconsistency, indirectness, and publication bias.
We summarized our findings in a summary of findings table.
R E S U L T S
Description of studies
Detailed descriptions of included studies, excluded studies, studies
awaiting classification, and ongoing studies are provided in the
Characteristics of included studies, Characteristics of excluded
studies, Characteristics of studies awaiting classification, and
Characteristics of ongoing studies tables, respectively.
Results of the search
The last published version of this review included 32 studies: two
cRCTs, eight non-randomized trials, and 22 uncontrolled before-
and-aLer studies (Poirot 2013).
Following the revised inclusion criteria, which restricted the
review to more rigorous study designs with a control group and
balanced co-interventions across study arms (described in detail
in DiGerences between protocol and review), the updated literature
search (to 11 February 2021) identified 462 records. ALer de-
duplication and removal of studies excluded by the previous
review's literature search in 2012, we screened 251 titles. Of those,
we assessed 39 full-text articles for study eligibility (Figure 1).
 
Figure 1.   Study flow diagram
 
Included studies
A total of 13 studies met the criteria for inclusion, comprising
five studies included in the previous review (Escudie 1962 BFA;
Molineaux 1980 NGA; Roberts 1964 KEN; Shekalaghe 2011 TZA;
von Seidlein 2003 GMB), and eight new studies (Eisele 2020 ZMBa;
Eisele 2020 ZMBb; Landier 2017 MMRa; McLean 2021 MMR; Morris
2018 TZA; Pongvongsa 2018 LAO; Tripura 2018 KHM; von Seidlein
2019 VNM). Since clusters in the Eisele trial were randomized by
areas of low and high malaria transmission and the outcomes
were stratified by endemicity (specified a priori by design), we
considered this trial as two studies (Eisele 2020  ZMBa; Eisele
2020  ZMBb). Four studies were part of a multi-county trial
conducted in Southeast Asia (Landier 2017 MMRa; Pongvongsa
2018 LAO; Tripura 2018 KHM; von Seidlein 2019 VNM). We analysed
these as separate studies due to diGerences in study design
(diGerences in antimalarial drug used for MDA, timing of MDA in
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relation to the transmission season, and follow-up time periods)
and heterogeneity of eGects.
Cluster-randomized trials
Ten cRCTs were included in the qualitative syntheses: two from
moderate- to high-endemicity areas (high: Eisele 2020 ZMBb; von
Seidlein 2003 GMB), and eight from very low- to low-endemicity
areas (very low: Morris 2018 TZA; Shekalaghe 2011 TZA; Tripura 2018
KHM; von Seidlein 2019 VNM; low: Eisele 2020 ZMBa; Landier 2017
MMRa; McLean 2021 MMR; Pongvongsa 2018 LAO).
Five studies were conducted in sub-Saharan Africa and five
studies were conducted in Southeast Asia. Trial locations in sub-
Saharan Africa were Southern Province, Zambia (Eisele 2020 ZMBa;
Eisele 2020  ZMBb), Unguja Island, Tanzania (Morris 2018 TZA),
Lower Moshi, Tanzania (Shekalaghe 2011 TZA), and Farafenni, The
Gambia (von Seidlein 2003 GMB). Study locations in Southeast
Asia included Kayin (Karen) state, Myanmar (Landier 2017 MMRa),
Southeast Myanmar (McLean 2021 MMR), Savannakhet province,
Laos (Pongvongsa 2018 LAO), Battambang province, Cambodia
(Tripura 2018 KHM), and Binh Phuoc and Ninh Thuan provinces,
Vietnam (von Seidlein 2019 VNM).
One cRCT conducted in an area of very low malaria transmission
of Tanzania reported zero events at both baseline and follow-
up time points for several outcomes and was excluded from
quantitative syntheses (Shekalaghe 2011 TZA). The nine remaining
cRCTs provided data for comparison of MDA versus no MDA in this
review: three studies compared MDA to placebo or no MDA (McLean
2021 MMR; Morris 2018 TZA; von Seidlein 2003 GMB), four studies
compared MDA to delayed MDA (Landier 2017 MMRa; Pongvongsa
2018 LAO; Tripura 2018 KHM; von Seidlein 2019 VNM), while two
studies (Eisele 2020 ZMBa; Eisele 2020 ZMBb) compared MDA and
focal MDA (household-level MDA where a member tested positive
by RDT) separately to no MDA and we included only the MDA arm
for comparison.
Interventions
Characteristics of the intervention have been summarized in Table
1.
Moderate- to high-transmission areas
One study administered four rounds of MDA with
dihydroartemisinin piperaquine (DHAp) to all persons older than
three months, except for pregnant women in the first trimester
(Eisele 2020 ZMBb). The four MDA rounds occurred at the start of the
rainy season, during the rainy season, during the dry season, and
again at the start of the rainy season. MDA coverage was 88.1% in
round one and 72.0% in round two. Both study arms received LLINs
and IRS with Actellic (an insecticide) at baseline before MDA. The
second trial administered a single round of MDA with sulfadoxine-
pyrimethamine plus artesunate at the start of the rainy season to all
persons six months of age or older, except for pregnant women (von
Seidlein 2003 GMB). MDA coverage among the target population
was 89% and no co-interventions were provided.
Very low- to low-transmission areas
Seven studies administered multiple rounds of MDA with
dihydroartemisinin piperaquine (Eisele 2020  ZMBa; Landier 2017
MMRa; McLean 2021 MMR; Morris 2018 TZA; Pongvongsa 2018 LAO;
Tripura 2018 KHM; von Seidlein 2019 VNM). Five of these studies
also added a single dose of primaquine at each round (Landier
2017 MMRa; McLean 2021 MMR; Morris 2018 TZA; Pongvongsa 2018
LAO; von Seidlein 2019 VNM). The interval between rounds varied
across studies. In  Eisele 2020  ZMBa, MDA was administered at
the start of the rainy season, during the rainy season, during the
dry season, and at the start of the rainy season. In McLean 2021
MMR, three rounds of MDA were administered one month apart
during the dry season. The two rounds of MDA in  Morris 2018
TZA  were administered two months apart. The three rounds of
MDA in Landier 2017 MMRa and Pongvongsa 2018 LAO, conducted
one month apart, were administered at the start and during
rainy season. Three rounds of MDA in  Tripura 2018 KHM  were
administered during rainy season, while three rounds of MDA took
place at the end of the transmission season in von Seidlein 2019
VNM.
Most studies administering MDA with dihydroartemisinin
piperaquine excluded pregnant women in their first trimester,
with the exception of  Tripura 2018 KHM, which excluded all
pregnant women from MDA. Studies administering a single dose
of primaquine excluded all pregnant women from primaquine.
ALer these exclusions, MDA was administered to all persons three
months of age and older (Eisele 2020  ZMBa), six months of age
and older (Landier 2017 MMRa; Morris 2018 TZA; Pongvongsa 2018
LAO; Tripura 2018 KHM; von Seidlein 2019 VNM), or 12 months
of age and older (McLean 2021 MMR). MDA coverage ranged from
66% to 95% in the first round and was generally lower (56% to
99%) in subsequent rounds for all studies except  von Seidlein
2019 VNM, in which coverage increased in subsequent rounds.
All studies provided ITNs to all study arms. In addition,  Eisele
2020  ZMBa  and  Morris 2018 TZA  included a single round of IRS
at baseline;  Landier 2017 MMRa,  Pongvongsa 2018 LAO,  Tripura
2018 KHM, and  von Seidlein 2019 VNM  provided uninterrupted
access to case management in study villages; and  Shekalaghe
2011 TZA included a single treatment campaign for trachoma with
azithromycin.
One study administered a single round of sulfadoxine-
pyrimethamine plus artesunate with a single dose of primaquine
three to five weeks prior to the start of the rainy season (Shekalaghe
2011 TZA). All persons older than 12 months received MDA.
However, pregnant women or individuals who were anaemic did
not receive primaquine.
Outcomes
Outcome data are summarized in Table 2.
Moderate- to high-transmission areas
All outcomes reported were for P falciparum. In Eisele 2020 ZMBb,
parasitaemia prevalence was measured by RDT prior to MDA, during
MDA (following the first two rounds), and one to three months
aLer MDA. In von Seidlein 2003 GMB, parasitaemia prevalence was
measured by microscopy prior to MDA and four to six months
aLer MDA. Both studies also reported parasitaemia incidence, but
measured the outcome diGerently.  Eisele 2020  ZMBb  measured
parasitaemia incidence by RDT through active surveillance in a
cohort of persons three months of age and older, for two months
following the fourth round of MDA. In  von Seidlein 2003 GMB,
parasitaemia incidence was captured through weekly surveillance
in children under 11 years for cases with temperatures of 37.5 °C
and higher, and P falciparum parasitaemia above 5000 parasites
per µL by microscopy for five months following MDA.  Eisele
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2020  ZMBb  reported confirmed malaria illness incidence prior
to MDA and one to three months aLer MDA. Only  von Seidlein
2003 GMB  reported the secondary outcomes of gametocytaemia
prevalence (pre-MDA and four to six months aLer MDA) and malaria-
specific mortality. Both studies monitored adverse eGects in the
MDA study arm.
Very low- to low-transmission areas
All studies reported P falciparum parasitaemia prevalence, but the
measurement of outcomes diGered across studies with respect
to follow-up time points, population sampled, and detection
method.  Eisele 2020  ZMBa,  Landier 2017 MMRa,  McLean 2021
MMR, Pongvongsa 2018 LAO, Tripura 2018 KHM, and von Seidlein
2019 VNM  reported prevalence at baseline before MDA. The
timing of the first prevalence measure reported by  Morris 2018
TZA started and extended past the first round of MDA and, therefore,
was classified as during MDA.  Eisele 2020  ZMBa  also reported
parasitaemia prevalence during MDA following the first two MDA
rounds. All studies reported the outcome at one to three months
aLer MDA. Four studies reported prevalence at four to six months
aLer MDA (Landier 2017 MMRa; Pongvongsa 2018 LAO; Tripura 2018
KHM; von Seidlein 2019 VNM). Five studies provided prevalence at
7 to 12 months aLer MDA (Landier 2017 MMRa; McLean 2021 MMR;
Pongvongsa 2018 LAO; Tripura 2018 KHM; von Seidlein 2019 VNM).
Additionally,  McLean 2021 MMR  reported outcomes at 13 to 18
months aLer MDA and at all additional follow-up intervals through
to 31 to 36 months aLer MDA.
Eisele 2020  ZMBa  measured parasitaemia prevalence by RDT in
children aged 5 years and older. Five studies evaluated the outcome
by ultrasensitive PCR (uPCR) in either adults aged 18 to 55 years
(McLean 2021 MMR), or persons six months of age and older
(Landier 2017 MMRa; Pongvongsa 2018 LAO; Tripura 2018 KHM;
von Seidlein 2019 VNM). Morris 2018 TZA measured prevalence by
18s-quantitative PCR (qPCR) in persons of all ages. P falciparum
parasitaemia incidence was only reported in Eisele 2020 ZMBa and
measured by RDT through active surveillance in a cohort of persons
three months of age and older, for two months following MDA.
Confirmed malaria illness incidence was reported prior to MDA and
at: one to three months aLer MDA in Eisele 2020 ZMBa, Morris 2018
TZA, and Tripura 2018 KHM; four to six months aLer MDA in Morris
2018 TZA; 7 to 12 months aLer MDA in Landier 2017 MMRa, Morris
2018 TZA, and Tripura 2018 KHM; and 13 to 18 months aLer MDA
only in Morris 2018 TZA. All studies monitored adverse eGects.
Shekalaghe 2011 TZA  reported parasitaemia prevalence by
microscopy and quantitative nucleic acid sequence-based
amplification   (QT-NASBA), confirmed malaria illness incidence,
and gametocytaemia prevalence by microscopy in all ages prior to
and aLer MDA up to four months, but these data were omitted from
quantitative synthesis at all time points due to either zero events
pre-MDA (outcomes by microscopy) or unclear timing of post-MDA
events (outcomes by QT-NASBA).
P vivax parasitaemia prevalence was reported by  Landier 2017
MMRa,  McLean 2021 MMR,  Pongvongsa 2018 LAO,  Tripura 2018
KHM, and  von Seidlein 2019 VNM, and included the same pre-
MDA and post-MDA follow-up time points, detection method,
and population sampled as P falciparum parasitaemia. Confirmed
malaria illness incidence for P vivax was reported prior to MDA
in Tripura 2018 KHM, and at 7 to 12 months aLer MDA in Landier
2017 MMRa; and Tripura 2018 KHM.
Non-randomized controlled studies
We included three CBA studies in qualitative syntheses. All
studies were conducted in areas of moderate to high endemicity
(moderate: Roberts 1964 KEN; high: Escudie 1962 BFA; Molineaux
1980 NGA). All studies were conducted in sub-Saharan Africa in the
countries of Burkina Faso (Escudie 1962 BFA), Kenya (Roberts 1964
KEN), and Nigeria (Molineaux 1980 NGA).
Escudie 1962 BFA included six arms (chloroquine plus primaquine
or amodiaquine plus primaquine every four weeks; chloroquine
plus primaquine or amodiaquine plus primaquine every two
weeks; chloroquine plus primaquine or amodiaquine plus
primaquine every four weeks with IRS; chloroquine plus
primaquine or amodiaquine plus primaquine every two weeks
with IRS; IRS only; non-IRS control). Of these six arms, three arms
with two comparisons contributed to this review: chloroquine plus
primaquine or amodiaquine plus primaquine every four weeks
('low frequency'); chloroquine plus primaquine or amodiaquine
plus primaquine every two weeks ('high frequency'); and non-
IRS control. Given similar mechanisms of antimalarial action for
chloroquine and amodiaquine, and the combined reporting of
outcomes at post-MDA time points, these drugs were not analysed
as separate groups within the six arms described. Of the four arms
included in Molineaux 1980 NGA (low frequency MDA plus IRS, high
frequency MDA plus IRS, IRS only, and no intervention), we included
three arms with two comparisons in this review: low frequency MDA
plus IRS, high frequency MDA plus IRS, and IRS only). Roberts 1964
KEN compared MDA to no MDA and all data provided comparisons
for this review.
Interventions
Characteristics of the intervention have been summarized in Table
1.
All studies administered multiple rounds of MDA using diGerent
antimalarials and at diGerent frequencies of MDA rounds. Escudie
1962 BFA administered MDA with a single dose of chloroquine plus
primaquine or amodiaquine plus primaquine every four weeks
for seven rounds, or every two weeks for 15 rounds to the entire
population (all ages). MDA coverage ranged from 75% to 91% per
round in the four-week low frequency MDA arm and 84% to 97% per
round in the two-week high frequency MDA arm. Molineaux 1980
NGA administered MDA with sulfalene-pyrimethamine either every
10 weeks ('low frequency MDA') or every 2 weeks during the wet
season and every 10 weeks during the dry season ('high frequency
MDA') to all ages except infants prior to their first malaria episode.
MDA coverage was similar across arms, ranging from 73% to 92%
per round in the low frequency MDA arm and 72% to 91% in the high
frequency MDA arm. In Roberts 1964 KEN, two rounds of MDA with
pyrimethamine were administered once a year (at the start of the
rainy season) to all ages with coverage of 95% in round one and 93%
in round two.
Molineaux 1980 NGA administered IRS using propoxur for three to
four rounds per year in all arms, but there were no co-interventions
in the other two studies.
Outcomes
Outcome data are summarized in Table 2.
All outcomes reported were for P falciparum. All studies reported
parasitaemia prevalence by microscopy at pre-MDA and during-
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MDA time points, but outcomes were assessed for diGerent lengths
of post-MDA follow-up and in diGerent age groups.  Molineaux
1980 NGA provided no post-MDA data, Escudie 1962 BFA reported
parasitaemia prevalence at one to three months aLer MDA,
and  Roberts 1964 KEN  provided parasitaemia prevalence at
time points up to 7 to 12 months aLer MDA. Two studies
assessed parasitaemia prevalence in all age groups (Molineaux
1980 NGA; Roberts 1964 KEN), and  Escudie 1962 BFA  assessed
parasitaemia prevalence only in children aged two to nine years.
Gametocytaemia prevalence was reported by Escudie 1962 BFA in
children aged two to nine years prior to MDA, during MDA, and
one to three months aLer MDA, and by Molineaux 1980 NGA in all
ages, prior to MDA and during MDA (no post-MDA time points). No
other outcomes, including adverse eGects, were reported by these
studies.
Excluded studies
We excluded 25 articles for the following reasons: 13  were
duplicates (cross-referenced articles of another study); 10 failed to
meet the study design inclusion criteria; and two were the incorrect
intervention or inadequate treatment dose. We have provided
detailed reasons in the Characteristics of excluded studies.
Two additional excluded  studies were unpublished trials that
are awaiting classification (Characteristics of studies awaiting
classification). We made several attempts to contact Song TGO, but
did not receive a response. We were unable to obtain suGicient
information from authors of El-Sayed SDN to assess the trial for
eligibility. However, we plan to screen the study should the authors
publish the results.
Risk of bias in included studies
Our summary assessment for risks of bias are shown in Figure
2 and Figure 3, and details are provided for each study in the
Characteristics of included studies tables.
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Eisele 2020 ZMBa + + + + ? + ? ? + ? + ? + + + + + + +
Eisele 2020 ZMBb + + + + ? + ? ? + ? + ? + + + + + + +
Escudie 1962 BFA - - ? ? ? - + + +
Landier 2017 MMRa + + - - ? ? + ? + + + + + + + +
McLean 2021 MMR - + + - ? + - + + + + + +
Molineaux 1980 NGA - - ? + ? + + + + +
Morris 2018 TZA + + - ? ? ? + ? + + + + + + + +
Pongvongsa 2018 LAO + + - - ? + + + + + + + +
Roberts 1964 KEN - - - - ? ? + + +
Shekalaghe 2011 TZA + + + + + + + + + + + + + + + +
Tripura 2018 KHM + + - - ? ? + ? + + + + + + + +
von Seidlein 2003 GMB + + + + + + + + + - + + + + + +
von Seidlein 2019 VNM + + + - ? + + + + + + + +
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Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies
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Allocation
We assessed nine studies as low risk of bias for random sequence
generation due to the use of a computerized randomization
algorithm (Eisele 2020  ZMBa; Eisele 2020  ZMBb; Landier 2017
MMRa; Morris 2018 TZA; Pongvongsa 2018 LAO; Shekalaghe 2011
TZA; Tripura 2018 KHM; von Seidlein 2003 GMB; von Seidlein 2019
VNM). We assessed the remaining four studies as high risk of
bias, due to lack of randomization (Escudie 1962 BFA; Molineaux
1980 NGA; Roberts 1964 KEN), or the use of a non-computerized
randomization method (McLean 2021 MMR). We judged all 10 cRCTs
to be at low risk for bias related to allocation concealment since
allocation was performed by an institution, and all non-randomized
studies to be at high risk of bias for allocation concealment.
Blinding
Parasitaemia prevalence
We assessed two placebo-controlled studies as low risk for
performance bias since participants and study staG were blinded
(Shekalaghe 2011 TZA; von Seidlein 2003 GMB). We judged all other
studies, which included non-MDA control groups, as unclear risk for
performance bias since participants were not blinded and it was
unclear whether or how this could aGect this outcome.
Outcome assessment by laboratory staG was blinded to study arm
in nine studies, and we judged these as low risk (Landier 2017
MMRa; McLean 2021 MMR; Molineaux 1980 NGA; Morris 2018 TZA;
Pongvongsa 2018 LAO; Shekalaghe 2011 TZA; Tripura 2018 KHM;
von Seidlein 2003 GMB; von Seidlein 2019 VNM). Three studies did
not describe blinding of laboratory staG, and we judged these as
unclear risk of detection bias (Eisele 2020 ZMBa; Eisele 2020 ZMBb;
Roberts 1964 KEN). Outcome assessment in one study was clearly
unblinded, and we considered this study as high risk of detection
bias (Escudie 1962 BFA).
Parasitaemia incidence
We judged all three studies reporting parasitaemia incidence as low
risk of both performance and detection bias since this outcome
was evaluated through active surveillance, so lack of blinding of
participants and study staG was presumed to minimally aGect the
outcome (Eisele 2020  ZMBa; Eisele 2020  ZMBb), or the trial was
placebo-controlled (von Seidlein 2003 GMB).
Confirmed malaria illness incidence
We judged one placebo-controlled trial as having low risk of
performance and detection bias due to blinding of participants,
study staG, and outcome assessment (Shekalaghe 2011 TZA). We
judged five studies as having unclear risk since it was unclear
how lack of blinding would aGect care-seeking behaviours by
participants, or outcome assessment (Eisele 2020  ZMBa; Eisele




We judged one trial that reported large variations in the size of
the population evaluated for parasitaemia prevalence outcomes
at diGerent time points as having high risk of bias since, based
on the described methodology, the population evaluated should
have remained consistent (McLean 2021 MMR). The remaining eight
studies had a low risk of attrition bias.
Parasitaemia incidence
We judged one study as high risk of bias due to a large proportion
of missed malaria infections (particularly, afebrile or low parasite
density malaria infections) due to outcome definitions (von
Seidlein 2003 GMB). We judged two studies as unclear risk of bias
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since loss to follow-up was not provided by baseline endemicity
strata (Eisele 2020 ZMBa, Eisele 2020 ZMBb).
Confirmed malaria illness incidence
We judged all six studies reporting this outcome as having low risk
of bias (Eisele 2020 ZMBa; Eisele 2020 ZMBb; Landier 2017 MMRa;
Morris 2018 TZA; Tripura 2018 KHM; Shekalaghe 2011 TZA).
Selective reporting
All studies reported the outcomes that were pre-specified and were
judged as having low risk of reporting bias.
Other potential sources of bias
No cRCTs were judged to have a high or unclear risk of bias from
recruitment, loss of clusters, incorrect analyses, or comparability
with individually randomized trials. All studies were judged to be at
low risk for other biases.
Baseline imbalance
We judged five studies to have high risk of bias due to unbalanced
baseline malaria prevalence in intervention and control arms
(Landier 2017 MMRa; Morris 2018 TZA; Pongvongsa 2018 LAO;
Roberts 1964 KEN; Tripura 2018 KHM). Two studies did not
report baseline demographic characteristics (other risk factors
for malaria), and we judged these to have unclear risk of bias
(Escudie 1962 BFA; Molineaux 1980 NGA). The remaining studies
were balanced for malaria and demographic characteristics across
arms at baseline.
Contamination protection
The study arms for six studies were either paired by geographic
proximity or located in close geographic proximity with a high
potential for population movement. We judged these studies as
having a high risk of contamination bias (Landier 2017 MMRa;
McLean 2021 MMR; Pongvongsa 2018 LAO; Roberts 1964 KEN;
Tripura 2018 KHM; von Seidlein 2019 VNM). Two studies did
not describe methods for contamination protection, and we
judged these as unclear risk (Escudie 1962 BFA; Morris 2018 TZA).
The remaining four studies included buGer zones to minimize
contamination of outcome assessment, and we judged these as low
risk (Eisele 2020 ZMBa; Eisele 2020 ZMBb; Shekalaghe 2011 TZA; von
Seidlein 2003 GMB).
E<ects of interventions
See: Summary of findings 1 MDA compared to no MDA for
Plasmodium falciparum malaria (moderate to high endemicity,
short-term follow-up); Summary of findings 2 MDA compared
to no MDA for Plasmodium falciparum malaria (very low to low
endemicity, short-term follow-up); Summary of findings 3 MDA
compared to no MDA for Plasmodium falciparum malaria (very low
to low endemicity, long-term follow-up); Summary of findings 4
MDA compared to no MDA for P vivax malaria (very low to low
endemicity, short-term follow-up); Summary of findings 5 MDA
compared to no MDA for P vivax malaria (very low to low endemicity,
long-term follow-up)
Cluster-randomized trials
Moderate- to high-transmission areas
E<ects reported on P falciparum outcomes
At one to three months aKer MDA
Eisele 2020 ZMBb found a non-significant increase in P falciparum
parasitaemia prevalence (RR 1.76, 95% CI 0.58 to 5.36; 1
study;  Analysis 1.1), a significant reduction in parasitaemia
incidence by 39% (rate ratio 0.61, 95% CI 0.40 to 0.92; 1
study; Analysis 1.2), and a non-significant reduction in confirmed
malaria illness incidence by 59% (RR 0.41, 95% CI 0.04 to 4.51; 1
study; Analysis 1.3) in MDA compared to non-MDA clusters at one to
three months aLer MDA.
At four to six months aKer MDA
As reported by von Seidlein 2003 GMB, at four to six months aLer
MDA, MDA did not reduce P falciparum parasitaemia prevalence (RR
1.18, 95% CI 0.89 to 1.56; 1 study; Analysis 1.1), and also did not
reduce the secondary outcomes of P falciparum gametocytaemia
prevalence (RR 1.13, 95% CI 0.20 to 6.54; 1 study;  Analysis 1.4),
and malaria-specific mortality (RR 1.42, 95% CI 0.12 to 17.15; 1
study; Analysis 1.5).
Very low- to low-transmission areas
E<ects reported on P falciparum outcomes
At less than one month aKer MDA
McLean 2021 MMR  reported that MDA reduced P falciparum
parasitaemia prevalence by 88% immediately (less than one
month) aLer MDA (RR 0.12, 95% CI 0.03 to 0.52; 1 study; Analysis
2.1).
At one to three months aKer MDA
Based on results from seven studies, MDA significantly reduced P
falciparum parasitaemia prevalence by 75% one to three months
aLer MDA (RR 0.25, 95% 0.15 to 0.41; 7 studies; Analysis 2.1). The
largest reduction was observed by Landier 2017 MMRa in Myanmar
(RR 0.06, 95% CI 0.01 to 0.45; 1 study;  Analysis 2.1), while the
opposite eGect was found by Morris 2018 TZA in Zanzibar (RR 1.34,
95% CI 0.30 to 5.92; Analysis 2.1). Although the I2 value(31%) did
not indicate inconsistency in the results, we explored diGerences in
malaria epidemiology by continent as a cause of heterogeneity in
this eGect. When the eGects were sub-grouped by continent (Africa
and Asia) in post-hoc analysis (Analysis 4.1), there was no eGect
of MDA in two studies in sub-Saharan Africa (pooled RR 0.97, 95%
CI 0.32 to 2.98;  Eisele 2020  ZMBa; Morris 2018 TZA), but a larger
reduction in the five studies in Southeast Asia (RR 0.19, 95% CI 0.11
to 0.33; Landier 2017 MMRa; McLean 2021 MMR; Pongvongsa 2018
LAO; Tripura 2018 KHM; von Seidlein 2019 VNM).
Eisele 2020  ZMBa  measured the eGect of MDA compared to no
MDA on P falciparum parasitaemia incidence in very low- to
low-endemicity areas, and found a statistically significant 63%
reduction one to three months aLer MDA (rate ratio 0.37, 95% CI
0.21 to 0.66; 1 study; Analysis 2.2).
MDA also reduced confirmed malaria illness incidence (rate ratio
0.58, 95% CI 0.12 to 2.73, 2 studies; Analysis 2.3). However, the eGect
was imprecise and not statistically significant.
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At four to six months aKer MDA
Based on findings from four studies in Southeast Asia, at four to
six months aLer MDA, there was a non-significant reduction in
P falciparum parasitaemia prevalence by 37% (RR 0.63, 95% CI
0.36 to 1.12; 4 studies; Analysis 2.1) in MDA compared to non-MDA
clusters. EGects across studies included few malaria cases and were
therefore very imprecise. The strongest reduction was observed
by Pongvongsa 2018 LAO in Laos (RR 0.07, 95% CI 0 to 1.31; Analysis
2.1), while the weakest eGect was found by Landier 2017 MMRa in
Myanmar (RR 0.89, 95% CI 0.27 to 2.95; Analysis 2.1).
There was no eGect of MDA on confirmed malaria illness incidence
four to six months aLer MDA as reported by a single study, Morris
2018 TZA (rate ratio 0.93, 95% CI 0.07 to 12.43; Analysis 2.3).
At 7 to 12 months aKer MDA
At 7 to 12 months aLer MDA, there was a small but non-significant
reduction in P falciparum parasitaemia prevalence (RR 0.86, 95%
CI 0.55 to 1.36; 5 studies; Analysis 2.1) in MDA compared to non-
MDA clusters. Due to few malaria cases, the eGect estimates across
studies were very imprecise. Additionally, the direction of eGect
was inconsistent across studies, with two studies showing a non-
significant increase in P falciparum parasitaemia prevalence in
the MDA compared to no-MDA arm (Landier 2017 MMRa; von
Seidlein 2019 VNM), while three studies found that MDA reduced
parasitaemia prevalence (McLean 2021 MMR; Pongvongsa 2018
LAO; Tripura 2018 KHM).
MDA reduced confirmed malaria illness incidence 7 to 12 months
aLer MDA (rate ratio 0.47, 95% CI 0.21 to 1.03; 3 studies; Analysis
2.3). However, the eGect was not statistically significant and there
was substantial heterogeneity (I2=72%, Analysis 2.3).
At longer time periods (> 12 months) aKer MDA
At 13 to 18 months aLer MDA, MDA did not significantly reduce P
falciparum parasitaemia prevalence in McLean 2021 MMR (RR 0.82,
95% CI 0.20 to 3.34; 1 study;  Analysis 2.1) or confirmed malaria
illness incidence in Morris 2018 TZA (rate ratio 0.77, 95% CI 0.2 to
3.03; 1 study; Analysis 2.3). McLean 2021 MMR reported no eGect on
parasitaemia prevalence at 19 to 24 months, 25 to 30 months and
31 to 36 months aLer MDA (Analysis 2.1).
E<ects reported on P vivax outcomes
At less than one month aKer MDA
McLean 2021 MMR showed that MDA had an immediate and large
reduction on P vivax parasitaemia prevalence at less than one
month aLer MDA (RR 0.18, 95% CI 0.08-0.40; 1 study; Analysis 3.1).
At one to three months aKer MDA
Although there was considerable heterogeneity across five studies
(I2 = 84%) in the eGect of MDA on P vivax parasitaemia prevalence
one to three months aLer MDA, we meta-analysed the results
since the direction of eGect was consistent and all reported eGect
estimates were very imprecise due to a small number of malaria
events. At one to three months aLer MDA, MDA significantly reduced
P vivax parasitaemia prevalence by 85% (RR 0.15, 95% CI 0.10 to
0.24; 5 studies; Analysis 3.1).
At four to six months aKer MDA
MDA significantly reduced P vivax parasitaemia prevalence by 22%
at four to six months aLer MDA (RR 0.78, 95% CI 0.63 to 0.95; 4
studies; Analysis 3.1).
At 7 to 12 months aKer MDA
At 7 to 12 months aLer MDA, MDA did not reduce P vivax
parasitaemia prevalence (RR 1.12, 95% CI 0.94 to 1.34; 5
studies;  Analysis 3.1). There was a non-significant increase in
confirmed malaria illness incidence (pooled rate ratio 1.38, 95% CI
0.97 to 1.95; 2 studies; Analysis 3.2) in MDA compared to non-MDA
clusters.
At longer time periods (> 12 months) aKer MDA
McLean 2021 MMR reported that MDA did not reduce parasitaemia
prevalence at 13 to 18 months, 19 to 24 months, 25 to 30 months,
and 31 to 36 months aLer MDA (Analysis 3.1).
Adverse e&ects
Adverse eGects (AEs) of MDA were reported by all ten cRCTs
included in qualitative synthesis (Eisele 2020  ZMBa; Eisele
2020 ZMBb; Landier 2017 MMRa; McLean 2021 MMR; Morris 2018
TZA; Pongvongsa 2018 LAO; Shekalaghe 2011 TZA; Tripura 2018
KHM; von Seidlein 2003 GMB; von Seidlein 2019 VNM). We have
provided details by study in the  Characteristics of included
studies  tables.  McLean 2021 MMR  reported AEs by relatedness
to MDA drug, but did not provide diagnoses of AEs.  Eisele
2020 ZMBa and Eisele 2020 ZMBb reported AEs by MDA and fMDA
arms combined and in aggregate across low- and high-transmission
strata clusters.
Two studies reported one serious AE with MDA using
dihydroartemisinin piperaquine (Eisele 2020  ZMBa  or  Eisele
2020  ZMBb), or dihydroartemisinin piperaquine plus primaquine
(McLean 2021 MMR). One study reported that 0.5% of all AEs
reported aLer MDA with dihydroartemisinin piperaquine plus
primaquine were perceived as serious by participants (Morris 2018
TZA). Two studies administering dihydroartemisinin piperaquine
plus primaquine reported multiple serious AEs that were not drug-
related (Landier 2017 MMRa; von Seidlein 2019 VNM). Landier 2017
MMRa also reported three cases of black urine. One study reported a
possibly drug-related severe skin reaction following administration
of MDA using sulfadoxine-pyrimethamine plus artesunate with
primaquine (Shekalaghe 2011 TZA).
Four studies indicated stomach pains or diarrhoea and
vomiting as commonly reported AEs to MDA with
dihydroartemisinin piperaquine (Eisele 2020  ZMBa; Eisele
2020  ZMBb), dihydroartemisinin piperaquine plus primaquine
(Morris 2018 TZA, Pongvongsa 2018 LAO, von Seidlein 2019 VNM),
and sulfadoxine-pyrimethamine plus artesunate (von Seidlein 2003
GMB). Dizziness and fever were mentioned as minor AEs to MDA
with dihydroartemisinin piperaquine (Morris 2018 TZA,  Tripura
2018 KHM) and sulfadoxine-pyrimethamine plus artesunate (von
Seidlein 2003 GMB). Dizziness was also a common AE in two studies
with MDA using dihydroartemisinin piperaquine plus primaquine
(Landier 2017 MMRa,  Pongvongsa 2018 LAO). Three studies also
indicated complaints of nausea, headache, and fatigue in relation
to MDA with dihydroartemisinin piperaquine plus primaquine
(Morris 2018 TZA,  von Seidlein 2019 VNM), or dihydroartemisinin
piperaquine alone (Tripura 2018 KHM). Pruritis or itching were
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reported by studies administering dihydroartemisinin piperaquine
plus primaquine (Landier 2017 MMRa; Pongvongsa 2018 LAO) and
a study administering MDA with sulfadoxine-pyrimethamine plus
amodiaquine (von Seidlein 2003 GMB). Common cold or dry cough
was reported as a common minor AE in two studies using MDA
with dihydroartemisinin piperaquine (Eisele 2020  ZMBa; Eisele
2020  ZMBb), or MDA with dihydroartemisinin piperaquine plus
primaquine (Pongvongsa 2018 LAO).
Among the four studies that reported the distribution of AEs
(as either percentage of participants or percentage of doses
with an AE), the frequency of at least one AE report was
highest in MDA with sulfadoxine-pyrimethamine plus amodiaquine
(33% of participants,  von Seidlein 2003 GMB), and lower
in MDA with dihydroartemisinin piperaquine (0.24% (Eisele
2020  ZMBa  or  Eisele 2020  ZMBb) to 11.6% (Morris 2018 TZA) of
participants) or dihydroartemisinin piperaquine plus primaquine
(3.6% of participants in McLean 2021 MMR).
Non-randomized studies
P falciparum parasitaemia prevalence
In the three non-randomized trials, we summarized changes in
parasitaemia prevalence from baseline to during-MDA or post-MDA,
in MDA compared to no-MDA groups, using a DiD analysis (Table 3).
MDA appeared to reduce parasitaemia prevalence in all studies
during MDA compared to pre-MDA, with a wide range of DiD
percentage point reductions from -15.8 (Roberts 1964 KEN), to
-61.4 (Escudie 1962 BFA). The smallest reduction was observed
in  Roberts 1964 KEN, in which two rounds of MDA using
pyrimethamine were administered one year apart and, therefore,
the during-MDA time period included multiple surveys between
the two rounds. Similar percentage point reductions from baseline
were observed between both the low-frequency MDA plus IRS
(-23.2 percentage  points) and high frequency MDA plus IRS
(-20.9 percentage  points) compared to the control (IRS only)
group in  Molineaux 1980 NGA  during the period that MDA was
administered with sulfalene-pyrimethamine. In Escudie 1962 BFA,
there was a substantially greater DiD reduction in parasitaemia
prevalence in the low-frequency MDA group (amodiaquine plus
primaquine or chloroquine plus primaquine every four weeks, -61.4
percentage  points) compared to the high-frequency MDA group
(amodiaquine plus primaquine or chloroquine plus primaquine
every two weeks; -36.3 percentage points) at during-MDA compared
to pre-MDA time periods.
At one to three months aLer MDA, parasitaemia prevalence was
reduced in the low-frequency MDA arm of  Escudie 1962 BFA  by
-42.1 percentage points, but there was an increase in parasitaemia
prevalence in the high-frequency MDA arm compared to control,
as reflected by a +14.9 percentage point DiD. There was an initial
reduction in parasitaemia prevalence (-28.1 percentage  points)
found in Roberts 1964 KEN at one to three months aLer MDA, which
decreased over time to -22.8 percentage points at four to six months
aLer MDA, and to -11.3 percentage points at 7 to 12 months aLer
MDA. Given the introduction of new interventions in  Molineaux
1980 NGA immediately following MDA, there were no post-MDA data
available.
P falciparum gametocytaemia prevalence
In the two non-randomized trials reporting gametocytaemia
prevalence, we summarized changes in the eGect of MDA from
baseline to during-MDA or post-MDA using DiD analysis (Table 4).
From pre-MDA to during-MDA, with the exception of the low-
frequency MDA arm in  Escudie 1962 BFA, there was a small
DiD reduction on gametocytaemia prevalence, ranging from -1
percentage point (Escudie 1962 BFA high-frequency MDA) to -5.0
percentage  points in both arms of  Molineaux 1980 NGA. A large
reduction from pre-MDA (-14.1 percentage  points) was observed
in the low-frequency MDA arm of  Escudie 1962 BFA during MDA.
However, compared to the pre-MDA period, gametocytaemia
prevalence at one to three months aLer MDA was increased in
both the low-frequency MDA arm (18.3 percentage  points) and
high-frequency MDA arm (53.4 percentage points) in Escudie 1962
BFA compared to no MDA.
D I S C U S S I O N
Summary of main results
We included 13 studies in this review: 10 cRCTs, of which two
were from areas of moderate to high transmission, and eight were
from areas of very low to low endemicity; and three CBAs, all from
settings of moderate to high transmission.
Areas of moderate- to high-endemicity (cRCTs)
The two included studies were both conducted in sub-Saharan
Africa. We included MDA versus no-MDA comparisons from  von
Seidlein 2003 GMB, which examined the eGect of one round of MDA
with sulfadoxine-pyrimethamine plus artesunate, and from Eisele
2020  ZMBb, which examined the eGect of four rounds of MDA
with dihydroartemisinin piperaquine. No co-interventions were
implemented in the von Seidlein 2003 GMB study, but IRS, ITNs, and
enhanced community case management practices were included
in all arms of Eisele 2020 ZMBb.
Based on these data, in comparison to no-MDA:
• at one to three months aLer MDA, P falciparum
parasitaemia prevalence may be higher (low-certainty
evidence), parasitaemia incidence is probably lower (moderate-
certainty evidence), and confirmed malaria illness incidence
may be lower (low-certainty evidence) in MDA compared to no-
MDA, as reported by a single study (Eisele 2020 ZMBb);
• at four to six months aLer MDA, MDA probably leads to
little or no eGect on P falciparum parasitaemia prevalence
(moderate-certainty evidence) and we do not know the eGect
on parasitaemia incidence (very low-certainty evidence) as
reported by a single study (von Seidlein 2003 GMB).
Longer-term eGects of MDA on outcomes were not reported by any
included studies in moderate- to high-transmission settings.
Areas of very low- to low-endemicity (cRCTs)
Of the eight studies included in qualitative synthesis, three
were carried out in sub-Saharan Africa and five were conducted
in Southeast Asia. One study that administered one round
of MDA with sulfadoxine-pyrimethamine plus artesunate plus
primaquine was excluded from quantitative synthesis due to
insuGicient data (Shekalaghe 2011 TZA). Of the remaining
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seven trials, we included one comparison (multiple rounds
of MDA with dihydroartemisinin piperaquine plus primaquine)
each from  Landier 2017 MMRa,  McLean 2021 MMR,  Morris 2018
TZA,  Pongvongsa 2018 LAO, and  von Seidlein 2019 VNM; and
one comparison (multiple rounds of MDA with dihydroartemisinin
piperaquine) each from Eisele 2020 ZMBa and Tripura 2018 KHM.
All studies implemented ITNs, while  Morris 2018 TZA  and  Eisele
2020 ZMBa also included IRS in both intervention and control arms.
Based on these data, in comparison to no-MDA:
• at less than one month aLer MDA, P falciparum parasitaemia
prevalence may be lower in MDA compared to no-MDA (low-
certainty evidence);
• at one to three months aLer MDA, MDA probably reduces
P falciparum parasitaemia incidence (moderate-certainty
evidence) and may reduce P falciparum parasitaemia prevalence
(low-certainty evidence), but we do not know if MDA has an
eGect on confirmed malaria illness incidence (very low-certainty
evidence);
• at 4 to 6 months and 7 to 12 months aLer MDA, we do not
know the eGect of MDA on P falciparum parasitaemia prevalence
and confirmed malaria illness incidence (very low-certainty
evidence);
• as reported by a single study (McLean 2021 MMR), we do
not know if MDA has an eGect on P falciparum parasitaemia
prevalence at longer-term follow-up periods (13 to 36 months,
very low-certainty evidence).
Despite the very low-certainty evidence available for outcomes
aLer four months post-MDA, there was a general trend of a
substantial reduction in P falciparum parasitaemia prevalence
immediately following MDA and the strength of the reduction
declined over time.
Five studies provided data for comparison of P vivax outcomes:
• at less than one month aLer MDA, P vivax parasitaemia
prevalence may be lower in MDA compared to no-MDA (low-
certainty evidence);
• at one to three months aLer MDA, P vivax parasitaemia
prevalence may be lower in MDA compared to no-MDA (low-
certainty evidence);
• at four to six months aLer MDA, we do not know if MDA reduces
P vivax parasitaemia prevalence (very low-certainty evidence);
• at 7 to 12 months aLer MDA, we do not know the eGect of MDA on
P vivax parasitaemia prevalence and confirmed malaria illness
incidence (very low-certainty evidence);
• as reported by a single study (McLean 2021 MMR), we do not
know if MDA has an eGect on P vivax parasitaemia prevalence
at longer-term follow-up periods (13 to 36 months, very low-
certainty evidence).
Very low-certainty evidence was available for multiple outcomes.
However, similar to P falciparum outcomes in this setting, there
was a general trend of a large and immediate reduction in P vivax
parasitaemia prevalence following MDA that waned over time.
In relation to the Objectives of this review:
• in moderate- to high-transmission settings, no studies provided
data at longer-term time periods to observe a 50% reduction
in median malaria parasite prevalence or incidence, or both, at
12 months aLer MDA. However, the available studies showed
a reduction in parasitaemia incidence, but not parasitaemia
prevalence, at time periods prior to six months aLer MDA;
• in very low- to low-transmission settings, there was a strong
reduction in P falciparum and P vivax parasitaemia prevalence
immediately following MDA, that decreased over time. However,
there was no evidence of interruption of transmission, defined
as a reduction in number of indigenous malaria infections to
zero at six months aLer MDA.
Overall completeness and applicability of evidence
This review highlights a renewed interest in MDA as a strategy
to accelerate progress towards malaria elimination, given the
more recent studies conducted since the previous review on this
topic (Poirot 2013). In areas of moderate to high transmission,
no studies reported outcomes under six months aLer MDA, but
available evidence from earlier post-MDA time periods showed
that MDA decreased parasitaemia incidence, but not parasitaemia
prevalence. In very low- to low-transmission areas, several
studies found substantial short-term reductions in parasitaemia
prevalence following MDA that were not sustained longer-term.
None of these studies found a reduction to zero indigenous malaria
cases at any post-MDA time period.
In both malaria transmission settings, we found that MDA
compared to no MDA led to significant reductions in P falciparum
parasitaemia incidence at one to three months aLer MDA, and in
very low- to low-transmission settings, correspondingly large and
statistically significant reductions in parasitaemia prevalence at
less than one month aLer MDA (one study) and at one to three
months aLer MDA (seven studies). However, in moderate- to high-
transmission settings, this trend was not mirrored by a reduction
in parasitaemia prevalence, based on a single study reporting at
one to three months and four to six months aLer MDA. We believe
one explanation for this counterintuitive finding of a reduction in
incidence but not prevalence is due to diGerences in the study
design and populations used to measure these outcomes. Studies
measured incidence in a fixed cohort and prevalence in a random
sample of the population in cross-sectional surveys. Since the
inclusion criteria for cohort studies typically requires establishment
of a period of residency in the study area, cohort participants may
also be more likely to receive at least one round of MDA compared
to a cross-section of the population that can include individuals
who recently moved to the study area aLer the MDA round (i.e.
did not receive the intervention) but prior to the survey. This
distinction also raises the concern about risk of re-introduction of
malaria. It is possible that we found no eGect of MDA on several
outcomes due to the high risk of re-introduction in the study areas
of included studies, possibly due to a combination of high levels of
migration and low eGective MDA coverage (i.e. the proportion of the
population that received at least one round of MDA).
In an area of moderate to high transmission,  Eisele
2020  ZMBb  found an unexpected increase in parasitaemia
prevalence in the MDA arm compared to no-MDA control at one to
three months, following four rounds of MDA. Although the eGect
estimate was very imprecise, it is worth noting that parasitaemia
prevalence decreased overall in the entire study area (both the
lower- and higher-transmission strata) and specifically in the
moderate- to high-transmission control clusters, from above 50%
at baseline to below 10% following four rounds of MDA. Other
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interventions such as ITNs, IRS and enhanced community case
management were implemented at high coverage in intervention
and control arms at the start of the study and may have contributed
to the overall decline in malaria transmission in the study area. This
finding may also highlight the importance of implementing MDA
as a component of a package of malaria control interventions to
achieve reductions in malaria transmission.
Although not an important cause of heterogeneity in our analysis,
the short-term eGects of MDA in studies conducted in very low- to
low- transmission settings diGered by geography. Trials conducted
in Southeast Asia generally found a large reduction in parasitaemia
prevalence at one to three months aLer MDA (Landier 2017
MMRa; McLean 2021 MMR; Pongvongsa 2018 LAO; Tripura 2018
KHM; von Seidlein 2019 VNM), while the two studies in Africa
showed a smaller or no reduction (Eisele 2020  ZMBa; Morris
2018 TZA). All studies administered MDA with dihydroartemisinin
piperaquine (primaquine was included in most Southeast Asia
trials and the Zanzibar study), implemented multiple rounds
of MDA, and had similar levels of coverage. Trials in Africa
included substantially larger MDA target populations (> 10,000
in Zanzibar; > 37,000 in Zambia) compared to Southeast Asia
(< 5000) and implemented additional co-interventions (mainly,
IRS) across arms. Although not measured directly, diGerences
in underlying malaria epidemiology, population movement and
risk of re-introduction, and implementation of the intervention
(more resource-intensive in larger trials) could have contributed to
variations in the short-term eGects by geography.
Of note, the certainty of evidence for outcomes in this review
was based on a small number of included studies that, aLer
stratification by endemicity and post-MDA time period, oLen
resulted in limited evidence. We assessed studies from very low-
to low-endemicity settings as high risk of bias for several criteria,
and the certainty of evidence from studies from all endemicities
was aGected by imprecision. This highlights the need for additional
studies with high-quality evidence (both randomized and non-
randomized designs) and with suGicient sample sizes to account
for the correlation due to clustering. Finally, we excluded many
studies due to reasons such as imbalanced co-interventions across
arms or insuGicient time points before and aLer MDA to conduct
interrupted time series (ITS) analyses. Although these studies did
not meet our criteria for inclusion, they may provide information
useful for policymakers.
Quality of the evidence
In settings of moderate to high transmission, we judged the two
trials as having low risk of bias (Figure 2), and  Summary of
findings 1 describes our assessment of the certainty of evidence
available. No pooled eGect estimates were provided for outcomes
in moderate- to high-transmission settings due to a single study
reporting aLer stratification by post-MDA time period.
We judged most studies from very low- to low-endemicity settings
to be at high risk or unclear risk of bias for some criteria (Figure
2), and our assessment of the certainty of evidence available for
important short-term outcomes is provided in Summary of findings
2, Summary of findings 3, Summary of findings 4, and Summary
of findings 5. Studies in this setting were generally underpowered
and there were only a few malaria events across arms, resulting in
imprecise estimates of eGect. Many outcomes were downgraded by
one or two levels due to imprecision aLer adjustment for clustering.
All parasitaemia prevalence outcomes at longer-term post-MDA
time periods were downgraded by one or two levels due to risk
of bias, mainly due to baseline imbalance or biased sampling
approaches for cross-sectional parasitaemia surveys.
Potential biases in the review process
Although we sought to examine short- and longer-term eGects of
MDA over a range of follow-up time periods, there were few studies
available within each follow-up time period. Therefore, we were
unable to examine whether variables, such as type of antimalarial
drug, MDA coverage or number of rounds, and co-interventions,
modified the eGect of MDA compared to no MDA.
Agreements and disagreements with other studies or
reviews
Previous reviews on this topic described substantial but temporary
reductions in malaria burden immediately following MDA (in
both low- and high-transmission settings) (Greenwood 2004;
Newby 2015; Poirot 2013; von Seidlein 2003). Our review provides
evidence of short-term reductions in parasitaemia incidence in
both transmission settings and evidence of short-term reductions
in parasitaemia prevalence in very low- to low-endemicity areas,
but not in moderate- to high-endemicity areas. This diGerence
is possibly due to the limited number of studies in moderate-
to high-transmission settings included in this review (two trials),
diGerent study design, or diGerences in malaria context between
older and newer studies. Many older studies included in previous
reviews were conducted in settings prior to scale-up of vector
control measures (e.g. ITNs), improvements in case management
(i.e. RDTs and ACTs), and potentially less population movement to
limit risk of re-introduction. This may have resulted in a larger eGect
of MDA, which is supported by our results from non-randomized
studies that showed large short-term reductions in parasitaemia
prevalence in older studies conducted in settings of moderate to
high endemicity. Additionally, it is possible that our inclusion of
more rigorous study designs provided less biased comparisons for
evaluating the eGect of MDA.
The 2013 Cochrane Review on this topic highlighted a few
studies on small islands or in highland settings in which malaria
transmission was interrupted by MDA (Poirot 2013), but these
studies did not meet inclusion criteria for our updated review.
Although MDA has been attributed to successful elimination of
malaria in Vanuatu (Kaneko 2000 VUT), we excluded this study due
to an imbalance in co-interventions, since MDA was administered
in combination with ITNs and larvivorous fish, while the no-MDA
control arm received delayed ITNs and no additional interventions.
Additionally, more recent studies from island settings did not meet
our inclusion criteria: ITNs were introduced concurrently with MDA
in a recent study conducted in Grande Comore, Comoros (AGane
2012 COM), and there were insuGicient data points collected to
adequately account for trends in malaria seasonality using the ITS
design in a study conducted on Anjouan island, Comoros (Deng
2018 COM).
Finally, the previous Cochrane Review also highlighted a paucity of
data to assess whether a reduction by MDA was sustained (Poirot
2013). Our findings address some of the knowledge gaps from
the previous review with the availability of longer-term follow-
up data post-MDA for parasitaemia prevalence, and confirmed
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malaria illness incidence from several studies in very low- to low-
transmission settings.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In moderate- to high-transmission settings, only two studies
contributed data to assess the eGect of MDA on outcomes. Based
on results from a single trial, MDA probably reduces parasitaemia
incidence, but does not reduce parasitaemia prevalence at one to
three months aLer MDA. However, it is worth noting that there
was a large overall reduction in parasitaemia prevalence in both
the intervention and control arms from baseline to post-MDA. The
second trial showed no eGect of a single round of MDA at four to
six months aLer MDA. Given the absence of data in moderate- to
high-transmission settings at time points aLer six months, we were
unable to determine the longer-term eGects of MDA on malaria
transmission.
In very low- to low-transmission settings, MDA probably reduces
P falciparum parasitaemia incidence at under one month, and P
falciparum and P vivax prevalence at one to three months aLer
MDA. The short- and long-term eGects of MDA on P falciparum and
P vivax parasitaemia prevalence at time periods aLer four months
is uncertain due to very low-certainty evidence, but the immediate
large reduction in parasitaemia prevalence is not sustained over
time. Based on data provided in studies conducted in very low- to
low-transmission settings, we did not find evidence in any study
of interruption of transmission as measured by a reduction to zero
indigenous cases following MDA.
Other variables, such as type of antimalarial drug, MDA coverage,
number of rounds, and co-interventions, may aGect the impact
of MDA on malaria outcomes and should be considered when
conducting MDA. Additionally, the degree of population mobility
and potential for importation of parasites also plays an important
role in the eGect of MDA. These considerations should be weighed
carefully in recommendations surrounding MDA.
Our findings in very low- to low-transmission settings support
the existing WHO  Malaria Policy Advisory Committee's (MPAC)
2015 recommendations on the use of MDA in areas approaching
elimination with high coverage of vector control and surveillance,
good access to treatment, and limited risk of re-introduction
of infection (WHO 2015a). These recommendations are currently
being updated through a revised guideline development process at
WHO (WHO 2020b).
Implications for research
Given the addition of several cRCTs since the publication of the
previous review on this topic (Poirot 2013), this updated review
provides additional information about MDA in the context of a
renewed interest in MDA as a strategy to accelerate progress
towards malaria elimination. Although several studies, conducted
more recently in very low- to low-endemicity settings, attempted
to collect data on outcomes at longer time points following MDA,
the certainty of the evidence on the sustained eGect of MDA was
very low due to high risk of bias and large imprecision. Although
of higher certainty evidence compared to trials conducted in very
low- to low-endemicity settings, none of the included studies in
moderate- to high-endemicity settings measured the eGect of MDA
aLer four to six months. Future studies should measure the longer-
term eGect of MDA and ensure that outcomes from a suGicient
number and representative sample of participants are collected to
obtain more precise estimates of eGect. In relation to study design,
cRCTs should be designed with a suGicient number of clusters to
help to ensure that measured and unmeasured confounders are
balanced across randomized arms, studies designed for interrupted
time series analysis should include suGicient pre- and post-
intervention data to adequately capture seasonal malaria trends,
and co-interventions should be balanced across study arms.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Dates of study: 2014-2017
Location of study: Zambia
Malaria endemicity (prevalence): Clusters stratified by ≤ 10% and > 10% parasite prevalence prior to
randomization. This study includes the low transmission strata [Low].
Transmission season: January to May
Malaria species: Plasmodium falciparum
Vector species: Anopheles funestus (hereafter An funestus) and Anopheles gambiae (hereafter An gambi-
ae)
Antimalarial drug resistance context: Widespread resistance to chloroquine and sulfadox-
ine-pyrimethamine, but no evidence of resistance to artemisinin.
Study design: Cluster-randomized trial (3 arms: MDA, fMDA, and a no fMDA or MDA control; only MDA
and control arms included in this review)
Statistical power: 80% power (alpha = 0.05) to detect a 50% reduction in parasite prevalence account-
ing for clustering, and 80% power (alpha = 0.05) to detect a 50% reduction in parasite incidence ac-
counting for clustering
For cluster-RCTs
Unit of randomization: Health facility catchment area (HFCA)
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using the study-provided ICC to calculate effective sample sizes
Adjustment method: Random intercept for HFCA
ICC (estimated at the HFCA level in the low transmission strata): 0.06517 (in 2014); 0.01753 (in 2015);
0.01515 (in 2016); 0.04184 (in 2017)
Number of clusters randomized: 20
Number of clusters analysed: 20
Number of people: 82,866 (low), 184,928 (total)
Average cluster size: 9246
Features: Stratified by low vs high (below and above 10%) transmission strata and HFCA population
size prior to randomization of clusters
Participants Age groups included: All ages above 3 months. Children < 3 months and pregnant women in first
trimester excluded from MDA with dihyrdroartemisinin piperaquine, but offered appropriate dose of
antimalarial treatment in accordance with national policy if found to be RDT positive (note: testing was
performed in fMDA and MDA arms, but all eligible persons were treated in the MDA arm, irrespective of
RDT result).
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• Ages ≥ 14 years (> 45 kg): Dihydroartemisinin plus piperaquine (120 mg/960 mg as 3 tablets) given for
three days
• Ages 8-13 years (25 to 40 kg): Dihydroartemisinin plus piperaquine (80 mg/640 mg as 2 tablets) given
for three days
• Ages 1-7 years (10 to 23 kg): Dihydroartemisinin plus piperaquine (40 mg/320 mg as 1 tablet) given
for three days
• Ages 3 months to 1 year (8 kg): Dihydroartemisinin plus piperaquine (20 mg/160 mg as ½ tablet) given
for three days
Number of rounds (timing/dates): 4 (December 2014 at the end of the dry season, February-March 2015
at the start of the rainy season, September-October 2015 during dry season, and February-March 2016
at start of the rainy season)
Interval: Variable
Duration implemented: 15 months
Coverage (%): 79% in round 1, 63% in round 2, 76% in round 3, and 66% in round 4
Co-interventions: Baseline IRS household coverage in the preceding 12 months was 6.9%; Baseline
household LLIN coverage of at least 1 net was 70.3%; Enhanced standard of care was scaled up in the
study area, which consisted of RDT or microscopic confirmation of all suspected cases presenting to
health facility and treating positives with artemether-lumefantrine and reactive case detection in areas
with manageable case counts.
Comparison:
Type: No MDA and no placebo
Co-interventions: Baseline IRS household coverage in the preceding 12 months was 16.9%; Baseline
household LLIN coverage of at least 1 net was 75.3%; Enhanced standard of care was scaled up in the
study area, which consisted of RDT or microscopic confirmation of all suspected cases presenting to
health facility and treating positives with artemether-lumefantrine and reactive case detection in areas
with manageable case counts.
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional surveys of P falciparum prevalence by RDT in children ≥ 3 months and <
6 years
Time points: Pre-MDA (April-May 2014), During MDA (April-May 2015), and Post-MDA 1-3 months (April-
May 2016)
Sample size (range): 372-545 (intervention); 361-453 (comparison)
Parasitaemia incidence
Measurement: Prospective cohort of persons ≥ 3 months of age to capture P falciparum incidence by
RDT
Time points: Followed through 2 months post-MDA (January 2015 - May 2016)
Sample size: 410 (intervention); 326 (comparison)
Eisele 2020 ZMBa  (Continued)
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Confirmed malaria illness incidence
Measurement: Passive surveillance as measured by outpatient department confirmed malaria cases
(by microscopy or RDT) reported through routine health management information systems data
Time points: Pre-MDA (January-May 2013 combined with January-May 2014) and Post-MDA 1-3 months
(January 2015 - May 2016)
Adverse effects (AEs) (reported in both MDA and fMDA arms)
A total of 687 AEs (0.24% of participants and 0.43% of treatments) were reported and one was a serious
AE. The most common AEs reported were stomach pains, dry cough, and vomiting.
Notes ClinicalTrials.gov: NCT02329301
Outcomes stratified by low and high transmission strata as specified a priori by study design (defined
as above and below 10% parasite prevalence)
Two out of ten low transmission strata clusters received two additional rounds of programmatic MDA
(for a total of six rounds) at 10 and 12 months following the fourth round of trial MDA, however no out-
comes were analysed following the first round of programmatic MDA.
Abbreviations:
ICC = intracluster correlation coefficient, fMDA = focal mass drug administration, IRS = indoor residual
spraying, LLIN = long-lasting insecticide-treated bed net, MDA = mass drug administration, RDT = rapid
diagnostic test
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Following stratification by transmission setting and health facility catchment




Low risk Allocation was conducted by an institution.
Baseline imbalance (selec-
tion bias)
Low risk The proportion of households that received IRS in the previous 12 months was
higher at baseline in control (17%) compared to MDA (7%) clusters, but other
baseline characteristics were balanced. Analysis adjusted for baseline differ-
ences.
Contamination protection Low risk Households within a 3 km buGer around HFCA borders were excluded from the





Unclear risk Participants were not blinded to allocation, but access to antimalarials





Low risk Participants were not blinded to allocation, but parasitaemia incidence was





Unclear risk Participants were not blinded to allocation, which may have impacted care-
seeking.
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Confirmed malaria illness
incidence
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence
Unclear risk Outcome assessment by microscopy not described.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia incidence
Low risk Blood samples for malaria testing collected from all individuals, irrespective of
study arm at follow-up visits.












Unclear risk "No statistically significant differences in primary outcomes or covariates be-
tween individuals" included in analysis and those lost to follow-up, "although
fewer individuals were lost to follow up in high transmission areas than in low
transmission areas". Based on this information provided, it is unclear whether






Low risk Based on routine data from health management information system with es-
tablished reporting from January 2011 onwards.
Selective reporting (re-
porting bias)
Low risk All pre-stated outcomes of interest were reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
Incorrect analysis (cluster
RCT)
Low risk Mixed models were used to adjust for clustering by investigators; however, in
this review, we performed cluster adjustment of the raw data using a study-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 2014 to 2017
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Location of study: Zambia
Malaria endemicity (prevalence): Clusters stratified by ≤ 10% and > 10% parasite prevalence prior to
randomization. This study includes the high transmission strata [High].
Transmission season: January to May
Malaria species: Plasmodium falciparum
Vector species: An funestus and An gambiae
Antimalarial drug resistance context: Widespread resistance to chloroquine and sulfadox-
ine-pyrimethamine, but no evidence of resistance to artemisinin.
Study design: Cluster-randomized trial (3 arms: MDA, fMDA, and a no fMDA or MDA control; only MDA
and control arms included in this review)
Statistical power: 80% power (alpha = 0.05) to detect a 50% reduction in parasite prevalence account-
ing for clustering, and 80% power (alpha = 0.05) to detect a 50% reduction in parasite incidence ac-
counting for clustering
For cluster RCTs
Unit of randomization: Health facility catchment area (HFCA)
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using the study-provided ICC to calculate effective sample sizes
Adjustment method: Random intercept for HFCA
ICC (estimated at the HFCA level for the high transmission strata): 0.16142 (in 2014); 0.11301 (in 2015);
0.08066 (in 2016); 0.13479 (in 2017)
Number of clusters randomized: 20
Number of clusters analysed: 20
Number of people: 102,062 (high), 184,928 (total)
Average cluster size: 9246
Features: Stratified by low vs high (below and above 10%) transmission strata and HFCA population
size prior to randomization of clusters
Participants Age groups included: All ages above 3 months. Children < 3 months and pregnant women in first
trimester excluded from MDA with dihydroartemisinin piperaquine, but offered appropriate dose of an-
timalarial treatment in accordance with national policy if found to be RDT positive (note: testing was







• Ages ≥ 14 years (> 45 kg): Dihydroartemisinin plus piperaquine (120 mg/960 mg as 3 tablets) given for
three days
• Ages 8-13 years (25 to 40 kg): Dihydroartemisinin plus piperaquine (80 mg/640 mg as 2 tablets) given
for three days
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• Ages 1-7 years (10 to 23 kg): Dihydroartemisinin plus piperaquine (40 mg/320 mg as 1 tablet) given
for three days
• Ages 3 months to 1 year (8 kg): Dihydroartemisinin plus piperaquine (20 mg/160 mg as ½ tablet) given
for three days
Number of rounds (timing/dates): 4 (December 2014 at the end of the dry season, February to March
2015 at the start of the rainy season, September to October 2015 during dry season, and February to
March 2016 at start of the rainy season)
Interval: Variable
Duration implemented: 15 months
Coverage (%): 79% in round 1, 63% in round 2, 76% in round 3, and 66% in round 4
Co-interventions: Baseline IRS household coverage in the preceding 12 months was 6.9%; Baseline
household LLIN coverage of at least 1 net was 70.3%; Enhanced standard of care was scaled up in the
study area, which consisted of RDT or microscopic confirmation of all suspected cases presenting to
health facility and treating positives with artemether-lumefantrine and reactive case detection in areas
with manageable case counts.
Comparison:
Type: No MDA and no placebo
Co-interventions: Baseline IRS household coverage in the preceding 12 months was 16.9%; Baseline
household LLIN coverage of at least 1 net was 75.3%; Enhanced standard of care was scaled up in the
study area, which consisted of RDT or microscopic confirmation of all suspected cases presenting to
health facility and treating positives with artemether-lumefantrine and reactive case detection in areas
with manageable case counts.
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional surveys of P falciparum prevalence by RDT in children ≥ 3 months and <
6 years
Time points: Pre-MDA (April to May 2014), During MDA (April to May 2015), and Post-MDA 1 to 3 months
(April to May 2016)
Sample size (range): 348 to 490 (intervention); 332 to 505 (comparison)
Parasitaemia incidence
Measurement: Prospective cohort of persons ≥ 3 months of age to capture P falciparum incidence by
RDT
Time points: Followed through 2 months post-MDA (January 2015 to May 2016)
Sample size: 371 (intervention); 368 (comparison)
Confirmed malaria illness incidence
Measurement: Passive surveillance as measured by outpatient department confirmed malaria cases
(by microscopy or RDT) reported through routine health management information systems data
Time points: Pre-MDA (January to May 2013 combined with January to May 2014) and Post-MDA 1 to 3
months (January to May 2015)
Adverse effects (AEs) (reported in both MDA and fMDA arms)
A total of 687 AEs (0.24% of participants and 0.43% of treatments) were reported and one was a serious
AE. The most common AEs reported were stomach pains, dry cough, and vomiting.
Notes ClinicalTrials.gov: NCT02329301
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Outcomes stratified by low and high transmission strata as specified a priori by study design (defined
as above and below 10% parasite prevalence)
Abbreviations:
ICC = intracluster correlation coefficient, fMDA = focal mass drug administration, IRS = indoor residual
spraying, LLIN = long-lasting insecticide-treated bed net, MDA = mass drug administration, RDT = rapid
diagnostic test
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Following stratification by transmission setting and health facility catchment




Low risk Allocation was conducted by an institution.
Baseline imbalance (selec-
tion bias)
Low risk The proportion of households that received IRS in the previous 12 months was
higher at baseline in control (17%) compared to MDA (7%) clusters, but other
baseline characteristics were balanced. Analysis adjusted for baseline differ-
ences.
Contamination protection Low risk Households within a 3 km buGer around HFCA borders were excluded from the





Unclear risk Participants were not blinded to allocation, but access to antimalarials





Low risk Participants were not blinded to allocation, but parasitaemia incidence was







Unclear risk Participants were not blinded to allocation, which may have impacted care-
seeking.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence
Unclear risk Outcome assessment by microscopy not described.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia incidence
Low risk Blood samples for malaria testing collected from all individuals, irrespective of
study arm at follow-up visits.




Unclear risk Blinding of health facility staG to allocation arm was not described.
Incomplete outcome data
(attrition bias)
Low risk Simple random sample of children at baseline and follow-up.
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Unclear risk "No statistically significant differences in primary outcomes or covariates be-
tween individuals" included in analysis and those lost to follow-up, "although
fewer individuals were lost to follow up in high transmission areas than in low
transmission areas". Based on this information provided, it is unclear whether






Low risk Based on routine data from health management information system with es-
tablished reporting from January 2011 onwards.
Selective reporting (re-
porting bias)
Low risk All pre-stated outcomes of interest were reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
Incorrect analysis (cluster
RCT)
Low risk Mixed models were used to adjust for clustering by investigators. However, in
this review, we performed cluster adjustment of the raw data using a study-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 1960 to 1961
Location of study: Burkina Faso
Malaria endemicity (prevalence): 56.1% prevalence in children 0 to 10 years at baseline in control [High]
Transmission season: June to December
Malaria species: P falciparum, P ovale, P malariae
Vector species: An gambiae, An funestus, Anopheles nili (hereafter An nili)
Antimalarial drug resistance context: Not described
Study design: Controlled before-and-after study (6 arm study: CQ+PQ or AQ+PQ every 4 weeks, CQ+PQ
or AQ+PQ every 2 weeks, CQ+PQ or AQ+PQ every 4 weeks with IRS, CQ+PQ or AQ+PQ every 2 weeks with
IRS, IRS only, non-IRS control; the 3 arms with IRS are excluded in this review since the population size
and number of villages for the IRS only control were not reported)
Statistical power: Not described
Participants Age groups included: All ages
Escudie 1962 BFA 
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Population targeted
Intervention (CQ+PQ or AQ+PQ every 4 weeks): 1890 in 5 villages
Intervention (CQ+PQ or AQ+PQ every 2 weeks): 2560 in 3 villages
Comparison (non-IRS control): 6 villages, population size not described
Interventions Drug/dose (for all intervention arms receiving MDA):
• Ages ≥10 years: Chloroquine-primaquine (600 mg/15 mg) or amodiaquine-primaquine (600 mg/15
mg) as a single dose
• Ages 5 to 9 years: Chloroquine-primaquine (400 mg/10 mg) or amodiaquine-primaquine (400 mg/10
mg) as a single dose
• Ages 0 to 4 years: Chloroquine-primaquine (200 mg/5 mg) or amodiaquine-primaquine (200 mg/5 mg)
as a single dose
Intervention (CQ+PQ or AQ-PQ every 4 weeks, "low frequency"):
Number of rounds (timing/dates): 8 (June, July, August, September, October, November, December
1960)
Interval: Every 28 days
Duration implemented: 7 months (June to December 1960)
Coverage (%): 75% to 91% per round
Co-interventions: None
Intervention (CQ+PQ or AQ+PQ every 2 weeks, "high frequency"):
Number of rounds (timing/dates): 15 (June to December 1960)
Interval: Every 14 days
Duration implemented: 7 months (June to December 1960)
Coverage (%): 84% to 97% per round
Co-interventions: None
Comparison (non-IRS control):
Type: No MDA and no placebo
Co-interventions: None
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional surveys in all children ages 2 to 9 years every 4 months (microscopy)
Time points: Pre-MDA (June 1960), During-MDA (October 1960), and at 3 months post-MDA (March 1961)
Sample size (range): 274 to 348 (intervention: CQ+PQ or AQ+PQ every 4 weeks); 390 to 467 (interven-
tion: CQ+PQ or AQ+PQ every 2 weeks); 217 to 691 (comparison: non-IRS control)
Gametocytaemia prevalence
Measurement: Cross-sectional surveys in all children ages 2 to 9 years every 4 months (microscopy)
Time points: Pre-MDA (June 1960), During MDA (October 1960), and at 3 months post-MDA (March 1961)
Sample size (range): 274 to 348 (intervention: CQ+PQ or AQ+PQ every 4 weeks); 390 to 467 (interven-
tion: CQ+PQ or AQ+PQ every 2 weeks); 217 to 691 (comparison: non-IRS control)
Escudie 1962 BFA  (Continued)
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Notes Samples for outcome assessment in June 1960 were collected prior to MDA distribution; therefore the
survey in June 1960 was considered as "pre-MDA".
Abbreviations:
AQ = amodiaquine, CQ = chloroquine, IRS = indoor residual spraying, MDA = mass drug administration,
PQ = primaquine
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Assignment to intervention or control was not randomized although drug as-




High risk Non-randomized controlled study (controlled before-and-after study)
Baseline imbalance (selec-
tion bias)
Unclear risk Baseline characteristics were not described.





Unclear risk Participants were not blinded to allocation.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence




Low risk Outcomes were assessed in all children ages 2 to 9 years in the study area.
Selective reporting (re-
porting bias)
Low risk All pre-stated outcomes were reported.





Methods Dates of study: 2013 to 2015
Location of study: Kayin (Karen) state, Myanmar
Malaria endemicity (prevalence): Plasmodium falciparum prevalence 11.0% in MDA villages and 5.4%
in control villages at baseline by ultrasensitive polymerase chain reaction (uPCR); P vivax prevalence
18.9% in MDA villages and 17.5% in control villages at baseline by uPCR [Low - estimated P falciparum
slide prevalence 1.2%]
Transmission season: June to October
Landier 2017 MMRa 
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Malaria species: P falciparum and P vivax
Vector species: Anopheles minimus s.l., An maculatus s.l., and An dirus s.l.
Antimalarial drug resistance context: “Area where artemisinin resistance is firmly established”
Statistical power: For the multi-country trial (Landier 2017 MMRa; Tripura 2018 KHM; Pongvongsa 2018
LAO; von Seidlein 2019 VNM), 80% power (alpha = 0.05) to detect a 95% reduction in parasite preva-
lence from a baseline prevalence of 10%
For cluster RCTs
Unit of randomization: Village
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using ICC values estimated from the study data to calculate effective sample sizes
Adjustment method: Generalized estimating equations
ICC: 0.03512 (P falciparum outcomes at baseline before MDA), 0 (P falciparum outcomes at post-MDA 1
to 3, 4 to 6, and 7 to 12 months); 0 (P vivax outcomes at baseline before MDA, post-MDA 4 to 6 months
and 7 to 12 months), 0.000798 (P vivax outcomes at post-MDA 1 to 3 months)
Number of clusters randomized: 4
Number of clusters analysed: 4
Number of people: 3238
Average cluster size: 810
Features: Two village pairs (4 villages) were established by geographical proximity, population size, and
parasite prevalence. Within each pair, one village was randomly selected to receive early MDA, while
the other village received deferred MDA
Participants Age groups included: All ages ≥ 6 months. All pregnant women in their first trimester were excluded





Drug/dose: Dihydroartemisinin (7 mg/kg) plus piperaquine (55 mg/kg) administered once a day for 3
days with a single dose of primaquine (0.25 mg/kg)
Number of rounds (timing/dates): 3 (May, June, July 2013 or June, July, August 2013)
Interval: Every 1 month
Duration implemented: 3 months
Coverage (%): 66% in round 1, 56% in round 2, and 65% in round 3
Co-interventions: LLITNs, uninterrupted access to diagnosis and treatment in study villages
Comparison:
Type: Deferred MDA administered in control villages in January, February, and March 2014
Co-interventions: LLITNs, uninterrupted access to diagnosis and treatment in study villages
Outcomes Parasitaemia prevalence ( P falciparum and P vivax )
Landier 2017 MMRa  (Continued)
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Measurement: Cross-sectional surveys in all ages every 3 months by uPCR; all individuals present at the
time of the survey in the study villages were sampled.
Time points: Pre-MDA (May 2013) and at 1 (Aug 2013), 4 (Nov 2013), and 7 (Jan 2014) months post-MDA
Sample size (range): 419 to 689 (intervention) and 750 to 848 (control)
Confirmed malaria illness incidence ( P falciparum and P vivax )
Measurement: Passive case detection at malaria posts for measured or self-reported fever (≥ 37.5C) and
confirmed P falciparum or P vivax infection by RDT or microscopy.
Time points: 7 (May 2013 to January 2014) months post-MDA
Adverse effects (AEs)
AEs monitored by active surveillance through structured interviews on the second, third, and seventh
day of MDA treatment course and by passive surveillance via reporting to medical assistants in mobile
clinics located in study villages during MDA rounds. From interviews, no serious AEs were reported.
The most common AEs were dizziness (n=192) and pruritus (n=17). There were three reports of black
urine, from glucose 6-phosphate dehydrogenase (G6PD) deficient (report prior to PQ), G6PD-normal (48
hours after PQ), and G6PD-heterozygous individuals. Among participants reporting passively to mobile
clinics, there were 23 serious AEs and 15 deaths that were not drug-related, 9 moderate AEs of which
4 were possibly related to the study drug, and 191 mild AEs of which 1 was highly likely related and 7
were possibly related to the study drug.
Notes One of four sites from a multi-country trial in Southeast Asia (ClinicalTrials.gov: NCT01872702)
Abbreviations:
ICC = intracluster correlation coefficient, LLITN = long-lasting insecticide-treated bed net, MDA = mass
drug administration, uPCR = ultrasensitive polymerase chain reaction
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The randomisation was based on computer-generated random numbers pro-
vided by the trial statistician"
Allocation concealment
(selection bias)
Low risk Allocation was conducted by an institution.
Baseline imbalance (selec-
tion bias)
High risk Small number of clusters (4 villages) randomized.
Contamination protection High risk Intervention and control clusters were pair-matched by geographical proxim-












Unclear risk Participants were not blinded to allocation, which may have impacted care-
seeking.
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Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence
Low risk Laboratory staG performing PCR were unaware of the study arm allocation of
samples.




Unclear risk Unclear if the health facility staG performing malaria testing were aware of




Low risk Parasitaemia surveys were performed in all individuals aged six months or old-





Low risk Data collected at malaria health posts with dedicated study staG.
Selective reporting (re-
porting bias)
Low risk All pre-specified outcomes reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
Incorrect analysis (cluster
RCT)
Low risk Although no adjustment for clustering was performed by investigators, in this
review, we performed cluster adjustment of the raw data using a study-provid-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 2014 to 2017
Location of study: Myanmar
Malaria endemicity (prevalence): P falciparum < 20 cases per 1000 population per year and P falci-
parum/P vivax 2.7% at baseline by rapid diagnostic test (RDT) [Low]
Transmission season: June to August
Malaria species: P falciparum, P vivax, P ovale, P malariae
Vector species: Not described
Antimalarial drug resistance context: Artemisinin resistance reported; Kelch 13 in 57% (54/94) of sam-
ples at baseline.
Study design: Cluster-randomized trial
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Statistical power: Not statistically powered for outcomes
For cluster RCTs
Unit of randomization: Village
Adjusted analyses for clustering: No; however, in this review, we performed cluster adjustment of the
raw data using the study-provided ICC to calculate effective sample sizes
Adjustment method: Not applicable
ICC: 0.056
Number of clusters randomized: 16
Number of clusters analysed: 16
Number of people: 8721
Average cluster size: 554
Features: Intervention and control clusters were pair-matched based on P falciparum prevalence (+/-
8%), geographical proximity and distance to main road
Participants Age groups included: All ages ≥ 1 year and pregnant women in first trimester excluded. No primaquine





Drug/dose: Dihydroartemisinin (7 mg/kg) plus piperaquine (55 mg/kg) administered once a day for
three days with a single dose of primaquine (0.25 mg/kg)
Number of rounds (timing/dates): 3 (March, April, May 2015, during dry season)
Interval: Every 1 month
Duration implemented: 3 months
Coverage (%): 90% completed at least one round; Round 1: 86%, Round 2: 86%, Round 3: 88%
Co-interventions: LLITNs distributed at the start of study; routine malaria control by village health
workers.
Comparison:
Type: No MDA and no placebo
Co-interventions: LLITNs distributed at the start of study; routine malaria control by village health
workers.
Outcomes Parasitaemia prevalence (P falciparum and P vivax)
Measurement: Cross-sectional surveys of P falciparum and P vivax prevalence by ultrasensitive PCR in
adults 18 to 55 years; up to 2 participants sampled from randomly selected households at baseline and
the same participants were sampled at follow-up surveys.
Time points: Pre-MDA (January 2015) and at < 1 (3-8 June 2015), 3 (24-29 August 2015), 8 (15-26 Janu-
ary 2016), 13 (7-14 June 2016), 19 (2-19 December 2016), 25 (13-18 June 2017), and 31 (1-13 December
2017) months post-MDA
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Sample size (range): 620 to 1106 (intervention); 412 to 543 (comparison)
Adverse effects (AEs)
A total of 151 (1.4% of all doses, 3.6% of treated individuals) adverse effects reported: 12 (7.9%) not re-
lated to drug, 40 (26.5%) unlikely related to drug, 81 (53.6%) possibly related to drug, and 18 (11.9%)
probably related to drug. 6 serious AEs: 1 possibly related, 5 unrelated
Notes Prior to randomization, villages selected based on baseline PCR prevalence survey conducted in 58 vil-
lages in study area. Selected villages: (1) had a population between 75 to 1200 people (excluded 15 vil-
lages), and (2) were a hotspot village defined as > 30% parasite prevalence (all types) or > 10% P falci-
parum prevalence by PCR (excluded 27 non-hotspot villages)
Abbreviations:
ICC = intracluster correlation coefficient, LLITN = long-lasting insecticide-treated bed net, MDA = mass
drug administration, PCR = polymerase chain reaction
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Randomization of clusters was performed by flipping a coin.
Allocation concealment
(selection bias)
Low risk Allocation was conducted by an institution.
Baseline imbalance (selec-
tion bias)
Low risk Baseline malaria risk and co-intervention coverage were similar across inter-
vention arms.
Contamination protection High risk Intervention and control clusters were pair-matched by geographical proxim-






Unclear risk Participants were not blinded to allocation.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence





High risk Outcome data was assessed only in participants aged 18 to 55 years. Up to 2
participants from randomly selected households at baseline were surveyed
at each time point and alternative participants (similarly matched by gender,
age, and occupation) were surveyed if selected participants were unavailable
during follow-up. Substantial variation in denominators suggesting different
participants sampled (non-randomly) during each survey.
Selective reporting (re-
porting bias)
Low risk All pre-specified outcomes reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
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Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
Incorrect analysis (cluster
RCT)
Low risk Although no adjustment for clustering was performed by investigators, in this
review, we performed cluster adjustment of the raw data using a study-provid-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 1970 to 1976 (included data from 1970 to 1973 in this review)
Location of study: Nigeria
Malaria endemicity (prevalence): 46% in all ages [High]
Transmission season: April to October
Malaria species: Plasmodium falciparum, P malariae, P ovale
Vector species: Anopheles gambiae, An funestus
Antimalarial drug resistance context: Not described
Study design: Controlled before-and-after study (4 arms: no intervention, IRS only, low frequency MDA
+IRS, and high frequency MDA+IRS; IRS only, low frequency+IRS, and high frequency+IRS arms included
in this review)
Statistical power: Consideration of statistical power was mentioned, but the parameters were not de-
scribed.
Participants Age groups included: All ages, but infants not included in MDA until their first malaria episode.
Population targeted
Intervention (low frequency MDA+IRS): 14,129
Intervention (high frequency MDA+IRS): 1810
Comparison (IRS only): 32,828
Interventions Drug/dose (for all intervention arms receiving MDA):
• Ages ≥10 years: Sulfalene-pyrimethamine (500 mg/25 mg as 1 tablet) as a single dose
• Ages 5 to 9 years: Sulfalene-pyrimethamine (250 mg/12.5 mg as ½ tablet) as a single dose
• Ages 1 to 4 years: Sulfalene-pyrimethamine (230 mg/12.0 mg as 30 drops syrup) as a single dose
• Ages 6 to 11 months: Sulfalene-pyrimethamine (150 mg/7.5 mg as 20 drops syrup) as a single dose
• Ages < 6 months: Sulfalene-pyrimethamine (90 mg/4.5 mg as 12 drops syrup) as a single dose
Intervention (Low frequency MDA+IRS group):
Number of rounds (timing/dates): 9 (April 1972 - October 1973)
Interval: Every 10 weeks
Molineaux 1980 NGA 
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Duration implemented: 18 months
Coverage (%): 73% to 92%
Co-interventions: IRS using propoxur 3 to 4 rounds per year
Intervention (High frequency MDA+IRS group):
Number of rounds (timing/dates): 23 (April 1972 - October 1973)
Interval: Every two weeks during the wet season (May-October 1972 and May-October 1973) and every
10 weeks during the dry season (December 1972, March 1973, and October-November 1973)
Duration implemented: 18 months
Coverage (%): 72% to 91%
Co-interventions: IRS using propoxur 3 to 4 rounds per year
Comparison (IRS only)
Type: No MDA and no placebo
Co-interventions: IRS using propoxur 3 to 4 rounds per year
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional surveys in selected village clusters (all ages) (microscopy)
Time points: Pre-MDA (8 surveys), During MDA (8 surveys)
Sample size (range): 1257 to 2099 (intervention: low frequency MDA+IRS); 1486 to 1679 (intervention:
high frequency MDA+IRS); 1104 to 1171 (comparison: IRS only)
Gametocytaemia prevalence
Measurement: Cross- sectional surveys in selected villages clusters (all ages) (microscopy)
Time points: Pre-MDA (8 surveys), During MDA (8 surveys)
Sample size (range): 1257 to 2099 (intervention: low frequency MDA+IRS); 1486 to 1679 (intervention:
high frequency MDA+IRS); 1104 to 1171 (comparison: IRS only)
Notes Abbreviations:
IRS = indoor residual spraying, MDA = mass drug administration
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Non-randomized controlled study
Allocation concealment
(selection bias)
High risk Non-randomized controlled study
Baseline imbalance (selec-
tion bias)
Unclear risk Similar malaria characteristics between groups at baseline, but unclear if oth-
er demographic factors were balanced.
Contamination protection Low risk Evaluation villages in both arms were surrounded by similarly treated buGer
zones to mitigate possible contamination due to migration.
Molineaux 1980 NGA  (Continued)
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Unclear risk Participants were not blinded to allocation, but there was limited access to an-
timalarials outside of MDA.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence
Low risk Microscopists were blinded to study arm allocation through the use of a nu-





Low risk Parasitaemia surveys were performed in all ages in selected study villages.
Selective reporting (re-
porting bias)
Low risk All pre-stated outcomes were reported.




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 2016 to 2017
Location of study: Zanzibar (three districts in Unguja, Central, South, and West districts)
Malaria endemicity (prevalence): 2.5% (range between clusters 0.7-4.5%) in control group at baseline
by quantitative polymerase chain reaction (qPCR) [Very low - estimated Plasmodium falciparum slide
prevalence 0.2%]
Transmission season: April to August
Malaria species: P falciparum (predominant), P malaria, P ovale, and P vivax (rare)
Vector species: Anopheles gambiae s.l., An arabiensis, An merus and An funestus
Antimalarial drug resistance context: No evidence of resistance to first line treatment arte-
sunate-amodiaquine, with 100% efficacy in clinical trial conducted in 2017.
Study design: Cluster-randomized trial (allocation of shehias, or administrative wards, within the trial
arms conducted using computerized block randomization based on shehia population size)
Statistical power: Assuming a coefficient of variation of 0.35 and baseline malaria incidence of 12 per
1000, there was 80% power (alpha = 0.05) to detect a 50% reduction in confirmed malaria illness inci-
dence in the intervention group. Study was not powered for parasitaemia prevalence.
For cluster-RCTs
Unit of randomization: Shehia (hotspot shehia, defined as a shehia with an with an annual parasite in-
dex of greater than 8 confirmed malaria cases per 1000 population)
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using an estimated ICC to calculate effective sample sizes
Adjustment method: Generalized estimating equations
Morris 2018 TZA 
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ICC: Not determined
Number of clusters randomized: 16
Number of clusters analysed: 16
Number of people: 23,251
Average cluster size: 1453
Participants Age groups included: All ages > 6 months. Pregnant women in their first trimester and anyone on con-
current antimalarial treatment at the time of MDA were excluded from MDA with dihydroartemisinin
piperaquine. Pregnant women (all trimesters) or women breast feeding infants < 6 months were exclud-






• Ages ≥ 14 years (> 40 kg): Dihydroartemisinin plus piperaquine (120 mg/960 mg as 3 tablets) given for
three days with a single dose of primaquine (15 mg as 2 tablets)
• Ages 8 to 13 years (21 to 40 kg): Dihydroartemisinin plus piperaquine (80 mg/640 mg as 2 tablets) given
for three days with a single dose of primaquine (7.5 mg as 1 tablet)
• Ages 2 to 7 years (10 to 20 kg): Dihydroartemisinin plus piperaquine (40 mg/320 mg as 1 tablet) given
for three days with a single dose of primaquine (4 mg as 4 cc solution)
• Ages 6 months to 1 year (5 to 9.9 kg): Dihydroartemisinin plus piperaquine (20 mg/160 mg as ½ tablet)
given for three days with a single dose of primaquine (2 mg as 2 cc solution)
Number of rounds (timing/dates): 2 (30 April to 7 May 2016 at the start of high transmission season, and
28 May to 4 June 4 2016 during the peak of high transmission season)
Interval: Every 4 weeks
Duration implemented: 6 weeks
Coverage (%): 91% in round 1 and 88% in round 2 (dihydroartemisinin piperaquine (DHAp)); 86% in
round 1 and 80% in round 2 (low dose primaquine).
Co-interventions: IRS (single round in March 2016 with pirimiphos methyl; 85% of households sprayed
at baseline) and ITNs (universal distribution campaign in 2015-2016; self-reported ITN use among all
ages 75% at baseline).
Comparison:
Type: No MDA and no placebo
Co-interventions: IRS (single round in March 2016 with pirimiphos methyl; 85% of households sprayed
at baseline)
and ITNs (universal distribution campaign in 2015-2016; self-reported ITN use among all ages 71% at
baseline).
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional surveys of P falciparum (and Plasmodium) prevalence by two-step
pooled 18s-quantitative PCR (qPCR) with first step screening by cytochrome b (Cytb) qPCR and 18s-
qPCR in participants of all ages from households randomly selected (50% of households randomly se-
lected at each time point).
Morris 2018 TZA  (Continued)
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Time points: During MDA (30 April to 7 May 2016) and 3 months post-MDA (30 August to 9 September
2016)
Sample size (range): 4402 to 4896 (intervention); 3875 to 4905 (comparison)
Confirmed malaria illness incidence
Measurement: Passive case detection at health facilities via malaria case notification system which
captures confirmed malaria infections in real time.
Time points: Pre-MDA (May - November 2015) and at 2 (May-August 2016), 5 (May-November 2016), 10
(May 2016 - April 2017), and 14 (May 2016 - August 2017) months post-MDA
Adverse effects (AEs)
Among participants receiving MDA, 11.6% and 3.2% reported at least one AE after the first and sec-
ond round, respectively. An additional 85 and 29 AE reports were passively identified at health facili-
ties after rounds 1 and 2, respectively. The most commonly reported AEs were: nausea and vomiting
(33.1%), stomach pain and diarrhoea (18.9%), and dizziness, headache, and fatigue (23.5%). Across all
AEs, 44.1% were considered mild, 52.0% as moderate, and 0.5% as severe. There were no MDA-associ-
ated deaths or other serious AEs.
Notes ClinicalTrials.gov: NCT02721186
The timing of the first parasitaemia survey coincided with the first round of MDA and continued for 10
days following the end of the first MDA distribution; therefore, the first parasitaemia survey was consid-
ered as "during MDA".
Abbreviations:
ICC = intracluster correlation coefficient, IRS = indoor residual spraying, ITN = insecticide-treated bed
net, MDA = mass drug administration, PCR = polymerase chain reaction
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random allocation of shehias to trial arms was conducted using computerized
block randomization based on shehia population size.
Allocation concealment
(selection bias)
Low risk Allocation was conducted by an institution.
Baseline imbalance (selec-
tion bias)
High risk Baseline malaria prevalence was higher in control (2.5%) compared to inter-
vention (0.8%) shehias. Baseline vector control interventions and demograph-
ic characteristics were balanced across arms.
Contamination protection Unclear risk Distance between hotspot shehias was not described and there was no men-











Unclear risk Participants were not blinded to allocation, which may have impacted care-
seeking.
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Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence
Low risk Laboratory staG performing PCR were unaware of the study arm allocation of
samples.




Unclear risk Unclear if the health facility staG performing malaria testing were aware of




Low risk Outcomes were assessed in participants of all ages residing in randomly sam-









Low risk All pre-specified outcomes were reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
Incorrect analysis (cluster
RCT)
Low risk Clustering accounted for using generalized estimating equations; however,
in this review, we performed cluster adjustment of the raw data using an esti-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 2016 to 2017
Location of study: Savannakhet Province, Laos
Malaria endemicity (prevalence): Plasmodium falciparum prevalence 4.8% in MDA villages and 17.5% in
control villages at baseline by ultrasensitive polymerase chain reaction (uPCR); P vivax prevalence 2.3%
in MDA villages and 14.7% in control villages at baseline by uPCR [Low - estimated P falciparum slide
prevalence 5.3%]
Transmission season: May to October
Malaria species: P falciparum and P vivax
Vector species: Not described
Antimalarial drug resistance context: Not described
Pongvongsa 2018 LAO 
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Statistical power: For the multi-country trial (Landier 2017 MMRa; Tripura 2018 KHM; Pongvongsa 2018
LAO; von Seidlein 2019 VNM), 80% power (alpha = 0.05) to detect a 95% reduction in parasite preva-
lence from a baseline prevalence of 10%
For cluster-RCTs
Unit of randomization: Village
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using ICC values estimated from the study data to calculate effective sample sizes
Adjustment method: Generalized estimating equations
ICC: 0.1416 (P falciparum outcomes at baseline before MDA), 0.0944 (P falciparum outcomes at post-
MDA 1-3 months), 0.05406 (P falciparum outcomes at post-MDA 4-6 months), 0.04319 (P falciparum out-
comes at post-MDA 7-12 months); 0.1438 (P vivax outcomes at baseline before MDA), 0.0913 (P vivax
outcomes at post-MDA 1-3 months), 0.02963 (P vivax outcomes at post-MDA 4-6 months), 0.01452 (P vi-
vax outcomes at post-MDA 7-12 months)
Number of clusters randomized: 4
Number of clusters analysed: 4
Number of people: 1889
Average cluster size: 472
Features: Two village pairs (4 villages) were established by geographical proximity, population size and
parasite prevalence. Within each pair, one village was randomly selected to receive early MDA, while
the other village received deferred MDA.





Drug/dose: Dihydroartemisinin (7 mg/kg) plus piperaquine (55 mg/kg) administered once a day for 3
days with a single dose of primaquine (0.25 mg/kg).
Number of rounds (timing/dates): 3 (April, June, and July 2016)
Interval: Every 1 month
Duration implemented: 3 months
Coverage (%): 81% in round 1, 80% in round 2, and 82% in round 3
Co-interventions: LLITNs, uninterrupted access to diagnosis and treatment in study villages
Comparison:
Type: Deferred MDA administered in control villages in April, June, and July 2017
Co-interventions: LLITNs, uninterrupted access to diagnosis and treatment in study villages
Outcomes Parasitaemia prevalence (P falciparum and P vivax)
Measurement: Cross-sectional surveys in all ages every 3 months by uPCR; all individuals present at the
time of the survey in the study villages were sampled.
Pongvongsa 2018 LAO  (Continued)
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Time points: Pre-MDA (April 2016, just prior to first MDA round) and at 1 (August 2016), 4 (late October
2016), 7 (January 2017), and 10* (April 2017) months post-MDA
Sample size (range): 745 to 859 (intervention) and 618 to 802 (control)
Adverse effects (AEs)
AEs were assessed by home visits from village volunteers and clinicians following a report of an AE. Fol-
lowing MDA rounds, 282 individuals reported 295 AEs: 291 (99%) were mild, 3 (1%) were moderate, and
1 (< 1%) was severe (case of pneumonia requiring hospitalization). The most common AEs were com-
mon cold (17%), gastritis (8%), diarrhoea (8%), vomiting (7%), dizziness (6%), pruritus (6%), watery
stool (4%), nausea (3%), and headache (3%).
Notes One of four sites from a multi-country trial in Southeast Asia (ClinicalTrials.gov: NCT01872702)
Abbreviations:
ICC = intracluster correlation coefficient, LLITN = long-lasting insecticide-treated bed net, MDA = mass
drug administration, uPCR = ultrasensitive polymerase chain reaction
* Data from this survey was analysed as post-MDA 7 to 12 month time period
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The randomisation was based on computer-generated random numbers pro-
vided by the trial statistician"
Allocation concealment
(selection bias)
Low risk Allocation was conducted by an institution.
Baseline imbalance (selec-
tion bias)
High risk Baseline prevalence of both P falciparum and P vivax substantially higher in
control compared to intervention villages. Small number of clusters (4 vil-
lages) randomized.
Contamination protection High risk Intervention and control clusters were pair-matched by geographical proxim-






Unclear risk Participants were not blinded to allocation.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence





Low risk Parasitaemia surveys were performed in all individuals aged six months or old-
er residing in the study villages.
Selective reporting (re-
porting bias)
Low risk All pre-specified outcomes reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
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Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
Incorrect analysis (cluster
RCT)
Low risk Although no adjustment for clustering was performed by investigators, in this
review, we performed cluster adjustment of the raw data using a study-provid-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 1953 to 1954
Location of study: Kenya
Malaria endemicity (prevalence): 37.6% (control) or 23% (intervention) at baseline in all ages by mi-
croscopy [Moderate]
Transmission season: May to July
Malaria species: P falciparum, P malariae
Vector species: Anopheles gambiae, An funestus
Antimalarial drug resistance context: Not described
Study design: Controlled before-and-after study
Statistical power: Not described
Participants Age groups included: All ages
Population targeted
Intervention (mean): 101,000
Comparison (mean): population not specified, but control area spans an entire district (Tiriki)
Interventions Intervention:
Drug/dose:
• Ages > 12 years: Pyrimethamine (50 mg as 2 tablets) as a single dose
• Ages 1 to 12 years: Pyrimethamine (25 mg as 1 tablet) as a single dose
• Ages < 1 years: Pyrimethamine (12.5 mg as ½ tablet) as a single dose
Number of rounds (timing/dates): 2 (May 1953 and May 1954, just prior to the start of the rainy season)
Interval: Every 1 year
Duration implemented: 13 months
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Type: No MDA and no placebo
Co-interventions: None
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional surveys conducted in a sub-sample of study population (see notes); 14
surveys in total (microscopy)
Time points: Pre-MDA, During MDA, and at 1, 2, 3, 4, 6, and 7 months post-MDA
Sample size (range): 300 to 2100 (intervention); 300 to 2100 (comparison)
Notes Roberts 1964 KEN (1956 article) states: “Three hundred blood films were taken at each of the two
places from people in the following age groups: 0-10 years (100 films), 11-20 years (100 films), 21 years
and over (100 films)”. Therefore, we assumed that the total participants examined at each survey was
300 in intervention and 300 in comparison groups in order to calculate number of events (malaria cas-
es) for parasitaemia prevalence. We also assumed that samples at each survey time point were inde-
pendent and aggregated data within follow-up time point categories.
Abbreviations:
MDA = mass drug administration
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Non-randomized controlled study
Allocation concealment
(selection bias)
High risk Non-randomized controlled study
Baseline imbalance (selec-
tion bias)
High risk Baseline parasitaemia in the control group was much higher than the interven-
tion group. No other baseline characteristics are described.
Contamination protection High risk The control area was located 10 miles from the centre of the intervention area





Unclear risk Participants were not blinded to allocation and unclear if this affected out-
comes since the sampling methodology at each parasitaemia survey was not
described.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence









Low risk All pre-stated outcomes were reported.
Other bias Low risk No other bias detected.
Roberts 1964 KEN  (Continued)
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Study characteristics
Methods Dates of study: 2008
Location of study: Tanzania
Malaria endemicity (prevalence): 0% in all ages at baseline by microscopy [Very low]
Transmission season: March to May, October to November
Malaria species: Plasmodium falciparum
Vector species: Not described
Antimalarial drug resistance context: Not described
Study design: Cluster-randomized trial
Statistical power: 80% power (alpha = 0.05) to detect a 10-fold lower malaria incidence in the interven-
tion arm vs control (assuming 0.5 episodes per child) accounting for repeated measures and clustering.
For cluster-RCTs
Unit of randomization: Geographical clusters of households
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using an estimated ICC to calculate effective sample sizes
Adjustment method: Generalized estimating equations
ICC: Not described
Number of clusters randomized: 16
Number of clusters analysed: 16
Number of people: 3457
Average cluster size: 216
Participants Age groups included: Ages > 1 year, but individuals who had received a full dose of artemisinin-based
combination therapy in the two weeks before the intervention were excluded. Pregnant women and in-






• Ages ≥ 1 year: Sulfadoxine-pyrimethamine (25 mg + 1.25 mg/kg as a single dose on the first day) plus
artesunate (4 mg/kg/day for three days) with primaquine (0.75 mg/kg as a single dose on the third day)
• Anaemic individuals: No primaquine. Sulfadoxine-pyrimethamine plus artesunate as described
above.
• Pregnant women: No primaquine. Sulfadoxine-pyrimethamine as described above plus amodiaquine
(10 mg/kg once daily for three days) instead of artesunate.
Number of rounds (timing/dates): 1 (February-March 2008)
Shekalaghe 2011 TZA 
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Interval: Not applicable
Duration implemented: 16 days
Coverage (%): 94.6% received at least one dose and 93% received a complete dose of an efficacious an-
ti-malarial drug prior to the transmission season or immediately upon arrival to the area
Co-interventions: Reported ITN use 36.1% (2007) and a single treatment campaign for trachoma with
azithromycin was undertaken by a non-governmental organization.
Comparison:
Type: Placebo administered to all persons in eight clusters once daily over three days.
Co-interventions: Reported ITN use 36.1% (2007) and a single treatment campaign for trachoma with
azithromycin was undertaken by a non-governmental organization.
If Placebo:
Number of rounds (timing/dates): 1 (February-March 2008)
Interval: Not applicable
Duration implemented: 16 days
Coverage (%): Not described
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional surveys of P falciparum prevalence by microscopy and QT-NASBA in 50
randomly-selected individuals per cluster
Time points: Pre-MDA (January-February 2008) and at < 1 (April 2008), 2 (May 2008), 3 (June 2008), and
4 (July 2008) months post-MDA
Sample size (range): 261 to 399 (intervention); 212 to 395 (comparison)
Confirmed malaria illness incidence
Measurement: Active case surveillance of 150 randomly-selected children (ages 1 to 10 years) from each
arm, visited every 2 weeks to monitor symptoms and test by RDT if febrile. Passive surveillance in entire
population.
Time points: Followed every 2 weeks for 6 months (February-July 2008)
Gametocytaemia prevalence
Measurement: Cross-sectional surveys of gametocytaemia prevalence by microscopy and QT-NASBA in
50 randomly selected individuals per cluster
Time points: Pre-MDA (January-February 2008) and at < 1 (April 2008), 2 (May 2008), 3 (June 2008), and
4 (July 2008) months post-MDA
Sample size (range): 261-399 (intervention); 212-395 (comparison)
Adverse effects
One individual was diagnosed with possibly-drug related severe skin reaction in the week following
MDA.
A second individual presented with non-drug related skin hyperpigmentation on the face. Both in-
dividuals were treated with steroids and monitored until symptoms disappeared. In those given pri-
maquine, moderate anaemia (Hb level of < 8 g/dL) was observed in 40% (6/15 individuals) of the G6PD
A-, 11.1% (3/27 individuals) of the G6PD A, and 4.5% (18/399 individuals) of the G6PD B individuals; one
case of severe anaemia (haemoglobin level of < 5 g/dL) was observed.
Notes ClinicalTrials.gov: NCT00509015
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Due to the following reasons, we excluded this study from quantitative synthesis in this review: out-
come evaluation by 18S QT-NASBA ended prematurely during the follow-up period; we were unable to
classify events in microscopy outcomes by post-MDA time point (reported in aggregate in the publica-
tion); and the baseline before MDA number of events for multiple outcomes was zero.
Abbreviations:
ICC = intracluster correlation coefficient, ITN = insecticide-treated bed net, MDA = mass drug adminis-
tration, QT-NASBA = real-time quantitative nucleic acid sequence based amplification, RDT = rapid di-
agnostic test
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Clusters were randomized to the intervention or control arm using computer
generated randomization tables using excel."
Allocation concealment
(selection bias)
Low risk Placebo-controlled trial, therefore allocation was concealed.
Baseline imbalance (selec-
tion bias)
Low risk Baseline demographic and malaria characteristics were similar across arms.
Contamination protection Low risk "Households that were located between clusters (i.e. within 1 km distance
from the boundary of intervention and/or control clusters) were considered as






Low risk Placebo-controlled trial and, at each cross-sectional survey, individuals were
randomly selected from computer-generated random tables. However, place-






Low risk Placebo-controlled trial.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence
Low risk Placebo-controlled trial; slides were read independently by two microscopists.













Low risk Active (visit by trained fieldworker every 2 weeks) and passive case detection.
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Selective reporting (re-
porting bias)
Low risk All pre-specified outcome measures were reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
Incorrect analysis (cluster
RCT)
Low risk Clustering accounted for using generalized estimating equations; however,
in this review, we performed cluster adjustment of the raw data using an esti-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 2014-2016
Location of study: Battambang province, Cambodia
Malaria endemicity (prevalence): Plasmodium falciparum prevalence 0.9% in MDA villages and 2.4%
in control villages at baseline by ultrasensitive polymerase chain reaction (uPCR); P vivax prevalence
10.7% in MDA villages and 8.8% in control villages at baseline by uPCR [Very low - estimated P falci-
parum slide prevalence 0.5%]
Transmission season: May to October
Malaria species: P falciparum and P vivax
Vector species: Not described
Antimalarial drug resistance context: Reduced susceptibility to artemisinins and ACT partner drug re-
sistance
Study design: Pair-matched cluster-randomized trial
Statistical power: For the multi-country trial (Landier 2017 MMRa; Tripura 2018 KHM; Pongvongsa 2018
LAO; von Seidlein 2019 VNM), 80% power (alpha = 0.05) to detect a 95% reduction in parasite preva-
lence from a baseline prevalence of 10%
For cluster-RCTs
Unit of randomization: Village
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using ICC values estimated from the study data to calculate effective sample sizes
Adjustment method: Generalized estimating equations
ICC: 0.004175 (P falciparum outcomes at baseline before MDA), 0 (P falciparum outcomes at post-MDA
1-3, 4-6, and 7-12 months); 0.02167 (P vivax outcomes at baseline before MDA), 0.01637 (P vivax out-
comes at post-MDA 1-3 months), 0.02229 (P vivax outcomes at post-MDA 4-6 months), 0.002531 (P vivax
outcomes at post-MDA 7-12 months)
Tripura 2018 KHM 
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Number of clusters randomized: 4
Number of clusters analysed: 4
Number of people: 2,770
Average cluster size: 693
Features: Two village pairs (4 villages) were established by geographical proximity, population size, and
parasite prevalence. Within each pair, one village was randomly selected to receive early MDA, while
the other village received deferred MDA





Drug/dose: Dihydroartemisinin (7 mg/kg) plus piperaquine tetraphosphate (55 mg/kg) adminis-
tered once a day for 3 days. Visitors or returning residents were offered a single course of piperaquine
tetraphosphate.
Number of rounds (timing/dates): 3 (July, August, September 2015)
Interval: Every 1 month
Duration implemented: 3 months
Coverage (%): 74% in round 1, 60% in round 2, and 71% in round 3
Co-interventions: LLITNs, uninterrupted access to diagnosis and treatment in study villages
Comparison:
Type: Deferred MDA administered in control villages in July, August, and September 2016
Co-interventions: LLITNs, uninterrupted access to diagnosis and treatment in study villages
Outcomes Parasitaemia prevalence (P falciparum and P vivax)
Measurement: Cross-sectional surveys in all ages every 3 months by uPCR; all individuals present at the
time of the survey in the study villages were sampled.
Time points: Pre-MDA (July 2015) and at 1 (Oct 2015), 4 (Jan 2016), 7 (April 2016), and 10* (July 2016)
months post-MDA
Sample size (range): 470 to 543 (intervention) and 583 to 1090 (control)
Confirmed malaria illness incidence (P falciparum and P vivax)
Measurement: Passive case detection at malaria posts for measured or self-reported fever (≥ 37.5 °C)
and confirmed P falciparum or P vivax infection by RDT or microscopy.
Time points: Pre-MDA (July 2014 - June 2015) and at 9 (July 2015 to June 2016) months' post-MDA
Adverse effects (AEs)
AEs were assessed through active surveillance on days 1, 2, 3, and 7 following MDA rounds. AEs were re-
ported by 46% (n=909) participants and a majority (96%) were mild; 4% (n=40) required medical atten-
tion and there were 3 non-study-related deaths. No serious AEs were reported. The most common AEs
reported were dizziness (22%), headache (18%), fever (10%), and nausea (8%).
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Notes One of four sites from a multi-country trial in Southeast Asia (ClinicalTrials.gov: NCT01872702)
Abbreviations:
ACT = artemisinin-based combination therapy, ICC = intracluster correlation coefficient, LLITN = long-
lasting insecticide-treated bed net, MDA = mass drug administration, uPCR = ultrasensitive polymerase
chain reaction
* Data from this survey was analysed as post-MDA 7-12 month time point
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The randomisation was based on computer-generated random numbers pro-
vided by the trial statistician"
Allocation concealment
(selection bias)
Low risk Allocation was conducted by an institution.
Baseline imbalance (selec-
tion bias)
High risk Baseline prevalence of P falciparum substantially higher in control compared
to intervention villages baseline. Small number of clusters (4 villages) random-
ized.
Contamination protection High risk Intervention and control clusters were pair-matched by geographical proxim-












Unclear risk Participants were not blinded to allocation, which may have impacted care-
seeking.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence
Low risk Laboratory staG performing PCR were unaware of the study arm allocation of
samples.




Unclear risk Unclear if the health facility staG performing malaria testing were aware of




Low risk Parasitaemia surveys were performed in all individuals aged six months or old-





Low risk Data collected at malaria health posts with dedicated study staG.
Selective reporting (re-
porting bias)
Low risk All pre-specified outcomes reported.
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Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
Incorrect analysis (cluster
RCT)
Low risk Although no adjustment for clustering was performed by investigators, in this
review, we performed cluster adjustment of the raw data using a study-provid-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-





Methods Dates of study: 1999
Location of study: The Gambia
Malaria endemicity: 42.9% in children ≤ 5 years in control at baseline [High]
Transmission season: June to December
Malaria species: Plasmodium falciparum
Vector species: Not described
Antimalarial drug resistance context: Not described
Study design: Cluster-randomized trial
Statistical power: 90% power (alpha = 0.05) to detect a 40% reduction in malaria incidence among chil-
dren < 11 years assuming coefficient of variation between pair-matched villages of 0.25, 20% loss to fol-
low-up, and mean incidence of malaria of 1 attack per child per week during the 20 week transmission
season.
For cluster-RCTs
Unit of randomization: Villages
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using an estimated ICC to calculate effective sample sizes
Adjustment method: Poisson regression model adjusting for population size
ICC: Not described
Number of clusters randomized: 18
Number of clusters analysed: 18
Number of people: 3655
Average cluster size: 203
von Seidlein 2003 GMB 
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Feature: Matched villages by population size, spleen rate in children < 5 years, and distance from the
river






• Adults: Sulfadoxine-pyrimethamine (1500 mg/75 mg as 3 tablets) plus artesunate (200 mg as 4 tablets)
given in a single day
• Children (< 10 kg): Sulfadoxine-pyrimethamine (250 mg/37.5 mg as ½ tablet) plus artesunate (4 mg/
kg) given in a single day. Additional quarter tablet of sulfadoxine-pyrimethamine given for every 5 kg
increment in weight
Number of rounds (timing/dates): 1 (June 1999)
Interval: Not applicable
Duration implemented: 1 month






Number of rounds (timing/dates): 1 (June 1999)
Interval: Not applicable
Duration implemented: 1 month
Coverage (%): 89% in total population, 90.8% in evaluated group
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional surveys of P falciparum prevalence by microscopy in children and week-
ly surveillance in all ages
Time points: Pre-MDA (children ≤ 5 years, May 1999) and at 6 months post-MDA (children < 11 years, No-
vember 1999)
Sample size (range): 808 to 985 (intervention); 605 or 606 (comparison)
Parasitaemia incidence
Measurement: Weekly surveillance in children aged < 11 years for cases with temperature ≥ 37.5 °C and
P falciparum parasitaemia > 5000 parasites per µL by microscopy
Time points: at 5 months post-MDA (20 July 1999 to 2 December 1999)
Sample size: 769 (intervention); 607 (comparison)
Gametocytaemia prevalence
von Seidlein 2003 GMB  (Continued)
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Measurement: Cross-sectional surveys of gametocytaemia prevalence by microscopy in children
Time points: Pre-MDA (children ≤ 5 years) and at 6 months post-MDA (children < 11 years)
Sample size (range): 808 to 985 (intervention); 605 or 606 (comparison)
Malaria-specific mortality
Measurement: Verbal autopsy confirmed by 3 physicians in children < 11 years
Adverse effects (AEs)
Monitored through passive and active surveillance. Active surveillance consisted of asking 90 randomly
selected individuals across all 42 study area villages about AEs one month following MDA.
AEs reported (passive surveillance system): 1 episode of pruritus in intervention group.
AEs reported (active surveillance system): 25 of 75 individuals in intervention group remembered one
or more complaints within 2 days of taking the drug including dizziness (13), fever (6), diarrhoea (5),
vomiting (5) and itching (4). In the comparison group, 2 of 15 individuals (13%) who had received place-
bo remembered complaints
Notes Abbreviations:
ICC = intracluster correlation coefficient, MDA = mass drug administration
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Method of randomization not described, but previous author correspondence
revealed that randomization was computer generated.
Allocation concealment
(selection bias)
Low risk One study nurse administered all study drugs to the 18 villages and leL the
study area following administration. Study personnel and participants were




Low risk Intervention and control villages were similar across baseline characteristics
reported.
Contamination protection Low risk All individuals in neighbouring non-randomized villages in the study area re-





Low risk Cluster-randomized, double-blind, placebo-controlled trial in which neither
study personnel nor participants were aware of the intervention status of vil-





Low risk Cluster-randomized, double-blind, placebo-controlled trial in which neither
study personnel nor participants were aware of the intervention status of vil-
lages. Placebo tablets identical to intervention drug.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence
Low risk Outcome assessment by microscopy was blinded to intervention status.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia incidence
Low risk Outcome assessment by microscopy was blinded to intervention status. Cas-
es diagnosed at health centre by RDT, but neither study personnel nor partici-
pants were aware of the intervention status of villages.
von Seidlein 2003 GMB  (Continued)
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High risk 78-92% of children were examined weekly by field workers and 87% of
planned visits took place. However, malaria cases were defined as a tempera-
ture ≥ 37.5 °C and parasitaemia > 5000/µL, which may have precluded asymp-




Low risk All pre-specified outcomes were reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
Loss of clusters (cluster
RCT)
Low risk One cluster pair (Daro Rahman and Misira villages) was not analysed due to
political and logistical problems, but sensitivity analysis indicated similar re-
sults. "Analyses which omitted these 2 villages yielded similar results as the
analyses including the 2 villages."
Incorrect analysis (cluster
RCT)
Low risk Analysis adjusted for clustering using Poisson regression model adjusting for
population size; however, in this review, we performed cluster adjustment of




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-
vant for the intervention evaluated in this review.




Methods Dates of study: 2013-2015
Location of study: Binh Phuoc and Ninh Thuan provinces, Vietnam
Malaria endemicity (prevalence): Plasmodium falciparum prevalence 3.9% in MDA villages and 4.1% in
control villages at baseline by ultrasensitive polymerase chain reaction (uPCR); P vivax prevalence 6.3%
in MDA villages and 7.3% in control villages at baseline by uPCR [Very low - estimated P falciparum slide
prevalence 0.9%]
Transmission season: May to November
Malaria species: P falciparum and P vivax
Vector species: Not described
Antimalarial drug resistance context: At the start of the study, no evidence of resistance to piperaquine
and cure rates following dihydroartemisinin piperaquine (DHAp) were satisfactory. In 2016, multidrug
resistance was first detected and treatment failures with DHAp have increased since then.
Statistical power: For the multi-country trial (Landier 2017 MMRa; Tripura 2018 KHM; Pongvongsa 2018
LAO; von Seidlein 2019 VNM), 80% power (alpha = 0.05) to detect a 95% reduction in parasite preva-
lence from a baseline prevalence of 10%
von Seidlein 2019 VNM 
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For cluster-RCTs
Unit of randomization: Village
Adjusted analyses for clustering: Yes; however, in this review, we performed cluster adjustment of the
raw data using ICC values estimated from the study data to calculate effective sample sizes
Adjustment method: Generalized estimating equations
ICC: 0.002464 (P falciparum outcomes at baseline before MDA), 0 (P falciparum outcomes at post-MDA
1-3 months), 0.003616 (P falciparum outcomes at post-MDA 4-6 months), 0.006523 (P falciparum out-
comes at post-MDA 7-12 months); 0.001502 (P vivax outcomes at baseline before MDA), 0.002539 (P vi-
vax outcomes at post-MDA 1-3 months), 0 (P vivax outcomes at post-MDA 4-6 and 7-12 months)
Number of clusters randomized: 4
Number of clusters analysed: 4
Number of people: 2846
Average cluster size: 712
Features: Two village pairs (4 villages) were established by geographical proximity, population size and
parasite prevalence. Within each pair, one village was randomly selected to receive early MDA, while
the other village received deferred MDA
Participants Age groups included: All ages ≥ 6 months. All pregnant women in their first trimester were excluded





Drug/dose: Dihydroartemisinin (7 mg/kg) plus piperaquine (55 mg/kg) administered once a day for 3
days with a single dose of primaquine (0.25 mg/kg).
Number of rounds (timing/dates): 3 (November 2013, January and February 2014)
Interval: Every 1 month
Duration implemented: 3 months
Coverage (%): 83% in round 1, 98% in round 2, and 99% in round 3
Co-interventions: LLITNs, uninterrupted access to diagnosis and treatment in study villages
Comparison:
Type: Deferred MDA administered in control villages in December 2014, January 2015, and February
2015
Co-interventions: LLITNs, uninterrupted access to diagnosis and treatment in study villages
Outcomes Parasitaemia prevalence (P falciparum and P vivax)
Measurement: Cross-sectional surveys in all ages every 3 months by uPCR; all individuals present at the
time of the survey in the study villages were sampled.
Time points: Pre-MDA (November 2013, just prior to first MDA round) and at 1 (March 2014), 4 (June
2014), 7 (September 2014), and 10* (December 2014) months post-MDA
von Seidlein 2019 VNM  (Continued)
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Sample size (range): 745 to 859 (intervention) and 618 to 802 (control)
Adverse effects (AEs)
22 AEs were reported which included vomiting, nausea, diarrhoea, labyrinth disorder, leg fracture and
urticaria. Seven serious AEs were reported within the first year of the study including death from sui-
cide, sudden death, drowning, decline due to aging, and gastric cancer.
Notes One of four sites from a multi-country trial in Southeast Asia (ClinicalTrials.gov: NCT01872702)
Abbreviations:
ICC = intracluster correlation coefficient, LLITN = long-lasting insecticide-treated bed net, MDA = mass
drug administration, uPCR = ultrasensitive polymerase chain reaction
* Data from this survey was analysed as post-MDA 7-12 month time point
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "The randomisation was based on computer-generated random numbers pro-
vided by the trial statistician"
Allocation concealment
(selection bias)
Low risk Allocation was conducted by an institution.
Baseline imbalance (selec-
tion bias)
Low risk Small number of clusters (4 villages) randomized, but baseline malaria preva-
lence is balanced across arms.
Contamination protection High risk Intervention and control clusters were pair-matched by geographical proxim-






Unclear risk Participants were not blinded to allocation.
Blinding of outcome as-
sessment (detection bias)
Parasitaemia prevalence





Low risk Parasitaemia surveys were performed in all individuals aged six months or old-
er residing in the study villages.
Selective reporting (re-
porting bias)
Low risk All pre-specified outcomes reported.
Other bias Low risk No other bias detected.
Recruitment bias (cluster
RCT)
Low risk No recruitment following randomization.
Loss of clusters (cluster
RCT)
Low risk No clusters were lost.
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Incorrect analysis (cluster
RCT)
Low risk Although no adjustment for clustering was performed by investigators, in this
review, we performed cluster adjustment of the raw data using a study-provid-




Low risk MDA, by definition, is applied at the population level, so this criteria is irrele-
vant for the intervention evaluated in this review.
von Seidlein 2019 VNM  (Continued)
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Affane 2012 COM Considered for ITS analysis, but since LLINs were distributed at the time of the first round of MDA, it
is not possible to evaluate the effect of MDA alone
Aregawi 2016 SLE Insufficient pre- and/or post-MDA coverage of data points for ITS analysis
Deng 2018 COM Insufficient pre- and/or post-MDA coverage of data points for ITS analysis
Escudie 1961 BFA No control group
Fraser 2020 ZMB Insufficient pre- and/or post-MDA coverage of data points for ITS analysis due to timing of IRS im-
plementation in relation to MDA rounds
Galatas 2020 MOZ Insufficient pre- and/or post-MDA coverage of data points for ITS analysis due to timing of IRS im-
plementation in relation to MDA rounds
Jones 1958 KEN Fewer than 2 sites or clusters per arm
Kagaya 2019 KEN Fewer than 2 sites or clusters per arm
Kaneko 2000 VUT Unbalanced co-interventions across arms (Intervention: MDA+ITNs+larvivorous fish, Control: no
MDA and delayed distribution of ITNs)
Landier 2017 MMRb Intervention targeted to hotspots of malaria infection (targeted MDA)
Mwesigwa 2018 GMB Insufficient pre- and post-MDA coverage of data points for ITS analysis
Najera 1973 NGA Unbalanced co-interventions across arms (Intervention: MDA+IRS, Control: no MDA and no IRS)
Singh 1953 IND Inadequate treatment dose
LLIN = long-lasting insecticide-treated bed net, IRS = indoor residual spraying, ITS = interrupted time series, MDA = mass drug
administration.
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Dates of study: 2006
Location of study: Sudan
Malaria endemicity: 15% [Moderate]
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Transmission season: October to November
Malaria species: Plasmodium falciparum
Vector species: Not described
Antimalarial drug resistance context: Not described
Study design: Cluster-randomized trial
Statistical power: 90% power (alpha = 0.05) to detect a reduction in malaria prevalence from 15%
to 5% among all ages, assuming a baseline malaria prevalence of 15%
For cluster-RCTs
Unit of randomization: Village
Adjusted analyses for clustering: No
Adjustment method: Not applicable
ICC: Not described
Number of clusters randomized: 8
Number of clusters analysed: 8
Number of people: Not described
Average cluster size: Not described
Participants Age groups included: All persons ≥ 1 year old; pregnant women and persons with a history of aller-




Drug/dose: Sulfadoxine-pyrimethamine (dose not described) plus artesunate (dose not described)
given over three days
Number of rounds (timing/dates): 1 (July 2006)
Interval: Not applicable
Duration implemented: Not described






Number of rounds (timing/dates): 1 (July 2006)
Interval: Not applicable
Duration implemented: Not described
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Coverage (%): Not described
Co-interventions: Not described
Outcomes Parasitaemia prevalence
Measurement: Cross-sectional survey of P falciparum prevalence by microscopy in all ages
Time points: at 4 months' post-MDA (November 2006)
Sample size: 200 participants per village; approximately 800 participants per study arm
Adverse events
Notes Placebo tablet similar to active drug in shape and size.
Unclear if a pre-MDA parasitaemia survey was conducted.
According to author communication: data collection complete and results from trial will be pub-
lished.





Methods Dates of study: Not described
Location of study: Est-Mono in the Plateaux region, Togo
Malaria endemicity (prevalence): Not described
Transmission season: Not described
Malaria species: Not described
Vector species: Not described
Antimalarial drug resistance context: Not described
Study design: Interrupted time series or controlled before-and-after study
Statistical power: Not described
Participants Age groups included: All persons ≥ 6 months old; pregnant women in their first trimester and per-
sons with serious illness or allergies to drug excluded.
Population targeted: 125,611
Interventions Artemisinin-piperaquine
Drug/dose: Artemisinin-piperaquine as a single tablet (62.5 mg artemisinin and 375 mg piper-
aquine) given for two days
Number of rounds (timing/dates): 3
Interval: 1 month
Duration implemented: 3 months
Coverage (%): Not described
Song TGO 
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Co-interventions: Not described
Outcomes Parasitaemia prevalence
Parasitaemia incidence among children < 5 years
Confirmed malaria illness incidence
Notes ChiCTR-POC-16009019




D A T A   A N D   A N A L Y S E S
 
Comparison 1.   MDA versus no MDA in moderate to high endemicity (cRCTs) on P falciparum outcomes
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
1.1 Parasitaemia prevalence (P
falciparum)
2   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1.1 Baseline before MDA 2   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1.2 During MDA 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1.3 Post-MDA 1-3 months 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1.4 Post-MDA 4-6 months 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.2 Parasitaemia incidence (P
falciparum)
2   Rate Ratio (IV, Fixed, 95% CI) Totals not selected
1.2.1 Post-MDA 1-3 months 1   Rate Ratio (IV, Fixed, 95% CI) Totals not selected
1.2.2 Post-MDA 4-6 months 1   Rate Ratio (IV, Fixed, 95% CI) Totals not selected
1.3 Confirmed malaria illness in-
cidence (P falciparum)
1   Rate Ratio (IV, Fixed, 95% CI) Totals not selected
1.3.1 Baseline before MDA 1   Rate Ratio (IV, Fixed, 95% CI) Totals not selected
1.3.2 Post-MDA 1-3 months 1   Rate Ratio (IV, Fixed, 95% CI) Totals not selected
1.4 Gametocytaemia preva-
lence (P falciparum)
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.4.1 Baseline before MDA 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.4.2 Post-MDA 4-6 months 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
1.5 Malaria-specific mortality 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
1.5.1 Post-MDA 4-6 months 1   Risk Ratio (IV, Fixed, 95% CI) Totals not selected
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Analysis 1.1.   Comparison 1: MDA versus no MDA in moderate to high endemicity
(cRCTs) on P falciparum outcomes, Outcome 1: Parasitaemia prevalence (P falciparum)
Study or Subgroup
1.1.1 Baseline before MDA
Eisele 2020 ZMBb (1)
von Seidlein 2003 GMB (2)
1.1.2 During MDA
Eisele 2020 ZMBb (3)
1.1.3 Post-MDA 1-3 months
Eisele 2020 ZMBb (4)
1.1.4 Post-MDA 4-6 months




























M-H, Fixed, 95% CI
0.91 [0.64 , 1.28]
0.98 [0.66 , 1.48]
0.99 [0.47 , 2.10]
1.76 [0.58 , 5.36]
1.18 [0.89 , 1.56]
Risk Ratio
M-H, Fixed, 95% CI
0.05 0.2 1 5 20
Favours MDA Favours no MDAFootnotes
(1) Children ≤ 5 years; RDT; raw data: 248 (MDA events), 490 (MDA total), 283 (Control events), 505 (Control total)
(2) Children ≤ 5 years; microscopy; raw data: 410 (MDA events), 985 (MDA total), 260 (Control events), 605 (Control total)
(3) Children ≤ 5 years; RDT; raw data: 56 (MDA events), 366 (MDA total), 55 (Control events), 332 (Control total)
(4) Children ≤ 5 years; RDT; raw data: 28 (MDA events), 348 (MDA total), 22 (Control events), 438 (Control total)
(5) Children < 11 years; microscopy; raw data: 530 (MDA events), 808 (MDA total), 333 (Control events), 606 (Control total)
 
 
Analysis 1.2.   Comparison 1: MDA versus no MDA in moderate to high endemicity
(cRCTs) on P falciparum outcomes, Outcome 2: Parasitaemia incidence (P falciparum)
Study or Subgroup
1.2.1 Post-MDA 1-3 months
Eisele 2020 ZMBb (1)
1.2.2 Post-MDA 4-6 months
















IV, Fixed, 95% CI
0.61 [0.40 , 0.92]
0.91 [0.55 , 1.50]
Rate Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours MDA Favours no MDAFootnotes
(1) Persons ≥ 3 months; RDT
(2) Malaria events defined as a temperature ≥ 37.5 °C and parasitaemia > 5000/սL in children < 11 years followed weekly
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Analysis 1.3.   Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs)
on P falciparum outcomes, Outcome 3: Confirmed malaria illness incidence (P falciparum)
Study or Subgroup
1.3.1 Baseline before MDA
Eisele 2020 ZMBb (1)









IV, Fixed, 95% CI
0.75 [0.19 , 2.94]
0.41 [0.04 , 4.42]
Rate Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours MDA Favours no MDAFootnotes
(1) All ages; January-May 2013 and 2014; denominator assumed to be average of 2013 and 2014 mid-year HFCA population
(2) All ages; January-May 2015 and 2016; denominator assumed to be average of 2015 and 2016 mid-year HFCA population
 
 
Analysis 1.4.   Comparison 1: MDA versus no MDA in moderate to high endemicity (cRCTs)
on P falciparum outcomes, Outcome 4: Gametocytaemia prevalence (P falciparum)
Study or Subgroup
1.4.1 Baseline before MDA
von Seidlein 2003 GMB (1)
1.4.2 Post-MDA 4-6 months
















M-H, Fixed, 95% CI
0.62 [0.09 , 4.26]
1.13 [0.20 , 6.54]
Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours MDA Favours no MDAFootnotes
(1) Children ≤ 5 years; microscopy; raw data: 19 (MDA events), 985 (MDA total), 22 (Control events), 605 (Control total)
(2) Children < 11 years; microscopy; raw data: 30 (MDA events), 808 (MDA total), 21 (Control events), 606 (Control total)
 
 
Analysis 1.5.   Comparison 1: MDA versus no MDA in moderate to high endemicity
(cRCTs) on P falciparum outcomes, Outcome 5: Malaria-specific mortality
Study or Subgroup
1.5.1 Post-MDA 4-6 months












IV, Fixed, 95% CI
1.42 [0.12 , 17.15]
Risk Ratio
IV, Fixed, 95% CI
0.05 0.2 1 5 20
Favours MDA Favours no MDAFootnotes
(1) Standard error adjusted using ICC of 0.01 due implausible error using ICC of 0.1225; raw data: 5 (MDA events), 3 (Control events)
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Comparison 2.   MDA versus no MDA in very low to low endemicity (cRCTs) on P falciparum outcomes
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
2.1 Parasitaemia prevalence (P
falciparum)
7   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1.1 Baseline before MDA 6 2093 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.62, 1.26]
2.1.2 During-MDA 2 991 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.07, 0.94]
2.1.3 Post-MDA <1 month 1 234 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.03, 0.52]
2.1.4 Post-MDA 1-3 months 7 5718 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.15, 0.41]
2.1.5 Post-MDA 4-6 months 4 3129 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.36, 1.12]
2.1.6 Post-MDA 7-12 months 5 3704 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.55, 1.36]
2.1.7 Post-MDA 13-18 months 1 243 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.20, 3.34]
2.1.8 Post-MDA 19-24 months 1 239 Risk Ratio (M-H, Fixed, 95% CI) 0.34 [0.06, 1.97]
2.1.9 Post-MDA 25-30 months 1 242 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.22, 3.62]
2.1.10 Post-MDA 31-36 months 1 246 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [0.25, 6.31]
2.2 Parasitaemia incidence (P
falciparum)
1   Rate Ratio (IV, Fixed, 95% CI) Totals not selected
2.2.1 Post-MDA 1-3 months 1   Rate Ratio (IV, Fixed, 95% CI) Totals not selected
2.3 Confirmed malaria illness
incidence (P falciparum)
4   Rate Ratio (IV, Fixed, 95% CI) Subtotals only
2.3.1 Baseline before MDA 3   Rate Ratio (IV, Fixed, 95% CI) 0.87 [0.45, 1.69]
2.3.2 Post-MDA 1-3 months 2   Rate Ratio (IV, Fixed, 95% CI) 0.58 [0.12, 2.73]
2.3.3 Post-MDA 4-6 months 1   Rate Ratio (IV, Fixed, 95% CI) 0.93 [0.07, 12.43]
2.3.4 Post-MDA 7-12 months 3   Rate Ratio (IV, Fixed, 95% CI) 0.47 [0.21, 1.03]
2.3.5 Post-MDA 13-18 months 1   Rate Ratio (IV, Fixed, 95% CI) 0.77 [0.20, 3.03]
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Analysis 2.1.   Comparison 2: MDA versus no MDA in very low to low endemicity (cRCTs) on P falciparum outcomes,
Outcome 1: Parasitaemia prevalence (P falciparum)
Study or Subgroup
2.1.1 Baseline before MDA
Eisele 2020 ZMBa (1)
Landier 2017 MMRa (2)
McLean 2021 MMR (3)
Pongvongsa 2018 LAO (4)
Tripura 2018 KHM (5)
von Seidlein 2019 VNM (6)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 3.00, df = 5 (P = 0.70); I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)
2.1.2 During-MDA
Eisele 2020 ZMBa (7)
Morris 2018 TZA (8)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.41, df = 1 (P = 0.52); I² = 0%
Test for overall effect: Z = 2.06 (P = 0.04)
2.1.3 Post-MDA <1 month




Test for overall effect: Z = 2.83 (P = 0.005)
2.1.4 Post-MDA 1-3 months
Eisele 2020 ZMBa (10)
Landier 2017 MMRa (11)
McLean 2021 MMR (12)
Morris 2018 TZA (13)
Pongvongsa 2018 LAO (14)
Tripura 2018 KHM (15)
von Seidlein 2019 VNM (15)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 8.72, df = 6 (P = 0.19); I² = 31%
Test for overall effect: Z = 5.61 (P < 0.00001)
2.1.5 Post-MDA 4-6 months
Landier 2017 MMRa (15)
Pongvongsa 2018 LAO (16)
Tripura 2018 KHM (15)
von Seidlein 2019 VNM (17)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 3.26, df = 3 (P = 0.35); I² = 8%
Test for overall effect: Z = 1.58 (P = 0.11)
2.1.6 Post-MDA 7-12 months
Landier 2017 MMRa (15)
















































































































































M-H, Fixed, 95% CI
0.83 [0.36 , 1.92]
2.05 [0.52 , 8.14]
0.91 [0.51 , 1.64]
0.46 [0.05 , 4.53]
0.37 [0.08 , 1.76]
0.94 [0.50 , 1.75]
0.89 [0.62 , 1.26]
0.16 [0.02 , 1.33]
0.38 [0.07 , 1.95]
0.26 [0.07 , 0.94]
0.12 [0.03 , 0.52]
0.12 [0.03 , 0.52]
0.62 [0.10 , 3.67]
0.06 [0.01 , 0.45]
0.30 [0.07 , 1.21]
1.34 [0.30 , 5.92]
0.14 [0.01 , 2.48]
0.42 [0.09 , 2.03]
0.21 [0.10 , 0.43]
0.25 [0.15 , 0.41]
0.89 [0.27 , 2.95]
0.07 [0.00 , 1.31]
0.34 [0.04 , 3.06]
0.83 [0.39 , 1.76]
0.63 [0.36 , 1.12]
1.19 [0.46 , 3.06]
0.51 [0.15 , 1.71]
Risk Ratio
M-H, Fixed, 95% CI
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Analysis 2.1.   (Continued)
Landier 2017 MMRa (15)
McLean 2021 MMR (18)
Pongvongsa 2018 LAO (19)
Tripura 2018 KHM (15)
von Seidlein 2019 VNM (20)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 8.38, df = 4 (P = 0.08); I² = 52%
Test for overall effect: Z = 0.65 (P = 0.52)
2.1.7 Post-MDA 13-18 months




Test for overall effect: Z = 0.28 (P = 0.78)
2.1.8 Post-MDA 19-24 months




Test for overall effect: Z = 1.21 (P = 0.23)
2.1.9 Post-MDA 25-30 months




Test for overall effect: Z = 0.17 (P = 0.87)
2.1.10 Post-MDA 31-36 months











































































1.19 [0.46 , 3.06]
0.51 [0.15 , 1.71]
0.08 [0.00 , 1.36]
0.21 [0.03 , 1.66]
1.55 [0.77 , 3.13]
0.86 [0.55 , 1.36]
0.82 [0.20 , 3.34]
0.82 [0.20 , 3.34]
0.34 [0.06 , 1.97]
0.34 [0.06 , 1.97]
0.89 [0.22 , 3.62]
0.89 [0.22 , 3.62]
1.25 [0.25 , 6.31]
1.25 [0.25 , 6.31]
0.05 0.2 1 5 20
Favours MDA Favours no MDAFootnotes
(1) Children ≤ 5 years; RDT; raw data: 42 (MDA events), 545 (MDA total), 42 (Control events), 453 (Control total)
(2) All ages ≥ 6 months; uPCR; raw data: 76 (MDA events), 689 (MDA total), 46 (Control events), 848 (Control total)
(3) Ages 18-55 years; uPCR; raw data: 101 (MDA events), 621 (MDA total), 74 (Control events), 412 (Control total) 
(4) All ages ≥ 6 months; uPCR; raw data: 41 (MDA events), 859 (MDA total), 140 (Control events), 802 (Control total)
(5) All ages ≥ 6 months; uPCR; raw data: 5 (MDA events), 543 (MDA total), 17 (Control events), 701 (Control total)
(6) All ages ≥ 6 months; uPCR; raw data: 48 (MDA events), 1247 (MDA total), 43 (Control events), 1054 (Control total)
(7) Children ≤ 5 years; RDT; raw data: 2 (MDA events), 372 (MDA total), 9 (Control events), 361 (Control total)
(8) All ages; qPCR; raw data: 24 (MDA events), 4042 (MDA total), 76 (Control events), 3875 (Control total)
(9) Ages 18-55 years; uPCR; raw data: 12 (MDA events), 747 (MDA total), 56 (Control events), 485 (Control total) 
(10) Children ≤ 5 years; RDT; raw data: 3 (MDA events), 392 (MDA total), 5 (Control events), 365 (Control total)
(11) All ages ≥ 6 months; uPCR; raw data: 1 (MDA events), 552 (MDA total), 24 (Control events), 812 (Control total)
(12) Ages 18-55 years; uPCR; raw data: 14 (MDA events), 675 (MDA total), 21 (Control events), 336 (Control total)
(13) All ages; qPCR; raw data: 67 (MDA events), 4896 (MDA total), 53 (Control events), 4905 (Control total)
(14) All ages ≥ 6 months; uPCR; raw data: 0 (MDA events), 745 (MDA total), 90 (Control events), 722 (Control total)
(15) All ages ≥ 6 months; uPCR; ICC = 0
(16) All ages ≥ 6 months; uPCR; raw data: 9 (MDA events), 801 (MDA total), 98 (Control events), 655 (Control total)
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(15) All ages ≥ 6 months; uPCR; ICC = 0
(16) All ages ≥ 6 months; uPCR; raw data: 9 (MDA events), 801 (MDA total), 98 (Control events), 655 (Control total)
(17) All ages ≥ 6 months; uPCR; raw data: 36 (MDA events), 1012 (MDA total), 35 (Control events), 837 (Control total)
(18) Ages 18-55 years; uPCR; raw data: 34 (MDA events), 1013 (MDA total), 33 (Control events), 515 (Control total)
(19) All ages ≥ 6 months; uPCR; raw data: 6 (MDA events), 808 (MDA total), 80 (Control events), 689 (Control total)
(20) All ages ≥ 6 months; uPCR; raw data: 86 (MDA events), 1026 (MDA total), 45 (Control events), 795 (Control total)
(21) Ages 18-55 years; uPCR; raw data: 34 (MDA events), 1029 (MDA total), 22 (Control events), 508 (Control total)
(22) Ages 18-55 years; uPCR; raw data: 14 (MDA events), 927 (MDA total), 15 (Control events), 466 (Control total)
(23) Ages 18-55 years; uPCR; raw data: 30 (MDA events), 993 (MDA total), 18 (Control events), 528 (Control total) 
(24) Ages 18-55 years; uPCR; raw data:  34 (MDA events), 1117 (MDA total), 17 (Control events), 562 (Control total) 
 
 
Analysis 2.2.   Comparison 2: MDA versus no MDA in very low to low endemicity
(cRCTs) on P falciparum outcomes, Outcome 2: Parasitaemia incidence (P falciparum)
Study or Subgroup













IV, Fixed, 95% CI
0.37 [0.21 , 0.66]
Rate Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours MDA Favours no MDAFootnotes
(1) Persons ≥ 3 months; RDT
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Analysis 2.3.   Comparison 2: MDA versus no MDA in very low to low endemicity (cRCTs) on P falciparum outcomes,
Outcome 3: Confirmed malaria illness incidence (P falciparum)
Study or Subgroup
2.3.1 Baseline before MDA
Eisele 2020 ZMBa (1)
Morris 2018 TZA (2)
Tripura 2018 KHM (3)
Subtotal (95% CI)
Heterogeneity: Chi² = 0.16, df = 2 (P = 0.92); I² = 0%
Test for overall effect: Z = 0.40 (P = 0.69)
2.3.2 Post-MDA 1-3 months
Eisele 2020 ZMBa (4)
Morris 2018 TZA (5)
Subtotal (95% CI)
Heterogeneity: Chi² = 0.09, df = 1 (P = 0.77); I² = 0%
Test for overall effect: Z = 0.69 (P = 0.49)
2.3.3 Post-MDA 4-6 months
Morris 2018 TZA (6)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2.3.4 Post-MDA 7-12 months
Landier 2017 MMRa (7)
Morris 2018 TZA (8)
Tripura 2018 KHM (9)
Subtotal (95% CI)
Heterogeneity: Chi² = 7.03, df = 2 (P = 0.03); I² = 72%
Test for overall effect: Z = 1.89 (P = 0.06)
2.3.5 Post-MDA 13-18 months
Morris 2018 TZA (10)
Subtotal (95% CI)
Heterogeneity: Not applicable








































IV, Fixed, 95% CI
0.73 [0.15 , 3.56]
1.14 [0.24 , 5.53]
0.85 [0.38 , 1.93]
0.87 [0.45 , 1.69]
0.50 [0.08 , 3.08]
0.85 [0.04 , 16.96]
0.58 [0.12 , 2.73]
0.93 [0.07 , 12.43]
0.93 [0.07 , 12.43]
0.71 [0.28 , 1.81]
0.92 [0.10 , 8.51]
0.04 [0.01 , 0.29]
0.47 [0.21 , 1.03]
0.77 [0.20 , 3.03]
0.77 [0.20 , 3.03]
Rate Ratio
IV, Fixed, 95% CI
0.05 0.2 1 5 20
Favours MDA Favours no MDAFootnotes
(1) All ages; January-May 2013 and 2014; denominator assumed to be average of 2013 and 2014 mid-year HFCA population
(2) All ages; May-Nov 2015
(3) All ages; July 2014 - June 2015; Plasmodium falciparum or mixed infections
(4) All ages; January-May 2015 and 2016; denominator assumed to be average of 2015 and 2016 mid-year HFCA population
(5) All ages; May-August 2016
(6) All ages; May-November 2016
(7) All ages; May 2013 to January 2014; Plasmodium falciparum or mixed infections
(8) All ages; May 2016 - April 2017
(9) All ages; July 2015 - June 2016; Plasmodium falciparum or mixed infections
(10) All ages; May 2016 - August 2017
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Analysis 2.3.   (Continued)
(9) All ages; July 2015 - June 2016; Plasmodium falciparum or mixed infections
(10) All ages; May 2016 - August 2017
 
 
Comparison 3.   MDA versus no MDA in very low to low endemicity (cRCTs) on P vivax outcomes
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
3.1 Parasitaemia prevalence (P
vivax)
5   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1.1 Baseline before MDA 5 3187 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.86, 1.21]
3.1.2 Post-MDA <1 month 1 234 Risk Ratio (M-H, Fixed, 95% CI) 0.18 [0.08, 0.40]
3.1.3 Post-MDA 1-3 months 5 2673 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.10, 0.24]
3.1.4 Post-MDA 4-6 months 4 3299 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.63, 0.95]
3.1.5 Post-MDA 7-12 months 5 4406 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.94, 1.34]
3.1.6 Post-MDA 13-18 months 1 243 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.44, 1.48]
3.1.7 Post-MDA 19-24 months 1 239 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.38, 1.83]
3.1.8 Post-MDA 25-30 months 1 242 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.41, 1.94]
3.1.9 Post-MDA 31-36 months 1 246 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.44, 3.29]
3.2 Confirmed malaria illness
incidence (P vivax)
2   Rate Ratio (IV, Fixed, 95% CI) Subtotals only
3.2.1 Baseline before MDA 1   Rate Ratio (IV, Fixed, 95% CI) 1.74 [0.67, 4.53]
3.2.2 Post-MDA 7-12 months 2   Rate Ratio (IV, Fixed, 95% CI) 1.38 [0.97, 1.95]
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Analysis 3.1.   Comparison 3: MDA versus no MDA in very low to low endemicity (cRCTs) on P vivax outcomes,
Outcome 1: Parasitaemia prevalence (P vivax)
Study or Subgroup
3.1.1 Baseline before MDA
Landier 2017 MMRa (1)
McLean 2021 MMR (2)
Pongvongsa 2018 LAO (3)
Tripura 2018 KHM (4)
von Seidlein 2019 VNM (5)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 2.44, df = 4 (P = 0.66); I² = 0%
Test for overall effect: Z = 0.24 (P = 0.81)
3.1.2 Post-MDA <1 month




Test for overall effect: Z = 4.20 (P < 0.0001)
3.1.3 Post-MDA 1-3 months
Landier 2017 MMRa (7)
McLean 2021 MMR (8)
Pongvongsa 2018 LAO (9)
Tripura 2018 KHM (10)
von Seidlein 2019 VNM (11)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 25.54, df = 4 (P < 0.0001); I² = 84%
Test for overall effect: Z = 8.67 (P < 0.00001)
3.1.4 Post-MDA 4-6 months
Landier 2017 MMRa (12)
Pongvongsa 2018 LAO (13)
Tripura 2018 KHM (14)
von Seidlein 2019 VNM (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 5.22, df = 3 (P = 0.16); I² = 42%
Test for overall effect: Z = 2.45 (P = 0.01)
3.1.5 Post-MDA 7-12 months
Landier 2017 MMRa (1)
McLean 2021 MMR (15)
Pongvongsa 2018 LAO (16)
Tripura 2018 KHM (17)
von Seidlein 2019 VNM (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 11.20, df = 4 (P = 0.02); I² = 64%
Test for overall effect: Z = 1.28 (P = 0.20)
3.1.6 Post-MDA 13-18 months















































































































































M-H, Fixed, 95% CI
1.08 [0.87 , 1.34]
0.99 [0.64 , 1.55]
0.19 [0.01 , 3.56]
1.30 [0.51 , 3.29]
0.87 [0.57 , 1.31]
1.02 [0.86 , 1.21]
0.18 [0.08 , 0.40]
0.18 [0.08 , 0.40]
0.05 [0.02 , 0.14]
0.75 [0.38 , 1.46]
0.19 [0.01 , 3.76]
0.13 [0.02 , 1.02]
0.15 [0.07 , 0.32]
0.15 [0.10 , 0.24]
0.87 [0.65 , 1.17]
0.08 [0.00 , 1.33]
0.17 [0.02 , 1.34]
0.78 [0.58 , 1.04]
0.78 [0.63 , 0.95]
1.49 [1.16 , 1.92]
0.87 [0.48 , 1.60]
0.08 [0.00 , 1.38]
0.73 [0.38 , 1.38]
0.98 [0.72 , 1.34]
1.12 [0.94 , 1.34]
0.81 [0.44 , 1.48]
0.81 [0.44 , 1.48]
Risk Ratio
M-H, Fixed, 95% CI
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Test for overall effect: Z = 0.69 (P = 0.49)
3.1.7 Post-MDA 19-24 months




Test for overall effect: Z = 0.44 (P = 0.66)
3.1.8 Post-MDA 25-30 months




Test for overall effect: Z = 0.30 (P = 0.76)
3.1.9 Post-MDA 31-36 months




Test for overall effect: Z = 0.35 (P = 0.72)









































0.81 [0.44 , 1.48]
0.81 [0.44 , 1.48]
0.84 [0.38 , 1.83]
0.84 [0.38 , 1.83]
0.89 [0.41 , 1.94]
0.89 [0.41 , 1.94]
1.20 [0.44 , 3.29]
1.20 [0.44 , 3.29]
0.05 0.2 1 5 20
Favours MDA Favours no MDA
Footnotes
(1) All ages ≥ 6 months; uPCR; ICC = 0
(2) Ages 18-55 years; uPCR; raw data: 164 (MDA events), 621 (MDA total), 109 (Control events), 412 (Control total)
(3) All ages ≥ 6 months; uPCR; raw data: 20 (MDA events), 859 (MDA total), 118 (Control events), 802 (Control total)
(4) All ages ≥ 6 months; uPCR; raw data: 58 (MDA events), 543 (MDA total), 62 (Control events), 701 (Control total)
(5) All ages ≥ 6 months; uPCR; raw data: 79 (MDA events), 1247 (MDA total), 77 (Control events), 1054 (Control total)
(6) Ages 18-55 years; uPCR; raw data: 37 (MDA events), 747 (MDA total), 131 (Control events), 485 (Control total)
(7) All ages ≥ 6 months; uPCR; raw data: 5 (MDA events), 552 (MDA total), 144 (Control events), 812 (Control total)
(8) Ages 18-55 years; uPCR; raw data: 82 (MDA events), 675 (MDA total), 54 (Control events), 336 (Control total) 
(9) All ages ≥ 6 months; uPCR; raw data: 0 (MDA events), 745 (MDA total), 84 (Control events), 722 (Control total)
(10) All ages ≥ 6 months; uPCR; raw data: 3 (MDA events), 470 (MDA total), 64 (Control events), 696 (Control total)
(11) All ages ≥ 6 months; uPCR; raw data: 14 (MDA events), 1061 (MDA total), 68 (Control events), 827 (Control total)
(12) All ages ≥ 6 months; uPCR; raw data: ICC = 0
(13) All ages ≥ 6 months; uPCR; raw data: 2 (MDA events), 801 (MDA total), 54 (Control events), 655 (Control total)
(14) All ages ≥ 6 months; uPCR; raw data: 11 (MDA events), 504 (MDA total), 63 (Control events), 692 (Control total)
(15) Ages 18-55 years; uPCR; raw data: 154 (MDA events), 1013 (MDA total), 88 (Control events), 515 (Control total) 
(16) All ages ≥ 6 months; uPCR; raw data: 3 (MDA events), 808 (MDA total), 33 (Control events), 689 (Control total)
(17) All ages ≥ 6 months; uPCR; raw data: 24 (MDA events), 512 (MDA total), 71 (Control events), 1090 (Control total)
(18) Ages 18-55 years; uPCR; raw data: 148 (MDA events), 1029 (MDA total), 87 (Control events), 508 (Control total)
(19) Ages 18-55 years; uPCR; raw data: 86 (MDA events), 927 (MDA total), 51 (Control events), 466 (Control total) 
(20) Ages 18-55 years; uPCR; raw data: 92 (MDA events), 993 (MDA total), 56 (Control events), 528 (Control total) 
(21) Ages 18-55 years; uPCR;  raw data: 85 (MDA events), 1117 (MDA total), 35 (Control events), 562 (Control total) 
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Analysis 3.2.   Comparison 3: MDA versus no MDA in very low to low endemicity
(cRCTs) on P vivax outcomes, Outcome 2: Confirmed malaria illness incidence (P vivax)
Study or Subgroup
3.2.1 Baseline before MDA
Tripura 2018 KHM (1)
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3.2.2 Post-MDA 7-12 months
Landier 2017 MMRa (2)
Tripura 2018 KHM (3)
Subtotal (95% CI)
Heterogeneity: Chi² = 2.10, df = 1 (P = 0.15); I² = 52%
















IV, Fixed, 95% CI
1.74 [0.67 , 4.53]
1.74 [0.67 , 4.53]
1.53 [1.05 , 2.24]
0.73 [0.29 , 1.84]
1.38 [0.97 , 1.95]
Rate Ratio
IV, Fixed, 95% CI
0.05 0.2 1 5 20
Favours MDA Favours no MDAFootnotes
(1) All ages; July 2014 - June 2015; Plasmodium vivax
(2) All ages; May 2013 to January 2014; Plasmodium vivax
(3) All ages; July 2015 - June 2016; Plasmodium vivax
 
 
Comparison 4.   Supplemental analysis: post-hoc subgroup analysis by continent
Outcome or subgroup title No. of studies No. of partici-
pants
Statistical method Effect size
4.1 Plasmodium falciparum para-
sitaemia prevalence post-MDA 1-3
months
7 5718 Risk Ratio (M-H, Fixed, 95% CI) 0.25 [0.15, 0.41]
4.1.1 Africa 2 1033 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.32, 2.98]
4.1.2 Asia 5 4685 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.11, 0.33]
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Analysis 4.1.   Comparison 4: Supplemental analysis: post-hoc subgroup analysis by




Morris 2018 TZA (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.42, df = 1 (P = 0.51); I² = 0%
Test for overall effect: Z = 0.05 (P = 0.96)
4.1.2 Asia
Landier 2017 MMRa (3)
McLean 2021 MMR (4)
Pongvongsa 2018 LAO (5)
Tripura 2018 KHM (6)
von Seidlein 2019 VNM (6)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 2.74, df = 4 (P = 0.60); I² = 0%
Test for overall effect: Z = 5.78 (P < 0.00001)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 8.72, df = 6 (P = 0.19); I² = 31%
Test for overall effect: Z = 5.61 (P < 0.00001)



























































M-H, Fixed, 95% CI
0.62 [0.10 , 3.67]
1.34 [0.30 , 5.92]
0.97 [0.32 , 2.98]
0.06 [0.01 , 0.45]
0.30 [0.07 , 1.21]
0.14 [0.01 , 2.48]
0.42 [0.09 , 2.03]
0.21 [0.10 , 0.43]
0.19 [0.11 , 0.33]
0.25 [0.15 , 0.41]
Risk Ratio
M-H, Fixed, 95% CI
0.05 0.2 1 5 20
Favours MDA Favours no MDA
Footnotes
(1) Children ≤ 5 years; RDT; raw data: 3 (MDA events), 392 (MDA total), 5 (Control events), 365 (Control total)
(2) All ages; qPCR; raw data: 67 (MDA events), 4896 (MDA total), 53 (Control events), 4905 (Control total)
(3) All ages ≥ 6 months; uPCR; raw data: 1 (MDA events), 552 (MDA total), 24 (Control events), 812 (Control total)
(4) Ages 18-55 years; uPCR; raw data: 14 (MDA events), 675 (MDA total), 21 (Control events), 336 (Control total)
(5) All ages ≥ 6 months; uPCR; raw data: 0 (MDA events), 745 (MDA total), 90 (Control events), 722 (Control total)
(6) All ages ≥ 6 months; uPCR; ICC = 0
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Table 1.   Description of studies  (Continued)
ACT = artemisinin-based combination therapy, AQ = amodiaquine, AS = artesunate, CBA = controlled before-and-aLer study, CQ = chloroquine, cRCT = cluster-randomized
controlled trial, DHAp = dihydroartemisinin piperaquine, ITNs = insecticide-treated bed nets, IRS = indoor residual spraying, MDA = mass drug administration, PQ = primaquine,
SP = sulfadoxine- (or sulfalene-) pyrimethamine, NA = not applicable, ND = not described.
aMalaria endemicity classified as very low (> 0% to < 1%), low (1% to < 10%), moderate (10% to < 35%) or high (≥ 35%) (WHO 2017).
bCo-interventions were balanced across intervention and control groups, as per inclusion criteria.
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Eisele 2020 ZMBa (cRCT) Yes Yes Yes No No Yes
Eisele 2020 ZMBb (cRCT) Yes Yes Yes No No Yes
Escudie 1962 BFA (CBA) Yes No No No Yes No
Landier 2017 MMRa (cRCT) Yes No Yes No No Yes
McLean 2021 MMR (cRCT) Yes No No No No Yes
Molineaux 1980 NGA (CBA) Yes No No No Yes No
Morris 2018 TZA (cRCT) Yes No Yes No No Yes
Pongvongsa 2018 LAO (cRCT) Yes No No No No Yes
Roberts 1964 KEN (CBA) Yes No No No No No
Shekalaghe 2011 TZA (cRCT) Yes No Yes No Yes Yes
Tripura 2018 KHM (cRCT) Yes No Yes No No Yes
von Seidlein 2003 GMB (cRCT) Yes Yes Yes Yes Yes Yes
von Seidlein 2019 VNM (cRCT) Yes No No No No Yes
Table 2.   Description of outcomes 
CBA = controlled before-and-aLer study, cRCT = cluster-randomized controlled trial
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Escudie 1962 BFA b
Low frequency MDA













ND ND -61.4 -42.1 ND ND
High frequency MDA













ND ND -36.3 14.9 ND ND


































26 (78) -15.8 -28.1 -22.8 -11.3
Table 3.   Di<erence-in-di<erences analysis of P falciparum parasitaemia prevalence in non-randomized studies 
AQ = amodiaquine, CQ = chloroquine, MDA = mass drug administration, ND = no data, PQ = primaquine, SP = sulfalene-pyrimethamine
aCalculated as diGerence in proportion at the time period of during MDA or post-MDA minus the proportion at pre-MDA in the intervention and control separately and the diGerence
in these two proportion diGerences between the intervention and control groups.
bMDA with AQ-PQ or CQ-PQ either every 4 weeks ('low frequency MDA') or every 2 weeks ('high frequency MDA').
cMDA with sulfalene-pyrimethamine either every 10 weeks (low frequency MDA') or every 2 weeks during the wet season and every 10 weeks during the dry season ('high frequency
MDA') to all ages except infants prior to their first malaria episode.
 
 
Study Intervention, % (n) Control, % (n) Difference-in-differences
percentage pointa


























































































































































Pre-MDA During MDA Post-MDA
1 to 3 months
Pre-MDA During MDA Post-MDA
1 to 3 months
During MDA Post-MDA
1 to 3 months
Escudie 1962 BFA b
Low frequency MDA with AQ-PQ or
CQ-PQ
20.3 (57) 0.9 (3) 38.3 (35) 19.4 (42) 14 (97) 19.1 (102) -14.1 18.3
High frequency MDA with AQ-PQ or
CQ-PQ
8.2 (32) 1.9 (9) 61.4 (107) 19.4 (42) 14 (97) 19.1 (102) -1.0 53.4
Molineaux 1980 NGA c
Low frequency MDA with SP 10.1 (127) 0.6 (12) ND 12.4 (124) 7.9 (92) ND -5.0 ND
High frequency MDA with SP 12.4 (208) 3.2 (48) ND 12.4 (124) 7.9 (92) ND -4.7 ND
Table 4.   Di<erence-in-di<erences analysis of P falciparum gametocytaemia prevalence in non-randomized studies  (Continued)
AQ = amodiaquine, CQ = chloroquine, MDA = mass drug administration, ND = no data, SP = sulfalene-pyrimethamine
aCalculated as diGerence in proportion at the time period of during MDA or post-MDA minus the proportion at pre-MDA in the intervention and control separately and the diGerence
in these two proportion diGerences between the intervention and control groups.
bMDA with AQ-PQ or CQ-PQ either every 4 weeks ('low frequency MDA') or every 2 weeks ('high frequency MDA').
cMDA with sulfalene-pyrimethamine either every 10 weeks ('low frequency MDA') or every 2 weeks during the wet season and every 10 weeks during the dry season ('high frequency
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A P P E N D I C E S
Appendix 1. Search strategies
The search strategies carried out for databases are provided below.
Search Name: Cochrane Central Register of Controlled Trials
 
ID Search
#2 "antimalarial":ti,ab,kw (Word variations have been searched)
#3 malaria:ti,ab,kw (Word variations have been searched)
#4 MeSH descriptor: [Malaria] explode all trees
#5 MeSH descriptor: [Antimalarials] explode all trees
#6 #2 or #3 or #4 or #5
#7 "mass chemoprophylaxis" or "mass drug administration" or "mass administration"
#8 "mass screening and treatment"
#9 "mass treatment"
#10 MDA or MSAT or iMSaT
#11 MeSH descriptor: [Mass Drug Administration] explode all trees
#12 #7 or #8 or #9 or #10 or #11
#13 #6 and #12
 
 
Database: Embase 1947-Present, updated daily
 
1 malaria/ or malaria control/
2 antimalarial agent/ or antimalarial*.mp.
3 (malaria or antimalarial*).ab. or (malaria or antimalarial*).ti.
4 1 or 2 or 3
5 ("mass chemoprophylaxis" or "mass drug administration" or "mass administration").mp.
6 mass drug administration.mp.
7 mass treatment.mp.
8 "mass screening and treatment".mp.
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9 5 or 6 or 7 or 8
10 4 and 9
11 randomized controlled trial/
12 controlled clinical trial.mp. or Controlled Clinical Trial/
13 (randomized or placebo or double-blind* or single-blind*).mp.
14 crossover procedure/ or crossover study.mp.
15 time series.mp. or time series analysis/
16 (before and after).mp.
17 11 or 12 or 13 or 14 or 15 or 16






#1 malaria Field: Title/Abstract
#2 antimalarial*or anti-malarial* Field:Title/Abstract
#3 (malaria[MeSH Terms]) OR antimalarials[MeSH Terms]
#4 #1 or #2 or #3
#5 ((mass chemoprophylaxis) OR mass drug administration) OR mass administration Field:Title/Ab-
stract
#6 "mass screening and treatment" Field: Title/Abstract
#7 (MDA[Title/Abstract] OR MSAT[Title/Abstract] OR iMSaT[Title/Abstract])
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Appendix 2. Prespecified changes for review update
 
Protocol section Author responses
Background and research
question
• We have updated the background section to highlight current gaps in knowledge surrounding
MDA in all malaria transmission settings and in light of evidence and policy recommendations
since the previous (2013) review was published.
• Given the focus on synthesizing evidence for the sustained impact of MDA in both low and moder-
ate- to high-transmission settings, the primary objectives have been modified to reflect evidence
of interruption of transmission in low transmission settings and reduction in transmission in mod-
erate- to high-transmission settings.
Inclusion criteria • Inclusion criteria (including selection of more rigorous study designs and control groups) has been
updated from the previous (2013) review.
• We have clarified the inclusion of special groups (i.e. refugees, soldiers) if these studies meet eli-
gibility criteria.
• The description of the intervention (MDA) has also been updated to reflect the current definition.
Methods • Primary and secondary outcomes have also been updated to align with the objectives and include
method of measurement.
• The search strategy has been refreshed since the previous review.
• Data items for the summary of findings table have been added and modified, including definitions
of malaria endemicities to match current criteria for very low, low, moderate, and high transmis-
sion settings (in the 'Data synthesis' section). In addition, we have specified that only molecular
data were available for baseline prevalence. A tool developed by Okell 2012 was used to estimate
equivalent microscopy prevalence from PCR data.
• Additional details on ICC estimation have been provided for methodology related to analysis of
cRCTs
• Subgroup analyses have been revised and pre-specified.




Abbreviations: MDA: mass drug administration.
This table was approved by the CIDG editorial team on 4 April 2018.
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Date Event Description
23 September 2021 New citation required and conclusions
have changed
The last published version of this review included 32 studies:
two cRCTs, eight non-randomized trials, and 22 uncontrolled be-
fore-and-after studies (Poirot 2013). Following the revised in-
clusion criteria, which restricted the review to more rigorous
study designs with a control group and balanced co-interven-
tions across study arms (described in detail in Differences be-
tween protocol and review), the updated literature search (to 11
February 2021) identified 13 studies that met the inclusion crite-
ria.
23 September 2021 New search has been performed The author team was amended for this review update version.
Pre-specified revisions made to the background, inclusion crite-
ria, and methods sections are detailed in Appendix 2. In addition,
we analysed non-randomized studies using a difference-in-dif-
ference analysis, as detailed in the Methods section. We also con-
ducted a post-hoc analysis to explore differences in malaria epi-
demiology by continent as a reason for heterogeneity in effect
of MDA on P falciparum parasitaemia prevalence at one to three
months after MDA in very low- to low-endemicity settings. 
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Di<erences between review and review update
A new author team was formed for this 2021 review update, with several authors from the previous review version (JH, SPK). Dr Monica
Shah is the contact author for this 2021 review update.
Pre-specified revisions made to the background, inclusion criteria, and methods sections are detailed in Appendix 2. In addition, we
analysed non-randomized studies using a diGerence-in-diGerence analysis, as detailed in the methods section of this review update. We
also conducted a post-hoc analysis to explore diGerences in malaria epidemiology by continent as a reason for heterogeneity in eGect
of MDA on P falciparum parasitaemia prevalence at one to three months aLer MDA in very low- to low-endemicity settings. The post-hoc
analysis by subgroup (studies conducted in Africa and Asia) is presented in Analysis 4.1.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Antimalarials  [*administration & dosage]  [adverse eGects];  Disease Eradication  [methods];  *Endemic Diseases;  Malaria  [*drug
therapy];  Parasitemia  [*drug therapy];  Program Evaluation
MeSH check words
Humans
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